SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

AIM ImmunoTech Inc. – ‘10-K’ for 12/31/23 – ‘XML’

On:  Friday, 3/29/24, at 9:18pm ET   ·   As of:  4/1/24   ·   For:  12/31/23   ·   Accession #:  1493152-24-12058   ·   File #:  1-27072

Previous ‘10-K’:  ‘10-K’ on 3/31/23 for 12/31/22   ·   Latest ‘10-K’:  This Filing   ·   68 References:   

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/01/24  AIM ImmunoTech Inc.               10-K       12/31/23   84:8.7M                                   M2 Compliance LLC/FA

Annual Report   —   Form 10-K   —   SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   2.15M 
 2: EX-4.25     Instrument Defining the Rights of Security Holders  HTML     37K 
 3: EX-10.104   Material Contract                                   HTML    187K 
 4: EX-10.105   Material Contract                                   HTML    103K 
 5: EX-21.1     Subsidiaries List                                   HTML     23K 
 6: EX-23.1     Consent of Expert or Counsel                        HTML     23K 
11: EX-97.1     Clawback Policy re: Recovery of Erroneously         HTML     34K 
                Awarded Compensation                                             
 7: EX-31.1     Certification -- §302 - SOA'02                      HTML     29K 
 8: EX-31.2     Certification -- §302 - SOA'02                      HTML     29K 
 9: EX-32.1     Certification -- §906 - SOA'02                      HTML     25K 
10: EX-32.2     Certification -- §906 - SOA'02                      HTML     25K 
17: R1          Cover                                               HTML     94K 
18: R2          Consolidated Balance Sheets                         HTML    116K 
19: R3          Consolidated Balance Sheets (Parenthetical)         HTML     50K 
20: R4          Consolidated Statements of Operations and           HTML     91K 
                Comprehensive Loss                                               
21: R5          Consolidated Statements of Changes in               HTML     59K 
                Stockholders' Equity                                             
22: R6          Consolidated Statements of Cash Flows               HTML    107K 
23: R7          Description of Business                             HTML     37K 
24: R8          Summary of Significant Accounting Policies          HTML     64K 
25: R9          Marketable Investments                              HTML     47K 
26: R10         Patents and Trademark Rights, Net                   HTML     52K 
27: R11         Accrued Expenses                                    HTML     32K 
28: R12         Stockholders? Equity                                HTML    351K 
29: R13         Segment and Related Information                     HTML     30K 
30: R14         Research, Consulting and Supply Agreements          HTML     64K 
31: R15         401(k) Plan                                         HTML     29K 
32: R16         Employment Agreements                               HTML     52K 
33: R17         Leases                                              HTML     49K 
34: R18         Income Taxes (FASB ASC 740 Income Taxes)            HTML     65K 
35: R19         Certain Relationships and Related Transactions      HTML     29K 
36: R20         Concentrations of Risk                              HTML     29K 
37: R21         Fair Value                                          HTML     75K 
38: R22         Contingencies                                       HTML     30K 
39: R23         Subsequent Events                                   HTML     31K 
40: R24         Summary of Significant Accounting Policies          HTML     96K 
                (Policies)                                                       
41: R25         Summary of Significant Accounting Policies          HTML     30K 
                (Tables)                                                         
42: R26         Marketable Investments (Tables)                     HTML     43K 
43: R27         Patents and Trademark Rights, Net (Tables)          HTML     52K 
44: R28         Accrued Expenses (Tables)                           HTML     31K 
45: R29         Stockholders? Equity (Tables)                       HTML    305K 
46: R30         Leases (Tables)                                     HTML     44K 
47: R31         Income Taxes (FASB ASC 740 Income Taxes) (Tables)   HTML     55K 
48: R32         Fair Value (Tables)                                 HTML     54K 
49: R33         Schedule of Property and Equipment (Details)        HTML     31K 
50: R34         Summary of Significant Accounting Policies          HTML     42K 
                (Details Narrative)                                              
51: R35         Schedule of Available of Sale (Details)             HTML     33K 
52: R36         Schedule of Equity Securities (Details)             HTML     30K 
53: R37         Marketable Investments (Details Narrative)          HTML     25K 
54: R38         Schedule of Patent and Trademark Rights (Details)   HTML     36K 
55: R39         Schedule of Changes in Patents, Trademark Rights    HTML     32K 
                (Details)                                                        
56: R40         Schedule of Amortization of Patents and Trademarks  HTML     39K 
                (Details)                                                        
57: R41         Patents and Trademark Rights, Net (Details          HTML     29K 
                Narrative)                                                       
58: R42         Schedule of Accrued Expenses (Details)              HTML     33K 
59: R43         Schedule of Options and Equity Estimated Based on   HTML     37K 
                Weighted Average Assumptions (Details)                           
60: R44         Schedule of Stock Option Activity (Details)         HTML     92K 
61: R45         Schedule of Vest Stock Option Activity (Details)    HTML    100K 
62: R46         Schedule of Unvested Stock Option Activity          HTML     77K 
                (Details)                                                        
63: R47         Schedule of Warrants Outstanding and Exercisable    HTML     72K 
                (Details)                                                        
64: R48         Stockholders? Equity (Details Narrative)            HTML    207K 
65: R49         Segment and Related Information (Details            HTML     25K 
                Narrative)                                                       
66: R50         Research, Consulting and Supply Agreements          HTML     80K 
                (Details Narrative)                                              
67: R51         401(k) Plan (Details Narrative)                     HTML     31K 
68: R52         Employment Agreements (Details Narrative)           HTML     55K 
69: R53         Schedule of AIM Recognized Rent Expense Associated  HTML     34K 
                with Operating Lease (Details)                                   
70: R54         Schedule of Operating Lease Future Payments         HTML     37K 
                (Details)                                                        
71: R55         Leases (Details Narrative)                          HTML     41K 
72: R56         Schedule of Components of Net Deferred Tax Assets   HTML     46K 
                and Liabilities (Details)                                        
73: R57         Schedule of Effective Tax Rate and Statutory Tax    HTML     91K 
                Rate (Details)                                                   
74: R58         Income Taxes (FASB ASC 740 Income Taxes) (Details   HTML     39K 
                Narrative)                                                       
75: R59         Schedule of Assets and Liabilities Measured at      HTML     36K 
                Fair Value on a Recurring Basis (Details)                        
76: R60         Schedule of Assumptions to Estimate Fair Value of   HTML     41K 
                Warrants (Details)                                               
77: R61         Schedule of Range of Probabilities (Details)        HTML     31K 
78: R62         Fair Value (Details Narrative)                      HTML     35K 
79: R63         Subsequent Events (Details Narrative)               HTML     41K 
81: XML         IDEA XML File -- Filing Summary                      XML    139K 
84: XML         XBRL Instance -- form10-k_htm                        XML   1.81M 
80: EXCEL       IDEA Workbook of Financial Report Info              XLSX    140K 
13: EX-101.CAL  Inline XBRL Taxonomy Extension Calculation           XML    210K 
                Linkbase Document -- aim-20231231_cal                            
14: EX-101.DEF  Inline XBRL Taxonomy Extension Definition Linkbase   XML    669K 
                Document -- aim-20231231_def                                     
15: EX-101.LAB  Inline XBRL Taxonomy Extension Label Linkbase        XML   1.22M 
                Document -- aim-20231231_lab                                     
16: EX-101.PRE  Inline XBRL Taxonomy Extension Presentation          XML    920K 
                Linkbase Document -- aim-20231231_pre                            
12: EX-101.SCH  Inline XBRL Taxonomy Extension Schema Document --    XSD    177K 
                aim-20231231                                                     
82: JSON        XBRL Instance as JSON Data -- MetaLinks              484±   706K 
83: ZIP         XBRL Zipped Folder -- 0001493152-24-012058-xbrl      Zip    482K

‘XML’   —   XBRL Instance — form10-k_htm

This Document is an XBRL File.

                                                                                                                                                                                
<?xml version="1.0" encoding="windows-1252"?>
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:AIM="http://aimimmuno.com/20231231" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<link:schemaRef xlink:href="aim-20231231.xsd" xlink:type="simple"/>
<context id="From2023-01-01to2023-12-31">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="AsOf2023-06-30">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
</entity>
<period>
<instant> 2023-06-30 </instant>
</period>
</context>
<context id="AsOf2024-03-27">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
</entity>
<period>
<instant> 2024-03-27 </instant>
</period>
</context>
<context id="AsOf2023-12-31">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="AsOf2022-12-31">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="AsOf2023-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> AIM:SeriesAJuniorParticipatingPreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="AsOf2022-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> AIM:SeriesAJuniorParticipatingPreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> AIM:SeriesBConvertiblePreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> AIM:SeriesBConvertiblePreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="From2022-01-012022-12-31">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-12-31 </endDate>
</period>
</context>
<context id="AsOf2022-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesBPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="AsOf2022-12-31_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AccumulatedOtherComprehensiveIncomeMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="AsOf2021-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesBPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2021-12-31_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AccumulatedOtherComprehensiveIncomeMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2021-12-31">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesBPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AccumulatedOtherComprehensiveIncomeMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesBPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-12-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-12-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-12-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AccumulatedOtherComprehensiveIncomeMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-12-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-12-31 </endDate>
</period>
</context>
<context id="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesBPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="AsOf2023-12-31_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AccumulatedOtherComprehensiveIncomeMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="AsOf2023-12-31_srt_MinimumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="AsOf2023-12-31_srt_MaximumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="From2021-01-012021-12-31">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="AsOf2023-12-31_custom_PatentAndTrademarkRightsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis"> AIM:PatentAndTrademarkRightsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="AsOf2023-12-31_custom_MutualFundsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis"> AIM:MutualFundsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="AsOf2022-12-31_custom_MutualFundsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis"> AIM:MutualFundsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="AsOf2023-12-31_us-gaap_PatentsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis"> us-gaap:PatentsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="AsOf2022-12-31_us-gaap_PatentsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis"> us-gaap:PatentsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="AsOf2023-12-31_us-gaap_TrademarksMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis"> us-gaap:TrademarksMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="AsOf2022-12-31_us-gaap_TrademarksMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis"> us-gaap:TrademarksMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="AsOf2023-12-31_custom_BoardMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> AIM:BoardMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="AsOf2023-05-10_custom_SeriesAJuniorParticipatingPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> AIM:SeriesAJuniorParticipatingPreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-05-10 </instant>
</period>
</context>
<context id="AsOf2023-05-09_custom_SeriesAJuniorParticipatingPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> AIM:SeriesAJuniorParticipatingPreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-05-09 </instant>
</period>
</context>
<context id="AsOf2023-12-31_us-gaap_RightsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:RightsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_RightsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:RightsMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> AIM:SeriesBConvertiblePreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="AsOf2023-12-31_us-gaap_WarrantMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="From2023-01-012023-12-31_us-gaap_RightsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:RightsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="From2023-01-012023-12-31_custom_SeriesBConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> AIM:SeriesBConvertiblePreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="AsOf2023-12-31_us-gaap_PreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="From2020-07-062020-07-07_custom_DirectorsOfficersAndEmployeesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> AIM:DirectorsOfficersAndEmployeesMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-07-06 </startDate>
<endDate> 2020-07-07 </endDate>
</period>
</context>
<context id="From2023-01-012023-12-31_us-gaap_CommonStockMember289842265">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="AsOf2023-12-31_us-gaap_CommonStockMember_srt_MinimumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="AsOf2023-12-31_us-gaap_CommonStockMember_srt_MaximumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="From2022-01-012022-12-31_us-gaap_CommonStockMember289842296">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-12-31 </endDate>
</period>
</context>
<context id="AsOf2022-12-31_us-gaap_CommonStockMember_srt_MinimumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="AsOf2022-12-31_us-gaap_CommonStockMember_srt_MaximumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="From2019-09-262019-09-27_custom_AllianceGlobalPartnersLLCMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> AIM:AllianceGlobalPartnersLLCMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-09-26 </startDate>
<endDate> 2019-09-27 </endDate>
</period>
</context>
<context id="AsOf2019-09-27_custom_AllianceGlobalPartnersLLCMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> AIM:AllianceGlobalPartnersLLCMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-09-27 </instant>
</period>
</context>
<context id="AsOf2019-09-27_custom_AllianceGlobalPartnersLLCMember_custom_WarrantsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> AIM:WarrantsMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> AIM:AllianceGlobalPartnersLLCMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-09-27 </instant>
</period>
</context>
<context id="AsOf2019-09-27_custom_AllianceGlobalPartnersLLCMember_custom_RepresentativeWarrantsMember_srt_MaximumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> AIM:RepresentativeWarrantsMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> AIM:AllianceGlobalPartnersLLCMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-09-27 </instant>
</period>
</context>
<context id="AsOf2019-09-27_custom_AllianceGlobalPartnersLLCMember_custom_PreFundedWarrantsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> AIM:PreFundedWarrantsMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> AIM:AllianceGlobalPartnersLLCMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-09-27 </instant>
</period>
</context>
<context id="AsOf2019-09-27_us-gaap_WarrantMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-09-27 </instant>
</period>
</context>
<context id="AsOf2019-09-27_custom_PreFundedWarrantsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> AIM:PreFundedWarrantsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-09-27 </instant>
</period>
</context>
<context id="From2020-01-012020-12-31_custom_PreFundedWarrantsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> AIM:PreFundedWarrantsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="From2020-01-012020-12-31_us-gaap_WarrantMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="AsOf2020-03-31_custom_AllianceGlobalPartnersLLCMember_custom_RepresentativeWarrantsMember_srt_MaximumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> AIM:RepresentativeWarrantsMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> AIM:AllianceGlobalPartnersLLCMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-03-31 </instant>
</period>
</context>
<context id="From2020-03-302020-03-31">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
</entity>
<period>
<startDate> 2020-03-30 </startDate>
<endDate> 2020-03-31 </endDate>
</period>
</context>
<context id="From2023-04-182023-04-19_custom_MaximGroupLLCMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> AIM:MaximGroupLLCMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-04-18 </startDate>
<endDate> 2023-04-19 </endDate>
</period>
</context>
<context id="From2023-01-012023-12-31_custom_MaximGroupLLCMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> AIM:MaximGroupLLCMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="AsOf2023-12-31_custom_MaximGroupLLCMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> AIM:MaximGroupLLCMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="From2024-01-012024-01-01_custom_MaximGroupLLCMember_us-gaap_SubsequentEventMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> AIM:MaximGroupLLCMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2024-01-01 </startDate>
<endDate> 2024-01-01 </endDate>
</period>
</context>
<context id="AsOf2024-01-01_custom_MaximGroupLLCMember_us-gaap_SubsequentEventMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> AIM:MaximGroupLLCMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2024-01-01 </instant>
</period>
</context>
<context id="AsOf2018-09-12_custom_EquityIncentivePlanTwoThousandNineMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> AIM:EquityIncentivePlanTwoThousandNineMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2018-09-12 </instant>
</period>
</context>
<context id="From2018-09-122018-09-12_custom_EquityIncentivePlanTwoThousandNineMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> AIM:EquityIncentivePlanTwoThousandNineMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2018-09-12 </startDate>
<endDate> 2018-09-12 </endDate>
</period>
</context>
<context id="From2023-01-012023-12-31_custom_EmployeesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> AIM:EmployeesMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-12-31_custom_EmployeesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> AIM:EmployeesMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-12-31 </endDate>
</period>
</context>
<context id="From2023-01-012023-12-31_custom_NonEmployeeMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> AIM:NonEmployeeMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-12-31_custom_NonEmployeeMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> AIM:NonEmployeeMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-12-31 </endDate>
</period>
</context>
<context id="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis"> us-gaap:ShareBasedPaymentArrangementNonemployeeMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis"> us-gaap:ShareBasedPaymentArrangementNonemployeeMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-12-31 </endDate>
</period>
</context>
<context id="From2023-01-012023-12-31_custom_EquityIncentivePlanTwoThousandNineMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> AIM:EquityIncentivePlanTwoThousandNineMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="From2023-01-012023-12-31_custom_EquityIncentivePlansTwoThousandAndEighteenMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> AIM:EquityIncentivePlansTwoThousandAndEighteenMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis"> us-gaap:ShareBasedPaymentArrangementEmployeeMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-12-31_srt_MinimumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-12-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-12-31_srt_MaximumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-12-31 </endDate>
</period>
</context>
<context id="AsOf2022-12-31_custom_EquityIncentivePlans2009Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> AIM:EquityIncentivePlans2009Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="AsOf2022-12-31_custom_EquityIncentivePlans2009Member_srt_MinimumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> AIM:EquityIncentivePlans2009Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="AsOf2022-12-31_custom_EquityIncentivePlans2009Member_srt_MaximumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> AIM:EquityIncentivePlans2009Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="AsOf2021-12-31_custom_EquityIncentivePlans2009Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> AIM:EquityIncentivePlans2009Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2021-12-31_custom_EquityIncentivePlans2009Member_srt_MinimumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> AIM:EquityIncentivePlans2009Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2021-12-31_custom_EquityIncentivePlans2009Member_srt_MaximumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> AIM:EquityIncentivePlans2009Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="From2023-01-012023-12-31_custom_EquityIncentivePlans2009Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> AIM:EquityIncentivePlans2009Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-12-31_custom_EquityIncentivePlans2009Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> AIM:EquityIncentivePlans2009Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-12-31 </endDate>
</period>
</context>
<context id="From2023-01-012023-12-31_custom_EquityIncentivePlans2009Member_srt_MinimumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> AIM:EquityIncentivePlans2009Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="From2023-01-012023-12-31_custom_EquityIncentivePlans2009Member_srt_MaximumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> AIM:EquityIncentivePlans2009Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-12-31_custom_EquityIncentivePlans2009Member_srt_MinimumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> AIM:EquityIncentivePlans2009Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-12-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-12-31_custom_EquityIncentivePlans2009Member_srt_MaximumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> AIM:EquityIncentivePlans2009Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-12-31 </endDate>
</period>
</context>
<context id="AsOf2023-12-31_custom_EquityIncentivePlans2009Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> AIM:EquityIncentivePlans2009Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="AsOf2023-12-31_custom_EquityIncentivePlans2009Member_srt_MinimumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> AIM:EquityIncentivePlans2009Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="AsOf2023-12-31_custom_EquityIncentivePlans2009Member_srt_MaximumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> AIM:EquityIncentivePlans2009Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="AsOf2022-12-31_custom_EquityIncentivePlans2018Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> AIM:EquityIncentivePlans2018Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="AsOf2022-12-31_custom_EquityIncentivePlans2018Member_srt_MinimumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> AIM:EquityIncentivePlans2018Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="AsOf2022-12-31_custom_EquityIncentivePlans2018Member_srt_MaximumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> AIM:EquityIncentivePlans2018Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="AsOf2021-12-31_custom_EquityIncentivePlans2018Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> AIM:EquityIncentivePlans2018Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2021-12-31_custom_EquityIncentivePlans2018Member_srt_MinimumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> AIM:EquityIncentivePlans2018Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2021-12-31_custom_EquityIncentivePlans2018Member_srt_MaximumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> AIM:EquityIncentivePlans2018Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="From2023-01-012023-12-31_custom_EquityIncentivePlans2018Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> AIM:EquityIncentivePlans2018Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="From2023-01-012023-12-31_custom_EquityIncentivePlans2018Member_srt_MinimumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> AIM:EquityIncentivePlans2018Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="From2023-01-012023-12-31_custom_EquityIncentivePlans2018Member_srt_MaximumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> AIM:EquityIncentivePlans2018Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-12-31_custom_EquityIncentivePlans2018Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> AIM:EquityIncentivePlans2018Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-12-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-12-31_custom_EquityIncentivePlans2018Member_srt_MinimumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> AIM:EquityIncentivePlans2018Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-12-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-12-31_custom_EquityIncentivePlans2018Member_srt_MaximumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> AIM:EquityIncentivePlans2018Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-12-31 </endDate>
</period>
</context>
<context id="AsOf2023-12-31_custom_EquityIncentivePlans2018Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> AIM:EquityIncentivePlans2018Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="AsOf2023-12-31_custom_EquityIncentivePlans2018Member_srt_MinimumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> AIM:EquityIncentivePlans2018Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="AsOf2023-12-31_custom_EquityIncentivePlans2018Member_srt_MaximumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> AIM:EquityIncentivePlans2018Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="AsOf2021-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis"> us-gaap:ShareBasedPaymentArrangementEmployeeMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="From2021-01-012021-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis"> us-gaap:ShareBasedPaymentArrangementEmployeeMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="AsOf2021-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis"> us-gaap:ShareBasedPaymentArrangementNonemployeeMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis"> us-gaap:ShareBasedPaymentArrangementEmployeeMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-12-31 </endDate>
</period>
</context>
<context id="AsOf2022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis"> us-gaap:ShareBasedPaymentArrangementEmployeeMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="AsOf2022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis"> us-gaap:ShareBasedPaymentArrangementNonemployeeMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis"> us-gaap:ShareBasedPaymentArrangementEmployeeMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis"> us-gaap:ShareBasedPaymentArrangementNonemployeeMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="From2021-01-012021-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis"> us-gaap:ShareBasedPaymentArrangementNonemployeeMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="AsOf2022-12-31_us-gaap_WarrantMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="AsOf2022-12-31_us-gaap_WarrantMember_srt_MinimumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="AsOf2022-12-31_us-gaap_WarrantMember_srt_MaximumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="AsOf2021-12-31_us-gaap_WarrantMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2021-12-31_us-gaap_WarrantMember_srt_MinimumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2021-12-31_us-gaap_WarrantMember_srt_MaximumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-12-31_us-gaap_WarrantMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-12-31 </endDate>
</period>
</context>
<context id="AsOf2023-12-31_us-gaap_WarrantMember289844531">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="AsOf2023-12-31_us-gaap_WarrantMember_srt_MinimumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="AsOf2023-12-31_us-gaap_WarrantMember_srt_MaximumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="From2022-01-012022-12-31_us-gaap_WarrantMember_srt_MinimumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-12-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-12-31_us-gaap_WarrantMember_srt_MaximumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-12-31 </endDate>
</period>
</context>
<context id="From2023-01-012023-12-31_custom_ClinicalStudiesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis"> AIM:ClinicalStudiesMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="From2023-01-012023-12-31_custom_ManufacturingAndEngineeringMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis"> AIM:ManufacturingAndEngineeringMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="From2023-01-012023-12-31_custom_QualityControlMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis"> AIM:QualityControlMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="From2023-01-012023-12-31_custom_RegulatoryMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis"> AIM:RegulatoryMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-12-31_custom_ClinicalStudiesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis"> AIM:ClinicalStudiesMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-12-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-12-31_custom_ManufacturingAndEngineeringMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis"> AIM:ManufacturingAndEngineeringMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-12-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-12-31_custom_QualityControlMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis"> AIM:QualityControlMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-12-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-12-31_custom_RegulatoryMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis"> AIM:RegulatoryMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-12-31 </endDate>
</period>
</context>
<context id="From2023-01-012023-12-31_custom_AmarexClinicalResearchLLCMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> AIM:AmarexClinicalResearchLLCMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-12-31_custom_AmarexClinicalResearchLLCMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> AIM:AmarexClinicalResearchLLCMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-12-31 </endDate>
</period>
</context>
<context id="From2022-04-012022-04-30_custom_AmarexClinicalResearchLLCMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> AIM:AmarexClinicalResearchLLCMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-04-01 </startDate>
<endDate> 2022-04-30 </endDate>
</period>
</context>
<context id="From2023-01-012023-12-31_custom_AmarexClinicalResearchLLCMember_custom_PancreaticCancerMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis"> AIM:PancreaticCancerMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> AIM:AmarexClinicalResearchLLCMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-12-31_custom_AmarexClinicalResearchLLCMember_custom_PancreaticCancerMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis"> AIM:PancreaticCancerMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> AIM:AmarexClinicalResearchLLCMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-12-31 </endDate>
</period>
</context>
<context id="From2022-09-012022-09-30_custom_AmarexClinicalResearchLLCMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> AIM:AmarexClinicalResearchLLCMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-09-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="From2023-01-012023-12-31_custom_AmarexClinicalResearchLLCMember_custom_PostCOVIDMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis"> AIM:PostCOVIDMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> AIM:AmarexClinicalResearchLLCMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-12-31_custom_AmarexClinicalResearchLLCMember_custom_PostCOVIDMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis"> AIM:PostCOVIDMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> AIM:AmarexClinicalResearchLLCMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-12-31 </endDate>
</period>
</context>
<context id="From2017-01-012017-12-31_custom_JubilantHollisterStierMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> AIM:JubilantHollisterStierMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2017-01-01 </startDate>
<endDate> 2017-12-31 </endDate>
</period>
</context>
<context id="From2023-01-012023-03-31_custom_JubilantHollisterStierMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> AIM:JubilantHollisterStierMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-03-31 </endDate>
</period>
</context>
<context id="AsOf2023-03-31_custom_JubilantHollisterStierMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> AIM:JubilantHollisterStierMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-03-31 </instant>
</period>
</context>
<context id="From2023-01-012023-12-31_custom_JubilantHollisterStierMember_custom_ResearchConsultingAndSupplyAgreementsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis"> AIM:ResearchConsultingAndSupplyAgreementsMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> AIM:JubilantHollisterStierMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-12-31_custom_JubilantHollisterStierMember_custom_ResearchConsultingAndSupplyAgreementsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis"> AIM:ResearchConsultingAndSupplyAgreementsMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> AIM:JubilantHollisterStierMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-12-31 </endDate>
</period>
</context>
<context id="From2023-01-012023-12-31_custom_PharmaSolutionsMember_custom_MasterServiceAgreementAndQualityAgreementMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis"> AIM:MasterServiceAgreementAndQualityAgreementMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> AIM:PharmaSolutionsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="From2022-12-012022-12-31_custom_ErasmusMember_custom_JointClinicalStudyAgreementMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis"> AIM:JointClinicalStudyAgreementMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> AIM:ErasmusMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-12-01 </startDate>
<endDate> 2022-12-31 </endDate>
</period>
</context>
<context id="From2023-01-012023-12-31_custom_ErasmusMember_custom_JjointClinicalStudyAgreementMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis"> AIM:JjointClinicalStudyAgreementMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> AIM:ErasmusMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="AsOf2023-10-31_custom_AzenovaSalesInternationalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> AIM:AzenovaSalesInternationalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-10-31 </instant>
</period>
</context>
<context id="From2023-01-012023-12-31_custom_AzenovaSalesInternationalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> AIM:AzenovaSalesInternationalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="From2023-09-012023-09-30_custom_AlcamiMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> AIM:AlcamiMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-09-01 </startDate>
<endDate> 2023-09-30 </endDate>
</period>
</context>
<context id="From2023-01-012023-12-31_custom_AlcamiMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> AIM:AlcamiMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-12-31_custom_AlcamiMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> AIM:AlcamiMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-12-31 </endDate>
</period>
</context>
<context id="From2023-01-012023-12-31_custom_FourZeroOnekPlanMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis"> AIM:FourZeroOnekPlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="From2023-01-012023-12-31_custom_EmploymentContractualAgreementsMember_custom_NamedExecutiveOfficersMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> AIM:NamedExecutiveOfficersMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis"> AIM:EmploymentContractualAgreementsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-12-31_custom_EmploymentContractualAgreementsMember_custom_NamedExecutiveOfficersMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> AIM:NamedExecutiveOfficersMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis"> AIM:EmploymentContractualAgreementsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-12-31 </endDate>
</period>
</context>
<context id="AsOf2023-12-31_custom_EmploymentContractualAgreementsMember_custom_NamedExecutiveOfficersMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> AIM:NamedExecutiveOfficersMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis"> AIM:EmploymentContractualAgreementsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="AsOf2022-12-31_custom_EmploymentContractualAgreementsMember_custom_NamedExecutiveOfficersMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> AIM:NamedExecutiveOfficersMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis"> AIM:EmploymentContractualAgreementsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_ThomasKEquelsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> AIM:ThomasKEquelsMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> AIM:StockOptionsMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis"> AIM:EmploymentAgreementMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_PeterRodinoMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> AIM:PeterRodinoMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> AIM:StockOptionsMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis"> AIM:EmploymentAgreementMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="From2023-01-012023-12-31_custom_EquelsandRodinoMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> AIM:EquelsandRodinoMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_ThomasKEquelsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> AIM:ThomasKEquelsMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> AIM:StockOptionsMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis"> AIM:EmploymentAgreementMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-12-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_PeterRodinoMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> AIM:PeterRodinoMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> AIM:StockOptionsMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis"> AIM:EmploymentAgreementMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-12-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_PeterRodinoMember_srt_MinimumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> AIM:PeterRodinoMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> AIM:StockOptionsMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis"> AIM:EmploymentAgreementMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-12-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_PeterRodinoMember_srt_MaximumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> AIM:PeterRodinoMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> AIM:StockOptionsMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis"> AIM:EmploymentAgreementMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-12-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_EllenLintalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> AIM:EllenLintalMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> AIM:StockOptionsMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis"> AIM:EmploymentAgreementMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-12-31 </endDate>
</period>
</context>
<context id="From2023-01-012023-12-31_custom_EquelsRodinoAndFormerOfficerLintalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> AIM:EquelsRodinoAndFormerOfficerLintalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="From2023-01-012023-12-31_srt_MinimumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="From2023-01-012023-12-31_srt_MaximumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis"> us-gaap:ResearchAndDevelopmentExpenseMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis"> us-gaap:ResearchAndDevelopmentExpenseMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-12-31 </endDate>
</period>
</context>
<context id="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis"> us-gaap:GeneralAndAdministrativeExpenseMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis"> us-gaap:GeneralAndAdministrativeExpenseMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-12-31 </endDate>
</period>
</context>
<context id="AsOf2023-12-31_us-gaap_DomesticCountryMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis"> us-gaap:DomesticCountryMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="AsOf2023-12-31_us-gaap_NewJerseyDivisionOfTaxationMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis"> us-gaap:NewJerseyDivisionOfTaxationMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis"> us-gaap:StateAndLocalJurisdictionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="AsOf2023-12-31_country_BE">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis"> country:BE </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="AsOf2023-12-31_stpr_NJ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis"> stpr:NJ </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="From2023-01-012023-12-31_stpr_NJ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis"> stpr:NJ </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-12-31_stpr_NJ">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis"> stpr:NJ </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-12-31 </endDate>
</period>
</context>
<context id="AsOf2022-12-31_srt_RestatementAdjustmentMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RestatementAxis"> srt:RestatementAdjustmentMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis"> us-gaap:FairValueInputsLevel1Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis"> us-gaap:FairValueInputsLevel2Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis"> us-gaap:FairValueInputsLevel3Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis"> us-gaap:FairValueInputsLevel1Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis"> us-gaap:FairValueInputsLevel2Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis"> us-gaap:FairValueInputsLevel3Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="AsOf2023-12-31_custom_MarchTwoThousandNineteenWarrantsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> AIM:MarchTwoThousandNineteenWarrantsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="AsOf2022-12-31_custom_MarchTwoThousandNineteenWarrantsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> AIM:MarchTwoThousandNineteenWarrantsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="AsOf2023-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputExercisePriceMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> AIM:MarchTwoThousandNineteenWarrantsMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis"> us-gaap:MeasurementInputExercisePriceMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="AsOf2022-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputExercisePriceMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> AIM:MarchTwoThousandNineteenWarrantsMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis"> us-gaap:MeasurementInputExercisePriceMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="AsOf2023-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> AIM:MarchTwoThousandNineteenWarrantsMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis"> us-gaap:MeasurementInputRiskFreeInterestRateMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="AsOf2022-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> AIM:MarchTwoThousandNineteenWarrantsMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis"> us-gaap:MeasurementInputRiskFreeInterestRateMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="AsOf2023-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputExpectedTermMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> AIM:MarchTwoThousandNineteenWarrantsMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis"> us-gaap:MeasurementInputExpectedTermMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="AsOf2022-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputExpectedTermMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> AIM:MarchTwoThousandNineteenWarrantsMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis"> us-gaap:MeasurementInputExpectedTermMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="AsOf2023-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> AIM:MarchTwoThousandNineteenWarrantsMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis"> us-gaap:MeasurementInputPriceVolatilityMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="AsOf2022-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> AIM:MarchTwoThousandNineteenWarrantsMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis"> us-gaap:MeasurementInputPriceVolatilityMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="AsOf2023-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> AIM:MarchTwoThousandNineteenWarrantsMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis"> us-gaap:MeasurementInputExpectedDividendRateMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-12-31 </instant>
</period>
</context>
<context id="AsOf2022-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> AIM:MarchTwoThousandNineteenWarrantsMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis"> us-gaap:MeasurementInputExpectedDividendRateMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis"> us-gaap:MeasurementInputExpectedDividendRateMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-12-31_us-gaap_WarrantMember289848921">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-12-31 </endDate>
</period>
</context>
<context id="From2023-01-012023-12-31_srt_WeightedAverageMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:WeightedAverageMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-12-31 </endDate>
</period>
</context>
<context id="From2024-02-162024-02-16_us-gaap_SubsequentEventMember_custom_UnsecuredPromissoryNoteMember_us-gaap_NonrelatedPartyMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="AIM:DebtIstrumentAxis"> AIM:UnsecuredPromissoryNoteMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> us-gaap:NonrelatedPartyMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2024-02-16 </startDate>
<endDate> 2024-02-16 </endDate>
</period>
</context>
<context id="From2024-03-282024-03-28_us-gaap_SubsequentEventMember_us-gaap_NonrelatedPartyMember_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> us-gaap:NonrelatedPartyMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2024-03-28 </startDate>
<endDate> 2024-03-28 </endDate>
</period>
</context>
<context id="From2024-03-012024-03-31_us-gaap_SubsequentEventMember_custom_EmployeesPurchasePlanMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> AIM:EmployeesPurchasePlanMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2024-03-01 </startDate>
<endDate> 2024-03-31 </endDate>
</period>
</context>
<context id="From2024-03-012024-03-31_us-gaap_SubsequentEventMember_custom_DirectorsPurchasePlanMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> AIM:DirectorsPurchasePlanMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2024-03-01 </startDate>
<endDate> 2024-03-31 </endDate>
</period>
</context>
<context id="AsOf2024-03-31_us-gaap_SubsequentEventMember_custom_EmployeesPurchasePlanMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> AIM:EmployeesPurchasePlanMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2024-03-31 </instant>
</period>
</context>
<context id="AsOf2024-03-31_us-gaap_SubsequentEventMember_custom_DirectorsPurchasePlanMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0000946644 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> AIM:DirectorsPurchasePlanMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2024-03-31 </instant>
</period>
</context>
<unit id="USD">
<measure> iso4217:USD </measure>
</unit>
<unit id="Shares">
<measure> shares </measure>
</unit>
<unit id="USDPShares">
<divide>
<unitNumerator>
<measure> iso4217:USD </measure>
</unitNumerator>
<unitDenominator>
<measure> shares </measure>
</unitDenominator>
</divide>
</unit>
<unit id="Integer">
<measure> AIM:Integer </measure>
</unit>
<unit id="Pure">
<measure> pure </measure>
</unit>
<dei:AmendmentFlag contextRef="From2023-01-01to2023-12-31" id="Fact000003"> false </dei:AmendmentFlag>
<dei:DocumentFiscalPeriodFocus contextRef="From2023-01-01to2023-12-31" id="Fact000004"> FY </dei:DocumentFiscalPeriodFocus>
<dei:EntityCentralIndexKey contextRef="From2023-01-01to2023-12-31" id="Fact000005"> 0000946644 </dei:EntityCentralIndexKey>
<us-gaap:CommitmentsAndContingencies contextRef="AsOf2023-12-31" id="xdx2ixbrl0111" unitRef="USD" xsi:nil="true"/>
<us-gaap:CommitmentsAndContingencies contextRef="AsOf2022-12-31" id="xdx2ixbrl0112" unitRef="USD" xsi:nil="true"/>
<us-gaap:PreferredStockValue contextRef="AsOf2023-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember" id="xdx2ixbrl0117" unitRef="USD" xsi:nil="true"/>
<us-gaap:PreferredStockValue contextRef="AsOf2022-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember" id="xdx2ixbrl0118" unitRef="USD" xsi:nil="true"/>
<us-gaap:PreferredStockSharesIssued contextRef="AsOf2023-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember" id="xdx2ixbrl0128" unitRef="Shares" xsi:nil="true"/>
<us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2023-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember" id="xdx2ixbrl0130" unitRef="Shares" xsi:nil="true"/>
<us-gaap:PreferredStockSharesIssued contextRef="AsOf2022-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember" id="xdx2ixbrl0132" unitRef="Shares" xsi:nil="true"/>
<us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2022-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember" id="xdx2ixbrl0134" unitRef="Shares" xsi:nil="true"/>
<us-gaap:ManufacturingCosts contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0206" unitRef="USD" xsi:nil="true"/>
<us-gaap:FairValueAdjustmentOfWarrants contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0229" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockholdersEquity contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0257" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0263" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0266" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0267" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0272" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0273" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0275" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0276" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0280" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0282" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0283" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0284" unitRef="USD" xsi:nil="true"/>
<us-gaap:ComprehensiveIncomeNetOfTax contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0288" unitRef="USD" xsi:nil="true"/>
<us-gaap:ComprehensiveIncomeNetOfTax contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0289" unitRef="USD" xsi:nil="true"/>
<us-gaap:ComprehensiveIncomeNetOfTax contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0290" unitRef="USD" xsi:nil="true"/>
<us-gaap:ComprehensiveIncomeNetOfTax contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0291" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockholdersEquity contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0298" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockholdersEquity contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0307" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockholdersEquity contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0316" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0322" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0323" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0325" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0326" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0331" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0332" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0334" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0335" unitRef="USD" xsi:nil="true"/>
<AIM:CashlessWarrantConversion contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0338" unitRef="USD" xsi:nil="true"/>
<AIM:CashlessWarrantConversion contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0339" unitRef="USD" xsi:nil="true"/>
<AIM:CashlessWarrantConversion contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0340" unitRef="USD" xsi:nil="true"/>
<AIM:CashlessWarrantConversion contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0341" unitRef="USD" xsi:nil="true"/>
<AIM:CashlessWarrantConversion contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0342" unitRef="USD" xsi:nil="true"/>
<AIM:CashlessWarrantConversion contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0343" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0348" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0350" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0351" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0352" unitRef="USD" xsi:nil="true"/>
<us-gaap:ComprehensiveIncomeNetOfTax contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0356" unitRef="USD" xsi:nil="true"/>
<us-gaap:ComprehensiveIncomeNetOfTax contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0357" unitRef="USD" xsi:nil="true"/>
<us-gaap:ComprehensiveIncomeNetOfTax contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0358" unitRef="USD" xsi:nil="true"/>
<us-gaap:ComprehensiveIncomeNetOfTax contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0359" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockholdersEquity contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0366" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockholdersEquity contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0375" unitRef="USD" xsi:nil="true"/>
<us-gaap:FairValueAdjustmentOfWarrants contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0393" unitRef="USD" xsi:nil="true"/>
<us-gaap:GainLossOnDispositionOfAssets1 contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0397" unitRef="USD" xsi:nil="true"/>
<AIM:AbandonmentOfPatentAndTrademarkRights contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0400" unitRef="USD" xsi:nil="true"/>
<AIM:LossGainFromSaleOfIncomeTaxOperatingLosses contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0408" unitRef="USD" xsi:nil="true"/>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0450" unitRef="USD" xsi:nil="true"/>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="AsOf2023-12-31_srt_MinimumMember" id="xdx2ixbrl0515"> P3Y </us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0817" unitRef="Pure" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0819" unitRef="Pure" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2009Member" id="xdx2ixbrl0853" unitRef="Shares" xsi:nil="true"/>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantedInPeriod contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2009Member" id="xdx2ixbrl0855" unitRef="USDPShares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2009Member" id="xdx2ixbrl0857" unitRef="USDPShares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2009Member" id="xdx2ixbrl0859" unitRef="Shares" xsi:nil="true"/>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantedInPeriod contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2009Member" id="xdx2ixbrl0861" unitRef="USDPShares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2009Member" id="xdx2ixbrl0863" unitRef="USDPShares" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2009Member" id="xdx2ixbrl0881" unitRef="Shares" xsi:nil="true"/>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2009Member" id="xdx2ixbrl0883" unitRef="USDPShares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2009Member" id="xdx2ixbrl0885" unitRef="USDPShares" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2009Member" id="xdx2ixbrl0887" unitRef="Shares" xsi:nil="true"/>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2009Member" id="xdx2ixbrl0889" unitRef="USDPShares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2009Member" id="xdx2ixbrl0891" unitRef="USDPShares" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2018Member" id="xdx2ixbrl0975" unitRef="Shares" xsi:nil="true"/>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2018Member" id="xdx2ixbrl0977" unitRef="USDPShares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2018Member" id="xdx2ixbrl0979" unitRef="USDPShares" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2018Member" id="xdx2ixbrl0981" unitRef="Shares" xsi:nil="true"/>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2018Member" id="xdx2ixbrl0983" unitRef="USDPShares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2018Member" id="xdx2ixbrl0985" unitRef="USDPShares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2021-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1033" unitRef="USD" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1045" unitRef="Shares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1047" unitRef="USDPShares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1055" unitRef="USD" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1077" unitRef="USD" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1085" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1093" unitRef="USD" xsi:nil="true"/>
<AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue contextRef="AsOf2021-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1114" unitRef="USD" xsi:nil="true"/>
<AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue contextRef="AsOf2022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1138" unitRef="USD" xsi:nil="true"/>
<AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1165" unitRef="USD" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2021-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1175" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1183" unitRef="Shares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1185" unitRef="USDPShares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1196" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1203" unitRef="Shares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1205" unitRef="USDPShares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1220" unitRef="USD" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1228" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1236" unitRef="USD" xsi:nil="true"/>
<AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue contextRef="AsOf2021-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1258" unitRef="USD" xsi:nil="true"/>
<AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue contextRef="AsOf2022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1278" unitRef="USD" xsi:nil="true"/>
<AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1305" unitRef="USD" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1333" unitRef="Shares" xsi:nil="true"/>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceGrantsInPeriodGross contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1334" unitRef="USDPShares" xsi:nil="true"/>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstandingGrantsInPeriod contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1336" unitRef="USDPShares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1338" unitRef="Shares" xsi:nil="true"/>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceGrantsInPeriodGross contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1339" unitRef="USDPShares" xsi:nil="true"/>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstandingGrantsInPeriod contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1341" unitRef="USDPShares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1355" unitRef="Shares" xsi:nil="true"/>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1356" unitRef="USDPShares" xsi:nil="true"/>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1358" unitRef="USDPShares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl1406" unitRef="Shares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl1408" unitRef="Shares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1410" unitRef="Shares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1412" unitRef="Shares" xsi:nil="true"/>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_ThomasKEquelsMember" id="xdx2ixbrl1513"> P10Y </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_PeterRodinoMember" id="xdx2ixbrl1520"> P10Y </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_ThomasKEquelsMember" id="xdx2ixbrl1530"> P10Y </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_PeterRodinoMember" id="xdx2ixbrl1537"> P10Y </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_EllenLintalMember" id="xdx2ixbrl1545"> P10Y </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<AIM:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour contextRef="AsOf2023-12-31" id="xdx2ixbrl1627" unitRef="USD" xsi:nil="true"/>
<AIM:IncomeTaxReconciliationNondeductibleStateNetOperatingLoss contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl1717" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncomeTaxExpenseBenefit contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl1745" unitRef="USD" xsi:nil="true"/>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1761" unitRef="USD" xsi:nil="true"/>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl1763" unitRef="USD" xsi:nil="true"/>
<us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1769" unitRef="USD" xsi:nil="true"/>
<us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl1771" unitRef="USD" xsi:nil="true"/>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1777" unitRef="USD" xsi:nil="true"/>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl1779" unitRef="USD" xsi:nil="true"/>
<us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1785" unitRef="USD" xsi:nil="true"/>
<us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl1787" unitRef="USD" xsi:nil="true"/>
<us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="AsOf2023-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="xdx2ixbrl1807" unitRef="Pure" xsi:nil="true"/>
<us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="AsOf2022-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="xdx2ixbrl1808" unitRef="Pure" xsi:nil="true"/>
<us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="AsOf2023-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="xdx2ixbrl1810" unitRef="Pure" xsi:nil="true"/>
<us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="AsOf2022-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="xdx2ixbrl1811" unitRef="Pure" xsi:nil="true"/>
<dei:DocumentType contextRef="From2023-01-01to2023-12-31" id="Fact000012"> 10-K </dei:DocumentType>
<dei:DocumentAnnualReport contextRef="From2023-01-01to2023-12-31" id="Fact000013"> true </dei:DocumentAnnualReport>
<dei:DocumentPeriodEndDate contextRef="From2023-01-01to2023-12-31" id="Fact000014"> 2023-12-31 </dei:DocumentPeriodEndDate>
<dei:CurrentFiscalYearEndDate contextRef="From2023-01-01to2023-12-31" id="Fact000015"> --12-31 </dei:CurrentFiscalYearEndDate>
<dei:DocumentFiscalYearFocus contextRef="From2023-01-01to2023-12-31" id="Fact000016"> 2023 </dei:DocumentFiscalYearFocus>
<dei:DocumentTransitionReport contextRef="From2023-01-01to2023-12-31" id="Fact000017"> false </dei:DocumentTransitionReport>
<dei:EntityFileNumber contextRef="From2023-01-01to2023-12-31" id="Fact000018"> 001-27072 </dei:EntityFileNumber>
<dei:EntityRegistrantName contextRef="From2023-01-01to2023-12-31" id="Fact000019"> AIM IMMUNOTECH INC. </dei:EntityRegistrantName>
<dei:EntityIncorporationStateCountryCode contextRef="From2023-01-01to2023-12-31" id="Fact000020"> DE </dei:EntityIncorporationStateCountryCode>
<dei:EntityTaxIdentificationNumber contextRef="From2023-01-01to2023-12-31" id="Fact000021"> 52-0845822 </dei:EntityTaxIdentificationNumber>
<dei:EntityAddressAddressLine1 contextRef="From2023-01-01to2023-12-31" id="Fact000022"> 2117 SW Highway 484 </dei:EntityAddressAddressLine1>
<dei:EntityAddressCityOrTown contextRef="From2023-01-01to2023-12-31" id="Fact000023"> Ocala </dei:EntityAddressCityOrTown>
<dei:EntityAddressStateOrProvince contextRef="From2023-01-01to2023-12-31" id="Fact000024"> FL </dei:EntityAddressStateOrProvince>
<dei:EntityAddressPostalZipCode contextRef="From2023-01-01to2023-12-31" id="Fact000025"> 34473 </dei:EntityAddressPostalZipCode>
<dei:CityAreaCode contextRef="From2023-01-01to2023-12-31" id="Fact000026"> (352) </dei:CityAreaCode>
<dei:LocalPhoneNumber contextRef="From2023-01-01to2023-12-31" id="Fact000027"> 448-7797 </dei:LocalPhoneNumber>
<dei:Security12bTitle contextRef="From2023-01-01to2023-12-31" id="Fact000028"> Common Stock, par value $0.001 per share </dei:Security12bTitle>
<dei:TradingSymbol contextRef="From2023-01-01to2023-12-31" id="Fact000029"> AIM </dei:TradingSymbol>
<dei:SecurityExchangeName contextRef="From2023-01-01to2023-12-31" id="Fact000030"> NYSEAMER </dei:SecurityExchangeName>
<dei:EntityWellKnownSeasonedIssuer contextRef="From2023-01-01to2023-12-31" id="Fact000031"> Yes </dei:EntityWellKnownSeasonedIssuer>
<dei:EntityVoluntaryFilers contextRef="From2023-01-01to2023-12-31" id="Fact000032"> No </dei:EntityVoluntaryFilers>
<dei:EntityCurrentReportingStatus contextRef="From2023-01-01to2023-12-31" id="Fact000033"> Yes </dei:EntityCurrentReportingStatus>
<dei:EntityInteractiveDataCurrent contextRef="From2023-01-01to2023-12-31" id="Fact000034"> Yes </dei:EntityInteractiveDataCurrent>
<dei:EntityFilerCategory contextRef="From2023-01-01to2023-12-31" id="Fact000035"> Non-accelerated Filer </dei:EntityFilerCategory>
<dei:EntitySmallBusiness contextRef="From2023-01-01to2023-12-31" id="Fact000036"> true </dei:EntitySmallBusiness>
<dei:EntityEmergingGrowthCompany contextRef="From2023-01-01to2023-12-31" id="Fact000037"> false </dei:EntityEmergingGrowthCompany>
<dei:IcfrAuditorAttestationFlag contextRef="From2023-01-01to2023-12-31" id="Fact000038"> false </dei:IcfrAuditorAttestationFlag>
<dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2023-01-01to2023-12-31" id="Fact000039"> false </dei:DocumentFinStmtErrorCorrectionFlag>
<dei:EntityShellCompany contextRef="From2023-01-01to2023-12-31" id="Fact000040"> false </dei:EntityShellCompany>
<dei:EntityPublicFloat contextRef="AsOf2023-06-30" decimals="0" id="Fact000041" unitRef="USD"> 31829482 </dei:EntityPublicFloat>
<dei:EntityCommonStockSharesOutstanding contextRef="AsOf2024-03-27" decimals="INF" id="Fact000042" unitRef="Shares"> 49901177 </dei:EntityCommonStockSharesOutstanding>
<dei:DocumentsIncorporatedByReferenceTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000043"> None </dei:DocumentsIncorporatedByReferenceTextBlock>
<dei:AuditorFirmId contextRef="From2023-01-01to2023-12-31" id="Fact000044"> 243 </dei:AuditorFirmId>
<dei:AuditorName contextRef="From2023-01-01to2023-12-31" id="Fact000045"> BDO USA, P.C. </dei:AuditorName>
<dei:AuditorLocation contextRef="From2023-01-01to2023-12-31" id="Fact000046"> Miami, Florida </dei:AuditorLocation>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2023-12-31" decimals="-3" id="Fact000054" unitRef="USD"> 5439000 </us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-12-31" decimals="-3" id="Fact000055" unitRef="USD"> 27053000 </us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2023-12-31" decimals="-3" id="Fact000057" unitRef="USD"> 7631000 </us-gaap:MarketableSecuritiesCurrent>
<us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2022-12-31" decimals="-3" id="Fact000058" unitRef="USD"> 7137000 </us-gaap:MarketableSecuritiesCurrent>
<us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2023-12-31" decimals="-3" id="Fact000060" unitRef="USD"> 1184000 </us-gaap:AccountsReceivableNetCurrent>
<us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2022-12-31" decimals="-3" id="Fact000061" unitRef="USD"> 1676000 </us-gaap:AccountsReceivableNetCurrent>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2023-12-31" decimals="-3" id="Fact000063" unitRef="USD"> 302000 </us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-12-31" decimals="-3" id="Fact000064" unitRef="USD"> 455000 </us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:AssetsCurrent contextRef="AsOf2023-12-31" decimals="-3" id="Fact000066" unitRef="USD"> 14556000 </us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent contextRef="AsOf2022-12-31" decimals="-3" id="Fact000067" unitRef="USD"> 36321000 </us-gaap:AssetsCurrent>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2023-12-31" decimals="-3" id="Fact000069" unitRef="USD"> 127000 </us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-12-31" decimals="-3" id="Fact000070" unitRef="USD"> 195000 </us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2023-12-31" decimals="-3" id="Fact000072" unitRef="USD"> 697000 </us-gaap:OperatingLeaseRightOfUseAsset>
<us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-12-31" decimals="-3" id="Fact000073" unitRef="USD"> 829000 </us-gaap:OperatingLeaseRightOfUseAsset>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2023-12-31" decimals="-3" id="Fact000075" unitRef="USD"> 2313000 </us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2022-12-31" decimals="-3" id="Fact000076" unitRef="USD"> 1941000 </us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:OtherAssetsNoncurrent contextRef="AsOf2023-12-31" decimals="-3" id="Fact000078" unitRef="USD"> 1688000 </us-gaap:OtherAssetsNoncurrent>
<us-gaap:OtherAssetsNoncurrent contextRef="AsOf2022-12-31" decimals="-3" id="Fact000079" unitRef="USD"> 1202000 </us-gaap:OtherAssetsNoncurrent>
<us-gaap:Assets contextRef="AsOf2023-12-31" decimals="-3" id="Fact000081" unitRef="USD"> 19381000 </us-gaap:Assets>
<us-gaap:Assets contextRef="AsOf2022-12-31" decimals="-3" id="Fact000082" unitRef="USD"> 40488000 </us-gaap:Assets>
<us-gaap:AccountsPayableCurrent contextRef="AsOf2023-12-31" decimals="-3" id="Fact000090" unitRef="USD"> 6443000 </us-gaap:AccountsPayableCurrent>
<us-gaap:AccountsPayableCurrent contextRef="AsOf2022-12-31" decimals="-3" id="Fact000091" unitRef="USD"> 377000 </us-gaap:AccountsPayableCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2023-12-31" decimals="-3" id="Fact000093" unitRef="USD"> 1986000 </us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="-3" id="Fact000094" unitRef="USD"> 806000 </us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2023-12-31" decimals="-3" id="Fact000096" unitRef="USD"> 223000 </us-gaap:OperatingLeaseLiabilityCurrent>
<us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2022-12-31" decimals="-3" id="Fact000097" unitRef="USD"> 178000 </us-gaap:OperatingLeaseLiabilityCurrent>
<us-gaap:LiabilitiesCurrent contextRef="AsOf2023-12-31" decimals="-3" id="Fact000099" unitRef="USD"> 8652000 </us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="-3" id="Fact000100" unitRef="USD"> 1361000 </us-gaap:LiabilitiesCurrent>
<us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2023-12-31" decimals="-3" id="Fact000105" unitRef="USD"> 495000 </us-gaap:OperatingLeaseLiabilityNoncurrent>
<us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2022-12-31" decimals="-3" id="Fact000106" unitRef="USD"> 659000 </us-gaap:OperatingLeaseLiabilityNoncurrent>
<us-gaap:Liabilities contextRef="AsOf2023-12-31" decimals="-3" id="Fact000108" unitRef="USD"> 9147000 </us-gaap:Liabilities>
<us-gaap:Liabilities contextRef="AsOf2022-12-31" decimals="-3" id="Fact000109" unitRef="USD"> 2020000 </us-gaap:Liabilities>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2023-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember" decimals="INF" id="Fact000120" unitRef="USDPShares"> 0.001 </us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2022-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember" decimals="INF" id="Fact000122" unitRef="USDPShares"> 0.001 </us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2023-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember" decimals="INF" id="Fact000124" unitRef="Shares"> 4000000 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember" decimals="INF" id="Fact000126" unitRef="Shares"> 250000 </us-gaap:PreferredStockSharesAuthorized>
<AIM:PreferredStockStatedValuePerShare contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember" decimals="INF" id="Fact000139" unitRef="USDPShares"> 1000 </AIM:PreferredStockStatedValuePerShare>
<AIM:PreferredStockStatedValuePerShare contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember" decimals="INF" id="Fact000141" unitRef="USDPShares"> 1000 </AIM:PreferredStockStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember" decimals="INF" id="Fact000143" unitRef="Shares"> 10000 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember" decimals="INF" id="Fact000145" unitRef="Shares"> 10000 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesIssued contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember" decimals="INF" id="Fact000147" unitRef="Shares"> 689 </us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember" decimals="INF" id="Fact000149" unitRef="Shares"> 689 </us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockSharesIssued contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember" decimals="INF" id="Fact000151" unitRef="Shares"> 696 </us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember" decimals="INF" id="Fact000153" unitRef="Shares"> 696 </us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockValue contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember" decimals="-3" id="Fact000136" unitRef="USD"> 689000 </us-gaap:PreferredStockValue>
<us-gaap:PreferredStockValue contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember" decimals="-3" id="Fact000137" unitRef="USD"> 696000 </us-gaap:PreferredStockValue>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2023-12-31" decimals="INF" id="Fact000161" unitRef="USDPShares"> 0.001 </us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2022-12-31" decimals="INF" id="Fact000163" unitRef="USDPShares"> 0.001 </us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized contextRef="AsOf2023-12-31" decimals="INF" id="Fact000165" unitRef="Shares"> 350000000 </us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" id="Fact000167" unitRef="Shares"> 350000000 </us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued contextRef="AsOf2023-12-31" decimals="INF" id="Fact000169" unitRef="Shares"> 49102484 </us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="AsOf2023-12-31" decimals="INF" id="Fact000171" unitRef="Shares"> 49102484 </us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesIssued contextRef="AsOf2022-12-31" decimals="INF" id="Fact000173" unitRef="Shares"> 48084287 </us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="INF" id="Fact000175" unitRef="Shares"> 48084287 </us-gaap:CommonStockSharesOutstanding>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="AsOf2023-12-31" decimals="INF" id="Fact000177" unitRef="Shares"> 701667 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="AsOf2022-12-31" decimals="INF" id="Fact000179" unitRef="Shares"> 694324 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
<us-gaap:CommonStockValue contextRef="AsOf2023-12-31" decimals="-3" id="Fact000158" unitRef="USD"> 49000 </us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="AsOf2022-12-31" decimals="-3" id="Fact000159" unitRef="USD"> 48000 </us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapital contextRef="AsOf2023-12-31" decimals="-3" id="Fact000181" unitRef="USD"> 419004000 </us-gaap:AdditionalPaidInCapital>
<us-gaap:AdditionalPaidInCapital contextRef="AsOf2022-12-31" decimals="-3" id="Fact000182" unitRef="USD"> 418270000 </us-gaap:AdditionalPaidInCapital>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2023-12-31" decimals="-3" id="Fact000184" unitRef="USD"> -409508000 </us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-12-31" decimals="-3" id="Fact000185" unitRef="USD"> -380546000 </us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:StockholdersEquity contextRef="AsOf2023-12-31" decimals="-3" id="Fact000187" unitRef="USD"> 10234000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="-3" id="Fact000188" unitRef="USD"> 38468000 </us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2023-12-31" decimals="-3" id="Fact000190" unitRef="USD"> 19381000 </us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-12-31" decimals="-3" id="Fact000191" unitRef="USD"> 40488000 </us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000196" unitRef="USD"> 202000 </us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="From2022-01-012022-12-31" decimals="-3" id="Fact000197" unitRef="USD"> 141000 </us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:Revenues contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000199" unitRef="USD"> 202000 </us-gaap:Revenues>
<us-gaap:Revenues contextRef="From2022-01-012022-12-31" decimals="-3" id="Fact000200" unitRef="USD"> 141000 </us-gaap:Revenues>
<us-gaap:ManufacturingCosts contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000205" unitRef="USD"> 42000 </us-gaap:ManufacturingCosts>
<us-gaap:ResearchAndDevelopmentExpense contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000208" unitRef="USD"> 10939000 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="From2022-01-012022-12-31" decimals="-3" id="Fact000209" unitRef="USD"> 6990000 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000211" unitRef="USD"> 21137000 </us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="From2022-01-012022-12-31" decimals="-3" id="Fact000212" unitRef="USD"> 13074000 </us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:CostsAndExpenses contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000214" unitRef="USD"> 32118000 </us-gaap:CostsAndExpenses>
<us-gaap:CostsAndExpenses contextRef="From2022-01-012022-12-31" decimals="-3" id="Fact000215" unitRef="USD"> 20064000 </us-gaap:CostsAndExpenses>
<us-gaap:OperatingIncomeLoss contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000217" unitRef="USD"> -31916000 </us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="From2022-01-012022-12-31" decimals="-3" id="Fact000218" unitRef="USD"> -19923000 </us-gaap:OperatingIncomeLoss>
<us-gaap:GainLossOnInvestments contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000220" unitRef="USD"> 200000 </us-gaap:GainLossOnInvestments>
<us-gaap:GainLossOnInvestments contextRef="From2022-01-012022-12-31" decimals="-3" id="Fact000221" unitRef="USD"> -1679000 </us-gaap:GainLossOnInvestments>
<us-gaap:OtherNonoperatingIncomeExpense contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000223" unitRef="USD"> 1069000 </us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:OtherNonoperatingIncomeExpense contextRef="From2022-01-012022-12-31" decimals="-3" id="Fact000224" unitRef="USD"> 629000 </us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000226" unitRef="USD"> 18000 </us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
<us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="From2022-01-012022-12-31" decimals="-3" id="Fact000227" unitRef="USD"> 3000 </us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
<us-gaap:FairValueAdjustmentOfWarrants contextRef="From2022-01-012022-12-31" decimals="-3" id="Fact000230" unitRef="USD"> -35000 </us-gaap:FairValueAdjustmentOfWarrants>
<AIM:GainFromSaleOfIncomeTaxOperatingLoss contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000232" unitRef="USD"> -1667000 </AIM:GainFromSaleOfIncomeTaxOperatingLoss>
<AIM:GainFromSaleOfIncomeTaxOperatingLoss contextRef="From2022-01-012022-12-31" decimals="-3" id="Fact000233" unitRef="USD"> -1490000 </AIM:GainFromSaleOfIncomeTaxOperatingLoss>
<us-gaap:NetIncomeLoss contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000235" unitRef="USD"> -28962000 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="From2022-01-012022-12-31" decimals="-3" id="Fact000236" unitRef="USD"> -19445000 </us-gaap:NetIncomeLoss>
<us-gaap:EarningsPerShareBasic contextRef="From2023-01-01to2023-12-31" decimals="INF" id="Fact000238" unitRef="USDPShares"> -0.60 </us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareDiluted contextRef="From2023-01-01to2023-12-31" decimals="INF" id="Fact000240" unitRef="USDPShares"> -0.60 </us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareBasic contextRef="From2022-01-012022-12-31" decimals="INF" id="Fact000242" unitRef="USDPShares"> -0.40 </us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareDiluted contextRef="From2022-01-012022-12-31" decimals="INF" id="Fact000244" unitRef="USDPShares"> -0.40 </us-gaap:EarningsPerShareDiluted>
<us-gaap:WeightedAverageNumberOfSharesIssuedBasic contextRef="From2023-01-01to2023-12-31" decimals="INF" id="Fact000246" unitRef="Shares"> 48585404 </us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2023-01-01to2023-12-31" decimals="INF" id="Fact000248" unitRef="Shares"> 48585404 </us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfSharesIssuedBasic contextRef="From2022-01-012022-12-31" decimals="INF" id="Fact000250" unitRef="Shares"> 48047288 </us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2022-01-012022-12-31" decimals="INF" id="Fact000252" unitRef="Shares"> 48047288 </us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember" decimals="-3" id="Fact000254" unitRef="USD"> 696000 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" decimals="INF" id="Fact000261" unitRef="Shares"> 48084287 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" decimals="-3" id="Fact000255" unitRef="USD"> 48000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact000256" unitRef="USD"> 418270000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact000258" unitRef="USD"> -380546000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="-3" id="Fact000259" unitRef="USD"> 38468000 </us-gaap:StockholdersEquity>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" decimals="INF" id="Fact000270" unitRef="Shares"> 1017399 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" decimals="-3" id="Fact000264" unitRef="USD"> 1000 </us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact000265" unitRef="USD"> 484000 </us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000268" unitRef="USD"> 485000 </us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact000274" unitRef="USD"> 243000 </us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000277" unitRef="USD"> 243000 </us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember" decimals="-3" id="Fact000279" unitRef="USD"> -7000 </us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" decimals="INF" id="Fact000286" unitRef="Shares"> 798 </us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact000281" unitRef="USD"> 7000 </us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
<us-gaap:ComprehensiveIncomeNetOfTax contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact000292" unitRef="USD"> -28962000 </us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:ComprehensiveIncomeNetOfTax contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000293" unitRef="USD"> -28962000 </us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:StockholdersEquity contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember" decimals="-3" id="Fact000295" unitRef="USD"> 689000 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" decimals="INF" id="Fact000302" unitRef="Shares"> 49102484 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" decimals="-3" id="Fact000296" unitRef="USD"> 49000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact000297" unitRef="USD"> 419004000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact000299" unitRef="USD"> -409508000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2023-12-31" decimals="-3" id="Fact000300" unitRef="USD"> 10234000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2021-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember" decimals="-3" id="Fact000304" unitRef="USD"> 715000 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" decimals="INF" id="Fact000311" unitRef="Shares"> 47994672 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" decimals="-3" id="Fact000305" unitRef="USD"> 48000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact000306" unitRef="USD"> 417217000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact000308" unitRef="USD"> -361101000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="-3" id="Fact000309" unitRef="USD"> 56879000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2021-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember" decimals="-3" id="Fact000313" unitRef="USD"> 715000 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" decimals="INF" id="Fact000320" unitRef="Shares"> 47994672 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" decimals="-3" id="Fact000314" unitRef="USD"> 48000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact000315" unitRef="USD"> 417217000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact000317" unitRef="USD"> -361101000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="-3" id="Fact000318" unitRef="USD"> 56879000 </us-gaap:StockholdersEquity>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" decimals="INF" id="Fact000329" unitRef="Shares"> 88749 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact000324" unitRef="USD"> 80000 </us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2022-01-012022-12-31" decimals="-3" id="Fact000327" unitRef="USD"> 80000 </us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact000333" unitRef="USD"> 954000 </us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2022-01-012022-12-31" decimals="-3" id="Fact000336" unitRef="USD"> 954000 </us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<AIM:CashlessWarrantConversionShares contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" decimals="INF" id="Fact000345" unitRef="Shares"> 638 </AIM:CashlessWarrantConversionShares>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember" decimals="-3" id="Fact000347" unitRef="USD"> -19000 </us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" decimals="INF" id="Fact000354" unitRef="Shares"> 228 </us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact000349" unitRef="USD"> 19000 </us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
<us-gaap:ComprehensiveIncomeNetOfTax contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact000360" unitRef="USD"> -19445000 </us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:ComprehensiveIncomeNetOfTax contextRef="From2022-01-012022-12-31" decimals="-3" id="Fact000361" unitRef="USD"> -19445000 </us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:StockholdersEquity contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember" decimals="-3" id="Fact000363" unitRef="USD"> 696000 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" decimals="INF" id="Fact000370" unitRef="Shares"> 48084287 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" decimals="-3" id="Fact000364" unitRef="USD"> 48000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact000365" unitRef="USD"> 418270000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact000367" unitRef="USD"> -380546000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="-3" id="Fact000368" unitRef="USD"> 38468000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember" decimals="-3" id="Fact000372" unitRef="USD"> 696000 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" decimals="INF" id="Fact000379" unitRef="Shares"> 48084287 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" decimals="-3" id="Fact000373" unitRef="USD"> 48000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact000374" unitRef="USD"> 418270000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact000376" unitRef="USD"> -380546000 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="-3" id="Fact000377" unitRef="USD"> 38468000 </us-gaap:StockholdersEquity>
<us-gaap:NetIncomeLoss contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000384" unitRef="USD"> -28962000 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="From2022-01-012022-12-31" decimals="-3" id="Fact000385" unitRef="USD"> -19445000 </us-gaap:NetIncomeLoss>
<us-gaap:Depreciation contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000390" unitRef="USD"> 39000 </us-gaap:Depreciation>
<us-gaap:Depreciation contextRef="From2022-01-012022-12-31" decimals="-3" id="Fact000391" unitRef="USD"> 38000 </us-gaap:Depreciation>
<us-gaap:FairValueAdjustmentOfWarrants contextRef="From2022-01-012022-12-31" decimals="-3" id="Fact000394" unitRef="USD"> -35000 </us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:GainLossOnDispositionOfAssets1 contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000396" unitRef="USD"> 18000 </us-gaap:GainLossOnDispositionOfAssets1>
<AIM:AbandonmentOfPatentAndTrademarkRights contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000399" unitRef="USD"> 14000 </AIM:AbandonmentOfPatentAndTrademarkRights>
<us-gaap:AmortizationOfIntangibleAssets contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000402" unitRef="USD"> 199000 </us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:AmortizationOfIntangibleAssets contextRef="From2022-01-012022-12-31" decimals="-3" id="Fact000403" unitRef="USD"> 218000 </us-gaap:AmortizationOfIntangibleAssets>
<AIM:NoncashLeaseExpense contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000405" unitRef="USD"> 287000 </AIM:NoncashLeaseExpense>
<AIM:NoncashLeaseExpense contextRef="From2022-01-012022-12-31" decimals="-3" id="Fact000406" unitRef="USD"> -680000 </AIM:NoncashLeaseExpense>
<AIM:LossGainFromSaleOfIncomeTaxOperatingLosses contextRef="From2022-01-012022-12-31" decimals="-3" id="Fact000409" unitRef="USD"> -197000 </AIM:LossGainFromSaleOfIncomeTaxOperatingLosses>
<us-gaap:ShareBasedCompensation contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000411" unitRef="USD"> 243000 </us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="From2022-01-012022-12-31" decimals="-3" id="Fact000412" unitRef="USD"> 954000 </us-gaap:ShareBasedCompensation>
<us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000414" unitRef="USD"> 200000 </us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments>
<us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments contextRef="From2022-01-012022-12-31" decimals="-3" id="Fact000415" unitRef="USD"> -1679000 </us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments>
<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000420" unitRef="USD"> -492000 </us-gaap:IncreaseDecreaseInAccountsReceivable>
<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2022-01-012022-12-31" decimals="-3" id="Fact000421" unitRef="USD"> 35000 </us-gaap:IncreaseDecreaseInAccountsReceivable>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000423" unitRef="USD"> -153000 </us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2022-01-012022-12-31" decimals="-3" id="Fact000424" unitRef="USD"> 151000 </us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000426" unitRef="USD"> -274000 </us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
<us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="From2022-01-012022-12-31" decimals="-3" id="Fact000427" unitRef="USD"> 688000 </us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
<us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000429" unitRef="USD"> 486000 </us-gaap:IncreaseDecreaseInOtherOperatingAssets>
<us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="From2022-01-012022-12-31" decimals="-3" id="Fact000430" unitRef="USD"> 83000 </us-gaap:IncreaseDecreaseInOtherOperatingAssets>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000432" unitRef="USD"> 6066000 </us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2022-01-012022-12-31" decimals="-3" id="Fact000433" unitRef="USD"> 179000 </us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000435" unitRef="USD"> 1180000 </us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="From2022-01-012022-12-31" decimals="-3" id="Fact000436" unitRef="USD"> 368000 </us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000438" unitRef="USD"> -21267000 </us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2022-01-012022-12-31" decimals="-3" id="Fact000439" unitRef="USD"> -16108000 </us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:ProceedsFromSaleOfInvestmentProjects contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000444" unitRef="USD"> 1299000 </us-gaap:ProceedsFromSaleOfInvestmentProjects>
<us-gaap:ProceedsFromSaleOfInvestmentProjects contextRef="From2022-01-012022-12-31" decimals="-3" id="Fact000445" unitRef="USD"> 10083000 </us-gaap:ProceedsFromSaleOfInvestmentProjects>
<us-gaap:PaymentsToAcquireInvestments contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000447" unitRef="USD"> 1593000 </us-gaap:PaymentsToAcquireInvestments>
<us-gaap:PaymentsToAcquireInvestments contextRef="From2022-01-012022-12-31" decimals="-3" id="Fact000448" unitRef="USD"> 2724000 </us-gaap:PaymentsToAcquireInvestments>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2022-01-012022-12-31" decimals="-3" id="Fact000451" unitRef="USD"> 86000 </us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000453" unitRef="USD"> 47000 </us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="From2022-01-012022-12-31" decimals="-3" id="Fact000454" unitRef="USD"> 3900000 </us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000456" unitRef="USD"> 585000 </us-gaap:PaymentsToAcquireIntangibleAssets>
<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="From2022-01-012022-12-31" decimals="-3" id="Fact000457" unitRef="USD"> 185000 </us-gaap:PaymentsToAcquireIntangibleAssets>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000459" unitRef="USD"> -832000 </us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2022-01-012022-12-31" decimals="-3" id="Fact000460" unitRef="USD"> 10988000 </us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000465" unitRef="USD"> 485000 </us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="From2022-01-012022-12-31" decimals="-3" id="Fact000466" unitRef="USD"> 80000 </us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000468" unitRef="USD"> 485000 </us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2022-01-012022-12-31" decimals="-3" id="Fact000469" unitRef="USD"> 80000 </us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000471" unitRef="USD"> -21614000 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="From2022-01-012022-12-31" decimals="-3" id="Fact000472" unitRef="USD"> -5040000 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2022-12-31" decimals="-3" id="Fact000474" unitRef="USD"> 27053000 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-12-31" decimals="-3" id="Fact000475" unitRef="USD"> 32093000 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2023-12-31" decimals="-3" id="Fact000477" unitRef="USD"> 5439000 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2022-12-31" decimals="-3" id="Fact000478" unitRef="USD"> 27053000 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
<AIM:UnrealizedGainLossOnMarketableInvestments contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000483" unitRef="USD"> 376000 </AIM:UnrealizedGainLossOnMarketableInvestments>
<AIM:UnrealizedGainLossOnMarketableInvestments contextRef="From2022-01-012022-12-31" decimals="-3" id="Fact000484" unitRef="USD"> -928000 </AIM:UnrealizedGainLossOnMarketableInvestments>
<AIM:ConversionOfSeriesBPreferred contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000486" unitRef="USD"> 7000 </AIM:ConversionOfSeriesBPreferred>
<AIM:ConversionOfSeriesBPreferred contextRef="From2022-01-012022-12-31" decimals="-3" id="Fact000487" unitRef="USD"> 19000 </AIM:ConversionOfSeriesBPreferred>
<AIM:OperatingLeaseLiabilityArisingFromObtainingRightOfUseAsset contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000489" unitRef="USD"> 73000 </AIM:OperatingLeaseLiabilityArisingFromObtainingRightOfUseAsset>
<AIM:OperatingLeaseLiabilityArisingFromObtainingRightOfUseAsset contextRef="From2022-01-012022-12-31" decimals="-3" id="Fact000490" unitRef="USD"> 736000 </AIM:OperatingLeaseLiabilityArisingFromObtainingRightOfUseAsset>
<us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000492">
<p id="xdx_804_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zYoXxHAglyRj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(1) <span id="xdx_82D_zOYCi5rn3MF3">Description of Business </span></b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and Basis of Presentation</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Business</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A<span style="color: Black">IM ImmunoTech Inc. and its subsidiaries (collectively, “AIM”, “Company”, “we” or “us”) are an immuno-pharma company headquartered in Ocala, Florida, and focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases and immune-deficiency disorders. We have established a strong foundation of laboratory, pre-clinical and clinical data with respect to the development of nucleic acids and natural interferon to enhance the natural antiviral defense system of the human body, and to aid the development of therapeutic products for the treatment of certain cancers and chronic diseases.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">AIM’s flagship products are Ampligen (rintatolimod), a first-in-class drug of large macromolecular RNA (ribonucleic acid) molecules, and Alferon N Injection (Interferon Alfa-N3). Ampligen has not been approved by the FDA or marketed in the United States. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (“CFS”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company’s primary business focus involves Ampligen. Ampligen is a double-stranded RNA (“dsRNA”) molecule being developed for globally important cancers, viral diseases and disorders of the immune system.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">AIM currently is proceeding primarily in four areas:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.6in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Conducting a randomized, controlled study to evaluate efficacy and safety of Ampligen compared to a control group to treat locally advanced pancreatic cancer patients.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Evaluating Ampligen in other cancers, as a potential therapy that modifies the tumor microenvironment with the goal of increasing anti-tumor responses to check point inhibitors.</span></p></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Exploring Ampligen’s antiviral activities and potential use as a prophylactic or treatment for existing viruses, new viruses and mutated viruses thereof. </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Evaluating Ampligen as a treatment for myalgic encephalomyelitis/chronic fatigue syndrome (“ME/CFS”) and fatigue and/or Post-COVID conditions of fatigue.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">AIM is prioritizing activities in an order related to the stage of development, with those clinical activities such as pancreatic cancer, ME/CFS and Post-COVID conditions having priority over antiviral experimentation. AIM intends that priority clinical work be conducted in trials authorized by the U.S. Food and Drug Administration (“FDA”) or European Medicines Agency (“EMA”), which trials support a potential future NDA. However, the Company’s antiviral experimentation is designed to accumulate additional preliminary data supporting its hypothesis that Ampligen is a powerful, broad-spectrum prophylaxis and early-onset therapeutic that may confer enhanced immunity and cross-protection. Accordingly, the Company will conduct antiviral programs in those venues most readily available and able to generate valid proof-of-concept data, including foreign venues.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b><i>Basis of Preparation and Consolidation</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">The accompanying consolidated financial statements include the accounts of AIM ImmunoTech and all entities in which a controlling interest is held by the Company. All significant intercompany balances and transactions have been eliminated in consolidation. The consolidated financial statements are prepared in accordance with accounting principles generally accepted in the U.S. (“GAAP”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b> </b></span></p>
</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000494">
<p id="xdx_809_eus-gaap--SignificantAccountingPoliciesTextBlock_zJ1ZOSYNwxG7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>(2) <span id="xdx_823_zw8y4UAd3rS8">Summary of Significant Accounting Policies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b> </b></span></p> <p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zEMbe0TZb6q" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(a) <span id="xdx_86B_zmgK91eyCGD6">Cash and Cash Equivalents</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Cash includes bank deposits maintained at several financial institutions. The Company considers highly liquid instruments with an original maturity of three months or less to be cash equivalents. At various times throughout the year ended December 31, 2023, some accounts held at financial institutions were in excess of the federally insured limit of $<span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_pn3n3_c20231231_zvmWs7SbPgOl" title="Federlly insured limit">250</span> thousand. The Company has not experienced any losses on these accounts and believes credit risk to be minimal.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_849_eus-gaap--MarketableSecuritiesPolicy_zMjHrxGrLQu8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(b) <span id="xdx_861_zilUSHqnAcu">Marketable Investment</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company’s marketable investments consist solely of mutual funds. We determine realized gains and losses for marketable investments using the specific identification method and measure the fair value of our marketable investments using a market approach where identical or comparable prices are available. If quoted market prices are not available, fair values of investments are determined using prices from a pricing service, pricing models, quoted prices of investments with similar characteristics or discounted cash flow models.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p> <p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zt86W6m9bIGe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(c) <span id="xdx_869_z8KJmsuGquql">Property and Equipment, net</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_89A_eus-gaap--PropertyPlantAndEquipmentTextBlock_zLX6LA2TACTe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B0_zXpk4uRIk7o7" style="display: none">Schedule of Property and Equipment</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" id="xdx_495_20231231_zBTXS1S9qlF" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" id="xdx_490_20221231_zlTanW87pzie" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">(in thousands) December 31,</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr id="xdx_405_eus-gaap--FurnitureAndFixturesGross_iI_pn3n3_maPPAENzOpl_ziOhCb9E1NVd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; color: Black; text-align: left">Furniture, fixture and equipment</td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">1,448</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">2,233</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzOpl_zIqM0sdA1y97" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(1,321</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(2,038</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzOpl_zCu6iyz0oMgl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Property and equipment, net</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">127</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">195</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table> <p id="xdx_8A2_zP7FoIv57dY2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets, ranging from <span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20231231__srt--RangeAxis__srt--MinimumMember_zQeGYbdvAT61" title="Estimated useful life::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0515">three</span></span> to <span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20231231__srt--RangeAxis__srt--MaximumMember_zjZDTdYNecA6" title="Estimated useful life">ten years</span>. Depreciation expense for the years ended December 31, 2023 and 2022 was $<span id="xdx_90B_eus-gaap--Depreciation_pp0p0_c20230101__20231231_zJEkdatNVYS" title="Depreciation expense">39,000</span> and $<span id="xdx_900_eus-gaap--Depreciation_pp0p0_c20220101__20221231_zurcxXJtkB1j" title="Depreciation expense">38,000</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company made a strategic shift on in-house manufacturing and recorded an impairment of the facility in the amount of $<span id="xdx_906_eus-gaap--OtherAssetImpairmentCharges_c20210101__20211231_ze1OKV82sk66" title="Impairment charges">1,800,000</span> during the year ended December 31, 2021. The Company sold the manufacturing facility on November 1, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_848_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zkfmnEf1SS5k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(d) <span id="xdx_862_zxLttbDekJv3">Patent and Trademark Rights, net</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Patents and trademarks are stated at cost (primarily legal fees) and are amortized using the straight-line method over the established useful life of <span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentAndTrademarkRightsMember_zv543jSCSu9d" title="Estimated useful lives of patent and trademark rights">17</span> years. The Company reviews its patents and trademark rights periodically to determine whether they have continuing value, or their value has become impaired. Such review includes an analysis of the patent and trademark’s ultimate revenue and profitability potential. Management’s review addresses whether each patent continues to fit into the Company’s strategic business plans.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_844_eus-gaap--UseOfEstimates_zji90h29FOr5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(e) <span id="xdx_86B_zSaIIheXlof5">Use of Estimates</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure (“GAAP”) of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those estimates, and those differences may be material. Accounts requiring the use of significant estimates include determination of other-than-temporary impairment on securities, valuation of deferred taxes, patent and trademark valuations, stock-based compensation calculations, fair value of warrants, and contingency accruals.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_84C_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zCyBjoarLLyl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(f) <span id="xdx_863_zYVcu2A7t1be">Revenue</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company accounts for revenue in accordance with Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts with Customers (“Topic 606”). Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Revenue from the sale of Ampligen under cost recovery clinical treatment protocols approved by the FDA is recognized when the product is shipped. The Company has no other obligation associated with its products once shipment has been accepted by the customer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Revenue from the sale Ampligen under the EAP is recognized as the product is distributed and administered to patients involved in the cost recovery program.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p> <p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zbNDmc81sD8d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(g) <span id="xdx_86A_zzDBc4KDPNel">Accounting for Income Taxes</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Deferred income tax assets and liabilities are determined based on differences between the financial statement reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws in effect when the differences are expected to reverse. The measurement of deferred income tax assets is reduced, if necessary, by a valuation allowance for any tax benefits which are not expected to be realized. The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company applies the provisions of FASB ASC 740-10 Uncertainty in Income Taxes. As a result of the implementation, there has been no material change to the Company’s tax positions as they have not paid any corporate income taxes due to operating losses. With the exception of net operating losses generated in New Jersey, all tax benefits will likely not be recognized due to the substantial net operating loss carryforwards which will most likely not be realized prior to expiration. With no tax due for the foreseeable future, the Company has determined that a policy to determine the accounting for interest or penalties related to the payment of tax is not necessary at this time.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zxT3b35BONPl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(h) <span id="xdx_86E_z3BzQaCVKJkf">Recent Accounting Standards and Pronouncements</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In October 2023, the FASB issued ASU 2023-06, <i>Disclosure Improvements. </i>The standard requires additional or amended disclosure requirements for a variety of transactions. The provisions most applicable to the Company include the method used in diluted earnings per share computation for each dilutive security including interim periods, preferences in involuntary liquidation for preferred stock. This ASU becomes effective dependent upon the SEC’s removal of related disclosures from Regulation S-X or S-K. Early adoption is permitted. The Company has evaluated the impact of adoption of this ASU on its financial condition, results of operations and cash flows, and, as such, has determined that the adoption of the new standard will not have a material effect on its financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In December 2023, the FASB issued ASU 2023-09, <i>Income Taxes (Topic 740) Improvements to Income Tax Disclosures. </i>The amendments in this Update require that public business entities on an annual basis (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5 percent of the amount computed by multiplying pretax income [or loss] by the applicable statutory income tax rate). Specifically, public business entities are required to disclose a tabular reconciliation, using both percentages and reporting currency amounts. The amendments in this Update require that all entities disclose on an annual basis the following information about income taxes paid: 1. The amount of income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign taxes 2. The amount of income taxes paid (net of refunds received) disaggregated by individual jurisdictions in which income taxes paid (net of refunds received) is equal to or greater than 5 percent of total income taxes paid (net of refunds received). The amendments in this Update require that all entities disclose the following information: 1. Income (or loss) from continuing operations before income tax expense (or benefit) disaggregated between domestic and foreign 2. Income tax expense (or benefit) from continuing operations disaggregated by federal (national), state, and foreign.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The amendments in this Update eliminate the requirement for all entities to (1) disclose the nature and estimate of the range of the reasonably possible change in the unrecognized tax benefits balance in the next 12 months or (2) make a statement that an estimate of the range cannot be made. The amendments in this Update remove the requirement to disclose the cumulative amount of each type of temporary difference when a deferred tax liability is not recognized because of the exceptions to comprehensive recognition of deferred taxes related to subsidiaries and corporate joint ventures. The Company has evaluated the impact of adoption of this ASU on its financial condition, results of operations and cash flows, and, as such, has determined that the adoption of the new standard will not have a material effect on its financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Other recent accounting pronouncements issued by the FASB did not or are not believed by management to have a material impact on the Company’s present or future financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_841_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zmYgeKZu2NQi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(i) <span id="xdx_86F_zmfAfvjRbn6g">Stock-Based Compensation</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company accounts for its stock-based compensation awards in accordance with FASB ASC Topic 718, “Compensation – Stock Compensation”, which requires recognition of compensation expense related to stock-based compensation awards over the period during which an employee is required to provide service for the award. Compensation expense is equal to the fair value of the award at the date of grant, net of estimated forfeitures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p> <p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zASBYDA4SHd9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(j) <span id="xdx_866_zorjzfOx4Rcg">Common Stock Per Share Calculation</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Basic and diluted net loss per share is computed using the weighted average number of shares of Common Stock outstanding during the period. Equivalent Common shares, consisting of <span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231_z8HgufNrRUs1" title="Equivalent Common shares">3,523,949</span> and <span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231_zrDjzIlgwIK6" title="Equivalent Common shares">2,966,538</span> of stock options and warrants, are excluded from the calculation of diluted net loss per share for the years ended December 31, 2023 and 2022, respectively, since their effect is antidilutive due to the net loss of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_845_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zD2EdXEU7LN4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(k) <span id="xdx_864_zU9Jock3a3v3">Long-Lived Assets</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company assesses long-lived assets for impairment when events or changes in circumstances indicate that the carrying value of the assets or the asset grouping may not be recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant decreases in the market price of a long-lived asset or group, a significant adverse change in the extent or manner in which a long-lived asset (asset group) is being used or its physical condition, a significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset (asset group), including an adverse action or assessment by a regulator, an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset (asset group), a current period operating or cash flow loss combined with a history of operating or cash flow losses or projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset (asset group) or a current expectation that, more likely than not, a long-lived asset (asset group) will be sold or otherwise disposed of significantly before the end of its previously estimated useful life.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">When assessing for impairment, the Company measures the recoverability of assets that it will continue to use in its operations by comparing the carrying value of the asset grouping to our estimate of the related total future undiscounted net cash flows. If an asset grouping’s carrying value is not recoverable through the related undiscounted cash flows, the asset grouping is considered to be impaired.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company measures the impairment by comparing the difference between the asset grouping’s carrying value and its fair value. Long-lived assets are considered a non-financial asset and are recorded at fair value only if an impairment charge is recognized. Impairments are determined for groups of assets related to the lowest level of identifiable independent cash flows. The Company makes subjective judgments in determining the independent cash flows that can be related to specific asset groupings. In addition, as the Company reviews its manufacturing process and other manufacturing planning decisions, if the useful lives of assets are shorter than the Company had originally estimated, it accelerates the rate of depreciation over the assets’ new, shorter useful lives.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">(l) Lease accounting</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company is a party to leases for office space, lab facilities and other equipment. The Company determines if a contract contains a lease arrangement at the inception of the contract. For leases in which the Company is the lessee, leases are classified as either finance or operating, with classification affecting the pattern of expense recognition. The Company records right of use assets and operating lease liabilities for its operating leases, which are initially recognized at the present value of future lease payments over the lease term. For leases that do not provide an implicit rate, the Company utilizes an estimated incremental borrowing rate based on market observations existing at lease inception to calculate the present value of future payments. The Company amortizes its right of use assets on a straight-line basis over the associated lease term.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The lease term is defined as the non-cancelable period of the lease, plus any options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option. The Company has elected to include both lease and non-lease components in the determination of lease payments. Payments made to a lessor for items such as taxes, insurance, common area maintenance, or other costs commonly referred to as executory costs, are also included in lease payments if they are fixed. The fixed portion of these payments are included in the calculation of the lease liability, while any variable portion is recognized as variable lease expenses as incurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company has elected not to recognize right of use assets and lease obligations for its short term leases, which are defined as leases with an initial term of 12 months or less. Lease payments for short term leases are recognized on a straight-line basis over the lease term.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">(m) <span>Reclassifications</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Certain prior year amounts have been reclassified to conform with current year presentation. These changes did not have any effect on net income, stockholders’ equity, or cash flows.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p> <p id="xdx_85A_z1fn1KYI6FM2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>
</us-gaap:SignificantAccountingPoliciesTextBlock>
<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000496">
<p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zEMbe0TZb6q" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(a) <span id="xdx_86B_zmgK91eyCGD6">Cash and Cash Equivalents</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Cash includes bank deposits maintained at several financial institutions. The Company considers highly liquid instruments with an original maturity of three months or less to be cash equivalents. At various times throughout the year ended December 31, 2023, some accounts held at financial institutions were in excess of the federally insured limit of $<span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_pn3n3_c20231231_zvmWs7SbPgOl" title="Federlly insured limit">250</span> thousand. The Company has not experienced any losses on these accounts and believes credit risk to be minimal.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p>
</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
<us-gaap:CashFDICInsuredAmount contextRef="AsOf2023-12-31" decimals="-3" id="Fact000498" unitRef="USD"> 250000 </us-gaap:CashFDICInsuredAmount>
<us-gaap:MarketableSecuritiesPolicy contextRef="From2023-01-01to2023-12-31" id="Fact000500">
<p id="xdx_849_eus-gaap--MarketableSecuritiesPolicy_zMjHrxGrLQu8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(b) <span id="xdx_861_zilUSHqnAcu">Marketable Investment</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company’s marketable investments consist solely of mutual funds. We determine realized gains and losses for marketable investments using the specific identification method and measure the fair value of our marketable investments using a market approach where identical or comparable prices are available. If quoted market prices are not available, fair values of investments are determined using prices from a pricing service, pricing models, quoted prices of investments with similar characteristics or discounted cash flow models.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>
</us-gaap:MarketableSecuritiesPolicy>
<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000502">
<p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zt86W6m9bIGe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(c) <span id="xdx_869_z8KJmsuGquql">Property and Equipment, net</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_89A_eus-gaap--PropertyPlantAndEquipmentTextBlock_zLX6LA2TACTe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B0_zXpk4uRIk7o7" style="display: none">Schedule of Property and Equipment</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" id="xdx_495_20231231_zBTXS1S9qlF" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" id="xdx_490_20221231_zlTanW87pzie" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">(in thousands) December 31,</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr id="xdx_405_eus-gaap--FurnitureAndFixturesGross_iI_pn3n3_maPPAENzOpl_ziOhCb9E1NVd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; color: Black; text-align: left">Furniture, fixture and equipment</td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">1,448</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">2,233</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzOpl_zIqM0sdA1y97" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(1,321</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(2,038</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzOpl_zCu6iyz0oMgl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Property and equipment, net</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">127</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">195</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table> <p id="xdx_8A2_zP7FoIv57dY2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets, ranging from <span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20231231__srt--RangeAxis__srt--MinimumMember_zQeGYbdvAT61" title="Estimated useful life::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0515">three</span></span> to <span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20231231__srt--RangeAxis__srt--MaximumMember_zjZDTdYNecA6" title="Estimated useful life">ten years</span>. Depreciation expense for the years ended December 31, 2023 and 2022 was $<span id="xdx_90B_eus-gaap--Depreciation_pp0p0_c20230101__20231231_zJEkdatNVYS" title="Depreciation expense">39,000</span> and $<span id="xdx_900_eus-gaap--Depreciation_pp0p0_c20220101__20221231_zurcxXJtkB1j" title="Depreciation expense">38,000</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company made a strategic shift on in-house manufacturing and recorded an impairment of the facility in the amount of $<span id="xdx_906_eus-gaap--OtherAssetImpairmentCharges_c20210101__20211231_ze1OKV82sk66" title="Impairment charges">1,800,000</span> during the year ended December 31, 2021. The Company sold the manufacturing facility on November 1, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p>
</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000504">
<p id="xdx_89A_eus-gaap--PropertyPlantAndEquipmentTextBlock_zLX6LA2TACTe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B0_zXpk4uRIk7o7" style="display: none">Schedule of Property and Equipment</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" id="xdx_495_20231231_zBTXS1S9qlF" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" id="xdx_490_20221231_zlTanW87pzie" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">(in thousands) December 31,</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr id="xdx_405_eus-gaap--FurnitureAndFixturesGross_iI_pn3n3_maPPAENzOpl_ziOhCb9E1NVd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; color: Black; text-align: left">Furniture, fixture and equipment</td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">1,448</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">2,233</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzOpl_zIqM0sdA1y97" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(1,321</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(2,038</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzOpl_zCu6iyz0oMgl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Property and equipment, net</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">127</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">195</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table>
</us-gaap:PropertyPlantAndEquipmentTextBlock>
<us-gaap:FurnitureAndFixturesGross contextRef="AsOf2023-12-31" decimals="-3" id="Fact000506" unitRef="USD"> 1448000 </us-gaap:FurnitureAndFixturesGross>
<us-gaap:FurnitureAndFixturesGross contextRef="AsOf2022-12-31" decimals="-3" id="Fact000507" unitRef="USD"> 2233000 </us-gaap:FurnitureAndFixturesGross>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2023-12-31" decimals="-3" id="Fact000509" unitRef="USD"> 1321000 </us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2022-12-31" decimals="-3" id="Fact000510" unitRef="USD"> 2038000 </us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2023-12-31" decimals="-3" id="Fact000512" unitRef="USD"> 127000 </us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-12-31" decimals="-3" id="Fact000513" unitRef="USD"> 195000 </us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="AsOf2023-12-31_srt_MaximumMember" id="Fact000517"> P10Y </us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:Depreciation contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact000519" unitRef="USD"> 39000 </us-gaap:Depreciation>
<us-gaap:Depreciation contextRef="From2022-01-012022-12-31" decimals="0" id="Fact000521" unitRef="USD"> 38000 </us-gaap:Depreciation>
<us-gaap:OtherAssetImpairmentCharges contextRef="From2021-01-012021-12-31" decimals="0" id="Fact000523" unitRef="USD"> 1800000 </us-gaap:OtherAssetImpairmentCharges>
<us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2023-01-01to2023-12-31" id="Fact000525">
<p id="xdx_848_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zkfmnEf1SS5k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(d) <span id="xdx_862_zxLttbDekJv3">Patent and Trademark Rights, net</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Patents and trademarks are stated at cost (primarily legal fees) and are amortized using the straight-line method over the established useful life of <span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentAndTrademarkRightsMember_zv543jSCSu9d" title="Estimated useful lives of patent and trademark rights">17</span> years. The Company reviews its patents and trademark rights periodically to determine whether they have continuing value, or their value has become impaired. Such review includes an analysis of the patent and trademark’s ultimate revenue and profitability potential. Management’s review addresses whether each patent continues to fit into the Company’s strategic business plans.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p>
</us-gaap:IntangibleAssetsFiniteLivedPolicy>
<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="AsOf2023-12-31_custom_PatentAndTrademarkRightsMember" id="Fact000527"> P17Y </us-gaap:FiniteLivedIntangibleAssetUsefulLife>
<us-gaap:UseOfEstimates contextRef="From2023-01-01to2023-12-31" id="Fact000529">
<p id="xdx_844_eus-gaap--UseOfEstimates_zji90h29FOr5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(e) <span id="xdx_86B_zSaIIheXlof5">Use of Estimates</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure (“GAAP”) of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those estimates, and those differences may be material. Accounts requiring the use of significant estimates include determination of other-than-temporary impairment on securities, valuation of deferred taxes, patent and trademark valuations, stock-based compensation calculations, fair value of warrants, and contingency accruals.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p>
</us-gaap:UseOfEstimates>
<us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000531">
<p id="xdx_84C_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zCyBjoarLLyl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(f) <span id="xdx_863_zYVcu2A7t1be">Revenue</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company accounts for revenue in accordance with Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts with Customers (“Topic 606”). Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Revenue from the sale of Ampligen under cost recovery clinical treatment protocols approved by the FDA is recognized when the product is shipped. The Company has no other obligation associated with its products once shipment has been accepted by the customer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Revenue from the sale Ampligen under the EAP is recognized as the product is distributed and administered to patients involved in the cost recovery program.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>
</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
<us-gaap:IncomeTaxPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000533">
<p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zbNDmc81sD8d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(g) <span id="xdx_86A_zzDBc4KDPNel">Accounting for Income Taxes</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Deferred income tax assets and liabilities are determined based on differences between the financial statement reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws in effect when the differences are expected to reverse. The measurement of deferred income tax assets is reduced, if necessary, by a valuation allowance for any tax benefits which are not expected to be realized. The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company applies the provisions of FASB ASC 740-10 Uncertainty in Income Taxes. As a result of the implementation, there has been no material change to the Company’s tax positions as they have not paid any corporate income taxes due to operating losses. With the exception of net operating losses generated in New Jersey, all tax benefits will likely not be recognized due to the substantial net operating loss carryforwards which will most likely not be realized prior to expiration. With no tax due for the foreseeable future, the Company has determined that a policy to determine the accounting for interest or penalties related to the payment of tax is not necessary at this time.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p>
</us-gaap:IncomeTaxPolicyTextBlock>
<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000535">
<p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zxT3b35BONPl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(h) <span id="xdx_86E_z3BzQaCVKJkf">Recent Accounting Standards and Pronouncements</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In October 2023, the FASB issued ASU 2023-06, <i>Disclosure Improvements. </i>The standard requires additional or amended disclosure requirements for a variety of transactions. The provisions most applicable to the Company include the method used in diluted earnings per share computation for each dilutive security including interim periods, preferences in involuntary liquidation for preferred stock. This ASU becomes effective dependent upon the SEC’s removal of related disclosures from Regulation S-X or S-K. Early adoption is permitted. The Company has evaluated the impact of adoption of this ASU on its financial condition, results of operations and cash flows, and, as such, has determined that the adoption of the new standard will not have a material effect on its financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In December 2023, the FASB issued ASU 2023-09, <i>Income Taxes (Topic 740) Improvements to Income Tax Disclosures. </i>The amendments in this Update require that public business entities on an annual basis (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5 percent of the amount computed by multiplying pretax income [or loss] by the applicable statutory income tax rate). Specifically, public business entities are required to disclose a tabular reconciliation, using both percentages and reporting currency amounts. The amendments in this Update require that all entities disclose on an annual basis the following information about income taxes paid: 1. The amount of income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign taxes 2. The amount of income taxes paid (net of refunds received) disaggregated by individual jurisdictions in which income taxes paid (net of refunds received) is equal to or greater than 5 percent of total income taxes paid (net of refunds received). The amendments in this Update require that all entities disclose the following information: 1. Income (or loss) from continuing operations before income tax expense (or benefit) disaggregated between domestic and foreign 2. Income tax expense (or benefit) from continuing operations disaggregated by federal (national), state, and foreign.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The amendments in this Update eliminate the requirement for all entities to (1) disclose the nature and estimate of the range of the reasonably possible change in the unrecognized tax benefits balance in the next 12 months or (2) make a statement that an estimate of the range cannot be made. The amendments in this Update remove the requirement to disclose the cumulative amount of each type of temporary difference when a deferred tax liability is not recognized because of the exceptions to comprehensive recognition of deferred taxes related to subsidiaries and corporate joint ventures. The Company has evaluated the impact of adoption of this ASU on its financial condition, results of operations and cash flows, and, as such, has determined that the adoption of the new standard will not have a material effect on its financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Other recent accounting pronouncements issued by the FASB did not or are not believed by management to have a material impact on the Company’s present or future financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p>
</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2023-01-01to2023-12-31" id="Fact000537">
<p id="xdx_841_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zmYgeKZu2NQi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(i) <span id="xdx_86F_zmfAfvjRbn6g">Stock-Based Compensation</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company accounts for its stock-based compensation awards in accordance with FASB ASC Topic 718, “Compensation – Stock Compensation”, which requires recognition of compensation expense related to stock-based compensation awards over the period during which an employee is required to provide service for the award. Compensation expense is equal to the fair value of the award at the date of grant, net of estimated forfeitures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>
</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
<us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000539">
<p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zASBYDA4SHd9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(j) <span id="xdx_866_zorjzfOx4Rcg">Common Stock Per Share Calculation</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Basic and diluted net loss per share is computed using the weighted average number of shares of Common Stock outstanding during the period. Equivalent Common shares, consisting of <span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231_z8HgufNrRUs1" title="Equivalent Common shares">3,523,949</span> and <span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231_zrDjzIlgwIK6" title="Equivalent Common shares">2,966,538</span> of stock options and warrants, are excluded from the calculation of diluted net loss per share for the years ended December 31, 2023 and 2022, respectively, since their effect is antidilutive due to the net loss of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p>
</us-gaap:EarningsPerSharePolicyTextBlock>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2023-01-01to2023-12-31" decimals="INF" id="Fact000541" unitRef="Shares"> 3523949 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2022-01-012022-12-31" decimals="INF" id="Fact000543" unitRef="Shares"> 2966538 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000545">
<p id="xdx_845_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zD2EdXEU7LN4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(k) <span id="xdx_864_zU9Jock3a3v3">Long-Lived Assets</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company assesses long-lived assets for impairment when events or changes in circumstances indicate that the carrying value of the assets or the asset grouping may not be recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant decreases in the market price of a long-lived asset or group, a significant adverse change in the extent or manner in which a long-lived asset (asset group) is being used or its physical condition, a significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset (asset group), including an adverse action or assessment by a regulator, an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset (asset group), a current period operating or cash flow loss combined with a history of operating or cash flow losses or projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset (asset group) or a current expectation that, more likely than not, a long-lived asset (asset group) will be sold or otherwise disposed of significantly before the end of its previously estimated useful life.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">When assessing for impairment, the Company measures the recoverability of assets that it will continue to use in its operations by comparing the carrying value of the asset grouping to our estimate of the related total future undiscounted net cash flows. If an asset grouping’s carrying value is not recoverable through the related undiscounted cash flows, the asset grouping is considered to be impaired.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company measures the impairment by comparing the difference between the asset grouping’s carrying value and its fair value. Long-lived assets are considered a non-financial asset and are recorded at fair value only if an impairment charge is recognized. Impairments are determined for groups of assets related to the lowest level of identifiable independent cash flows. The Company makes subjective judgments in determining the independent cash flows that can be related to specific asset groupings. In addition, as the Company reviews its manufacturing process and other manufacturing planning decisions, if the useful lives of assets are shorter than the Company had originally estimated, it accelerates the rate of depreciation over the assets’ new, shorter useful lives.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">(l) Lease accounting</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company is a party to leases for office space, lab facilities and other equipment. The Company determines if a contract contains a lease arrangement at the inception of the contract. For leases in which the Company is the lessee, leases are classified as either finance or operating, with classification affecting the pattern of expense recognition. The Company records right of use assets and operating lease liabilities for its operating leases, which are initially recognized at the present value of future lease payments over the lease term. For leases that do not provide an implicit rate, the Company utilizes an estimated incremental borrowing rate based on market observations existing at lease inception to calculate the present value of future payments. The Company amortizes its right of use assets on a straight-line basis over the associated lease term.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The lease term is defined as the non-cancelable period of the lease, plus any options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option. The Company has elected to include both lease and non-lease components in the determination of lease payments. Payments made to a lessor for items such as taxes, insurance, common area maintenance, or other costs commonly referred to as executory costs, are also included in lease payments if they are fixed. The fixed portion of these payments are included in the calculation of the lease liability, while any variable portion is recognized as variable lease expenses as incurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company has elected not to recognize right of use assets and lease obligations for its short term leases, which are defined as leases with an initial term of 12 months or less. Lease payments for short term leases are recognized on a straight-line basis over the lease term.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">(m) <span>Reclassifications</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Certain prior year amounts have been reclassified to conform with current year presentation. These changes did not have any effect on net income, stockholders’ equity, or cash flows.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"> </p>
</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
<us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000547">
<p id="xdx_804_eus-gaap--InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_zTbja26Cmuk5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>(3) <span id="xdx_82A_zSViMNDiu0Ed">Marketable Investments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Marketable investments consist of mutual funds. At December 31, 2023 and 2022, it was determined that none of the marketable investments had an other-than-temporary impairment. At December 31, 2023 and 2022, all securities were measured as Level 1 instruments of the fair value measurements standard (See Note 15: Fair Value). As of December 31, 2023 and 2022, the Company held $<span id="xdx_909_eus-gaap--MarketableSecuritiesCurrent_iI_pp0p0_c20231231_zaK6yejGQ241" title="Marketable securities">7,631,000</span> and $<span id="xdx_908_eus-gaap--MarketableSecuritiesCurrent_iI_pp0p0_c20221231_zComyrmh8nje" title="Marketable securities">7,137,000</span>, respectively, in mutual funds.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_89A_eus-gaap--InvestmentIncomeTextBlock_gL3IITB-MRQXJLX_zawSbmUnjXd3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Mutual Funds classified as available for sale consisted of:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(in thousands)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">December 31, 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8BA_z2SSJvsud5uh" style="display: none">Schedule of Available of Sale</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; color: Black">Securities</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"><p style="margin: 0pt">Fair</p> <p style="margin: 0pt">Value</p></td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Short-Term Investments</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; width: 64%; color: Black; text-align: left">Mutual Funds</td><td style="padding-bottom: 1.5pt; width: 2%; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left">$</td><td id="xdx_983_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_zEzMh98ckm5k" style="border-bottom: Black 1.5pt solid; width: 14%; color: Black; text-align: right" title="Fair Value">7,631</td><td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; width: 2%; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left">$</td><td id="xdx_984_eus-gaap--ShortTermInvestments_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_zsSyuNwNsPYi" style="border-bottom: Black 1.5pt solid; width: 14%; color: Black; text-align: right" title="Short-Term Investments">7,631</td><td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black">Totals</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td id="xdx_982_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231_zEq0xHy4IhXc" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Fair Value">7,631</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td id="xdx_988_eus-gaap--ShortTermInvestments_iI_pn3n3_c20231231_zMSiEellIrAg" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Short-Term Investments">7,631</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> </table> <p id="xdx_8A4_z6vVU3pLgF7e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(in thousands)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">December 31, 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_891_eus-gaap--TradingSecuritiesAndCertainTradingAssetsTextBlock_gL3TSACTATB-ODD_zoD58OSmTXgl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B1_zUPSSRfoE6P7" style="display: none">Schedule of Equity Securities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" id="xdx_496_20230101__20231231_zo7axtVjrHnl" style="border-bottom: Black 1.5pt solid; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; color: Black">Securities</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr id="xdx_407_eus-gaap--EquitySecuritiesFvNiGainLoss_pn3n3_zMcKVnqaRsG1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 82%; color: Black; text-align: left">Net gain recognized during the year on equity securities</td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">200</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--EquitySecuritiesFvNiRealizedGainLoss_pn3n3_zUJebfHrNdf2" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Less: Net gains and losses recognized during the year on equity securities sold during the year</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(176</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_pn3n3_zPGkT0qmkTxc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Unrealized gains and losses recognized during the year on equity securities still held at the end of the year</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">376</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table> <p id="xdx_8AB_z0kzXWEdl8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_C02_gL3IITB-MRQXJLX_zIFPIMa84vC9">Mutual Funds classified as available for sale consisted of:</span></span></p> <div id="xdx_C02_gL3IITB-MRQXJLX_zRHdn8ayZMe7" style="margin: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(in thousands)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">December 31, 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_306_134_zu1pC4E1zr3i" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - Schedule of Available of Sale (Details)"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; color: Black">Securities</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Short-Term Investments</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; width: 64%; color: Black; text-align: left">Mutual Funds</td><td style="padding-bottom: 1.5pt; width: 2%; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left">$</td><td id="xdx_985_eus-gaap--MarketableSecurities_iI_pn3n3_c20221231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_z3k12DcUzTz5" style="border-bottom: Black 1.5pt solid; width: 14%; color: Black; text-align: right" title="Fair Value">7,137</td><td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; width: 2%; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShortTermInvestments_iI_pn3n3_c20221231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_zYJwmW50BXP4" style="border-bottom: Black 1.5pt solid; width: 14%; color: Black; text-align: right" title="Short-Term Investments">7,137</td><td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; color: Black">Totals</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_987_eus-gaap--MarketableSecurities_iI_pn3n3_c20221231_zrAMmxiVvmLl" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Fair Value">7,137</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShortTermInvestments_iI_pn3n3_c20221231_zzNqdDHNDj43" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Short-Term Investments">7,137</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_C0B_gL3IITB-MRQXJLX_zg71DmxfXC4c"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span id="xdx_C0A_gL3TSACTATB-ODD_zwKXQc3515c9"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(in thousands)</span></span></p> <div id="xdx_C09_gL3TSACTATB-ODD_zph8HTxAKTql" style="margin: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">December 31, 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_305_134_zwD3uXDq1SQd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - Schedule of Equity Securities (Details)"> <tr style="display: none; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" id="xdx_49E_20220101__20221231_zdzvY7OURvTb" style="padding-bottom: 1.5pt; color: Black; text-align: right"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; color: Black">Securities</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr id="xdx_407_eus-gaap--EquitySecuritiesFvNiGainLoss_pn3n3_zAlE6NSGtK1i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 82%; color: Black; text-align: left">Net losses recognized during the period on equity securities</td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">(1,679</td><td style="width: 1%; color: Black; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--EquitySecuritiesFvNiRealizedGainLoss_pn3n3_zBwBR2AQSmQd" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Less: Net gains and losses recognized during the period on equity securities sold during the year</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(751</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_pn3n3_zWCJniVZcw4c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Unrealized gains and losses recognized during the reporting period on equity securities still held at the end of the year</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(928</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span id="xdx_C04_gL3TSACTATB-ODD_zItYqthd6dId"> </span></b></span></p>
</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
<us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2023-12-31" decimals="0" id="Fact000549" unitRef="USD"> 7631000 </us-gaap:MarketableSecuritiesCurrent>
<us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2022-12-31" decimals="0" id="Fact000551" unitRef="USD"> 7137000 </us-gaap:MarketableSecuritiesCurrent>
<us-gaap:InvestmentIncomeTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000556">
<p id="xdx_89A_eus-gaap--InvestmentIncomeTextBlock_gL3IITB-MRQXJLX_zawSbmUnjXd3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Mutual Funds classified as available for sale consisted of:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(in thousands)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">December 31, 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8BA_z2SSJvsud5uh" style="display: none">Schedule of Available of Sale</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; color: Black">Securities</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"><p style="margin: 0pt">Fair</p> <p style="margin: 0pt">Value</p></td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Short-Term Investments</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; width: 64%; color: Black; text-align: left">Mutual Funds</td><td style="padding-bottom: 1.5pt; width: 2%; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left">$</td><td id="xdx_983_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_zEzMh98ckm5k" style="border-bottom: Black 1.5pt solid; width: 14%; color: Black; text-align: right" title="Fair Value">7,631</td><td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; width: 2%; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left">$</td><td id="xdx_984_eus-gaap--ShortTermInvestments_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_zsSyuNwNsPYi" style="border-bottom: Black 1.5pt solid; width: 14%; color: Black; text-align: right" title="Short-Term Investments">7,631</td><td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black">Totals</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td id="xdx_982_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231_zEq0xHy4IhXc" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Fair Value">7,631</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td id="xdx_988_eus-gaap--ShortTermInvestments_iI_pn3n3_c20231231_zMSiEellIrAg" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Short-Term Investments">7,631</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> </table> Mutual Funds classified as available for sale consisted of:<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(in thousands)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">December 31, 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_306_134_zu1pC4E1zr3i" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - Schedule of Available of Sale (Details)"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; color: Black">Securities</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Short-Term Investments</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; width: 64%; color: Black; text-align: left">Mutual Funds</td><td style="padding-bottom: 1.5pt; width: 2%; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left">$</td><td id="xdx_985_eus-gaap--MarketableSecurities_iI_pn3n3_c20221231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_z3k12DcUzTz5" style="border-bottom: Black 1.5pt solid; width: 14%; color: Black; text-align: right" title="Fair Value">7,137</td><td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; width: 2%; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShortTermInvestments_iI_pn3n3_c20221231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_zYJwmW50BXP4" style="border-bottom: Black 1.5pt solid; width: 14%; color: Black; text-align: right" title="Short-Term Investments">7,137</td><td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; color: Black">Totals</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_987_eus-gaap--MarketableSecurities_iI_pn3n3_c20221231_zrAMmxiVvmLl" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Fair Value">7,137</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShortTermInvestments_iI_pn3n3_c20221231_zzNqdDHNDj43" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Short-Term Investments">7,137</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span>
</us-gaap:InvestmentIncomeTextBlock>
<us-gaap:InvestmentsFairValueDisclosure contextRef="AsOf2023-12-31_custom_MutualFundsMember" decimals="-3" id="Fact000558" unitRef="USD"> 7631000 </us-gaap:InvestmentsFairValueDisclosure>
<us-gaap:ShortTermInvestments contextRef="AsOf2023-12-31_custom_MutualFundsMember" decimals="-3" id="Fact000560" unitRef="USD"> 7631000 </us-gaap:ShortTermInvestments>
<us-gaap:InvestmentsFairValueDisclosure contextRef="AsOf2023-12-31" decimals="-3" id="Fact000562" unitRef="USD"> 7631000 </us-gaap:InvestmentsFairValueDisclosure>
<us-gaap:ShortTermInvestments contextRef="AsOf2023-12-31" decimals="-3" id="Fact000564" unitRef="USD"> 7631000 </us-gaap:ShortTermInvestments>
<us-gaap:TradingSecuritiesAndCertainTradingAssetsTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000569">
<p id="xdx_891_eus-gaap--TradingSecuritiesAndCertainTradingAssetsTextBlock_gL3TSACTATB-ODD_zoD58OSmTXgl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B1_zUPSSRfoE6P7" style="display: none">Schedule of Equity Securities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" id="xdx_496_20230101__20231231_zo7axtVjrHnl" style="border-bottom: Black 1.5pt solid; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; color: Black">Securities</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr id="xdx_407_eus-gaap--EquitySecuritiesFvNiGainLoss_pn3n3_zMcKVnqaRsG1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 82%; color: Black; text-align: left">Net gain recognized during the year on equity securities</td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">200</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--EquitySecuritiesFvNiRealizedGainLoss_pn3n3_zUJebfHrNdf2" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Less: Net gains and losses recognized during the year on equity securities sold during the year</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(176</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_pn3n3_zPGkT0qmkTxc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Unrealized gains and losses recognized during the year on equity securities still held at the end of the year</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">376</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(in thousands)</span><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">December 31, 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_305_134_zwD3uXDq1SQd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - Schedule of Equity Securities (Details)"> <tr style="display: none; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" id="xdx_49E_20220101__20221231_zdzvY7OURvTb" style="padding-bottom: 1.5pt; color: Black; text-align: right"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; color: Black">Securities</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr id="xdx_407_eus-gaap--EquitySecuritiesFvNiGainLoss_pn3n3_zAlE6NSGtK1i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 82%; color: Black; text-align: left">Net losses recognized during the period on equity securities</td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">(1,679</td><td style="width: 1%; color: Black; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--EquitySecuritiesFvNiRealizedGainLoss_pn3n3_zBwBR2AQSmQd" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Less: Net gains and losses recognized during the period on equity securities sold during the year</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(751</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_pn3n3_zWCJniVZcw4c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Unrealized gains and losses recognized during the reporting period on equity securities still held at the end of the year</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(928</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p>  
</us-gaap:TradingSecuritiesAndCertainTradingAssetsTextBlock>
<us-gaap:EquitySecuritiesFvNiGainLoss contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000571" unitRef="USD"> 200000 </us-gaap:EquitySecuritiesFvNiGainLoss>
<us-gaap:EquitySecuritiesFvNiRealizedGainLoss contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000573" unitRef="USD"> -176000 </us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
<us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000575" unitRef="USD"> 376000 </us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
<us-gaap:MarketableSecurities contextRef="AsOf2022-12-31_custom_MutualFundsMember" decimals="-3" id="Fact000577" unitRef="USD"> 7137000 </us-gaap:MarketableSecurities>
<us-gaap:ShortTermInvestments contextRef="AsOf2022-12-31_custom_MutualFundsMember" decimals="-3" id="Fact000579" unitRef="USD"> 7137000 </us-gaap:ShortTermInvestments>
<us-gaap:MarketableSecurities contextRef="AsOf2022-12-31" decimals="-3" id="Fact000581" unitRef="USD"> 7137000 </us-gaap:MarketableSecurities>
<us-gaap:ShortTermInvestments contextRef="AsOf2022-12-31" decimals="-3" id="Fact000583" unitRef="USD"> 7137000 </us-gaap:ShortTermInvestments>
<us-gaap:EquitySecuritiesFvNiGainLoss contextRef="From2022-01-012022-12-31" decimals="-3" id="Fact000585" unitRef="USD"> -1679000 </us-gaap:EquitySecuritiesFvNiGainLoss>
<us-gaap:EquitySecuritiesFvNiRealizedGainLoss contextRef="From2022-01-012022-12-31" decimals="-3" id="Fact000587" unitRef="USD"> -751000 </us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
<us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="From2022-01-012022-12-31" decimals="-3" id="Fact000589" unitRef="USD"> -928000 </us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
<us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000591">
<p id="xdx_806_eus-gaap--IntangibleAssetsDisclosureTextBlock_zhCBjNsh8aZ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>(4) <span id="xdx_824_zIwSq2BmzXGd">Patents and Trademark Rights, Net</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b></b></span></p> <p id="xdx_89C_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zeZl2SnX3HQ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Patent and trademark rights consist of the following (in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b> <span id="xdx_8BC_zivttU9adyx8">Schedule of Patent and Trademark Rights</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b></b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Gross Carrying Value</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Net Carrying Value</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Gross Carrying Value</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Net Carrying Value</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Patents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zzvNjdk7uxNj" style="width: 6%; text-align: right" title="Gross carrying value">2,947</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zuEHFRVno8Ge" style="width: 6%; text-align: right" title="Accumulated amortization">(750</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z6xMddfMv6e" style="width: 6%; text-align: right" title="Net carrying value">2,197</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zgIY2qunWgI3" style="width: 6%; text-align: right" title="Gross carrying value">2,389</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zIgKRmUMCSWj" style="width: 6%; text-align: right" title="Accumulated amortization">(595</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zPH5MCb8XEjd" style="width: 6%; text-align: right" title="Net carrying value">1,794</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Trademarks</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zTs9laN5Csuj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gross carrying value">229</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zirHDIOXETv6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization">(113</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zEFQz01qQE5b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net carrying value">116</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zVhl8YLs7un2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gross carrying value">216</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z6SgSVZnxDE" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization">(69</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zRP7uw6GWs5e" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net carrying value">147</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left">Net amortizable patents and trademarks rights</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231_zzT8MWSMSGIl" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross carrying value">3,176</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231_zTbz9oVbWAah" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization">(863</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231_zWKCRe2eohkb" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying value">2,313</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20221231_zTEMciTBq7Tj" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross carrying value">2,605</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231_zq6sAwxaDIdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization">(664</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20221231_zZVHq8bHupJd" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying value">1,941</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AB_zltZ3lxz6Vhd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 31.5pt">The following table presents the changes in the patents and trademark rights:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b></b></span></p> <p id="xdx_89F_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zYtNsydlyl54" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span id="xdx_8BF_z0tf6fFOuc0c" style="display: none">Schedule of Changes in Patents, Trademark Rights</span></b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: right"> </td><td style="color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">(in thousands)</p></td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 82%; color: Black">December 31, 2022</td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_pn3n3_c20230101__20231231_zWf1azlUCzjh" style="width: 14%; color: Black; text-align: right" title="Beginning balance">1,941</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black">Acquisitions</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98A_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn3n3_c20230101__20231231_zlvaUo9dNZWg" style="color: Black; text-align: right" title="Acquisitions">585</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black">Abandonments</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98D_ecustom--FinitelivedIntangibleAssetsAbandonments_iN_pn3n3_di_c20230101__20231231_zpySyQpF5fy7" style="color: Black; text-align: right" title="Abandonments">(14</td><td style="color: Black; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left"> Amortization</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_983_eus-gaap--AmortizationOfIntangibleAssets_iN_pn3n3_di_c20230101__20231231_z57U6T6P5Gqe" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Accumulated Amortization">(199</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; color: Black">December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iE_pn3n3_c20230101__20231231_z9INryp97Ec2" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Ending balance">2,313</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zc2mmwIFrD0k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Patents and trademarks are stated at cost (primarily legal fees) and are amortized using the straight-line method of the estimated useful life of <span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zwhL5qbgPzK4" title="Finite lived intangible assets, estimated useful life">17</span> years and <span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zOWuHlDIF6i2" title="Finite lived intangible assets, estimated useful life">10</span> years, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p> <p id="xdx_89E_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zHnSpfwsAuH" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Amortization of patents and trademarks for each of the next five years is as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B9_zhAkaswPrKwl" style="display: none">Schedule of Amortization of Patents and Trademarks</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td id="xdx_496_20231231_zCKkXJBtsaz9" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="4" style="padding-left: 10pt; font-weight: bold; text-align: left">Year Ending December 31,</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzzOp_zbJLLb14u2z6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2024</td><td style="width: 2%; text-align: left"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">241</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzzOp_zPNQZrxa9Ja1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">232</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANzzOp_zDGbXedYbRol" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2026</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">230</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANzzOp_zCtJZhxKZ7cl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">208</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maFLIANzzOp_zOUaQlCLJmCj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">189</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pn3n3_maFLIANzzOp_zlBjww1Mhkag" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">Thereafter</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,213</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzzOp_zLS4S6CRxsel" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-size: 10pt"><b>Total</b></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,313</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AB_zGJII59iaimi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>
</us-gaap:IntangibleAssetsDisclosureTextBlock>
<us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000593">
<p id="xdx_89C_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zeZl2SnX3HQ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Patent and trademark rights consist of the following (in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b> <span id="xdx_8BC_zivttU9adyx8">Schedule of Patent and Trademark Rights</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b></b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Gross Carrying Value</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Net Carrying Value</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Gross Carrying Value</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Net Carrying Value</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Patents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zzvNjdk7uxNj" style="width: 6%; text-align: right" title="Gross carrying value">2,947</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zuEHFRVno8Ge" style="width: 6%; text-align: right" title="Accumulated amortization">(750</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z6xMddfMv6e" style="width: 6%; text-align: right" title="Net carrying value">2,197</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zgIY2qunWgI3" style="width: 6%; text-align: right" title="Gross carrying value">2,389</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zIgKRmUMCSWj" style="width: 6%; text-align: right" title="Accumulated amortization">(595</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zPH5MCb8XEjd" style="width: 6%; text-align: right" title="Net carrying value">1,794</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Trademarks</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zTs9laN5Csuj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gross carrying value">229</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zirHDIOXETv6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization">(113</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zEFQz01qQE5b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net carrying value">116</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zVhl8YLs7un2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gross carrying value">216</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z6SgSVZnxDE" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization">(69</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zRP7uw6GWs5e" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net carrying value">147</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left">Net amortizable patents and trademarks rights</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231_zzT8MWSMSGIl" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross carrying value">3,176</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231_zTbz9oVbWAah" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization">(863</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231_zWKCRe2eohkb" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying value">2,313</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20221231_zTEMciTBq7Tj" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross carrying value">2,605</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231_zq6sAwxaDIdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization">(664</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20221231_zZVHq8bHupJd" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying value">1,941</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2023-12-31_us-gaap_PatentsMember" decimals="-3" id="Fact000595" unitRef="USD"> 2947000 </us-gaap:FiniteLivedIntangibleAssetsGross>
<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2023-12-31_us-gaap_PatentsMember" decimals="-3" id="Fact000597" unitRef="USD"> -750000 </us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2023-12-31_us-gaap_PatentsMember" decimals="-3" id="Fact000599" unitRef="USD"> 2197000 </us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2022-12-31_us-gaap_PatentsMember" decimals="-3" id="Fact000601" unitRef="USD"> 2389000 </us-gaap:FiniteLivedIntangibleAssetsGross>
<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2022-12-31_us-gaap_PatentsMember" decimals="-3" id="Fact000603" unitRef="USD"> -595000 </us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2022-12-31_us-gaap_PatentsMember" decimals="-3" id="Fact000605" unitRef="USD"> 1794000 </us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2023-12-31_us-gaap_TrademarksMember" decimals="-3" id="Fact000607" unitRef="USD"> 229000 </us-gaap:FiniteLivedIntangibleAssetsGross>
<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2023-12-31_us-gaap_TrademarksMember" decimals="-3" id="Fact000609" unitRef="USD"> -113000 </us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2023-12-31_us-gaap_TrademarksMember" decimals="-3" id="Fact000611" unitRef="USD"> 116000 </us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2022-12-31_us-gaap_TrademarksMember" decimals="-3" id="Fact000613" unitRef="USD"> 216000 </us-gaap:FiniteLivedIntangibleAssetsGross>
<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2022-12-31_us-gaap_TrademarksMember" decimals="-3" id="Fact000615" unitRef="USD"> -69000 </us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2022-12-31_us-gaap_TrademarksMember" decimals="-3" id="Fact000617" unitRef="USD"> 147000 </us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2023-12-31" decimals="-3" id="Fact000619" unitRef="USD"> 3176000 </us-gaap:FiniteLivedIntangibleAssetsGross>
<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2023-12-31" decimals="-3" id="Fact000621" unitRef="USD"> -863000 </us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2023-12-31" decimals="-3" id="Fact000623" unitRef="USD"> 2313000 </us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2022-12-31" decimals="-3" id="Fact000625" unitRef="USD"> 2605000 </us-gaap:FiniteLivedIntangibleAssetsGross>
<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2022-12-31" decimals="-3" id="Fact000627" unitRef="USD"> -664000 </us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2022-12-31" decimals="-3" id="Fact000629" unitRef="USD"> 1941000 </us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000631">
<p id="xdx_89F_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zYtNsydlyl54" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span id="xdx_8BF_z0tf6fFOuc0c" style="display: none">Schedule of Changes in Patents, Trademark Rights</span></b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: right"> </td><td style="color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">(in thousands)</p></td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 82%; color: Black">December 31, 2022</td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_pn3n3_c20230101__20231231_zWf1azlUCzjh" style="width: 14%; color: Black; text-align: right" title="Beginning balance">1,941</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black">Acquisitions</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98A_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn3n3_c20230101__20231231_zlvaUo9dNZWg" style="color: Black; text-align: right" title="Acquisitions">585</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black">Abandonments</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98D_ecustom--FinitelivedIntangibleAssetsAbandonments_iN_pn3n3_di_c20230101__20231231_zpySyQpF5fy7" style="color: Black; text-align: right" title="Abandonments">(14</td><td style="color: Black; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left"> Amortization</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_983_eus-gaap--AmortizationOfIntangibleAssets_iN_pn3n3_di_c20230101__20231231_z57U6T6P5Gqe" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Accumulated Amortization">(199</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; color: Black">December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iE_pn3n3_c20230101__20231231_z9INryp97Ec2" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Ending balance">2,313</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table>
</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2022-12-31" decimals="-3" id="Fact000633" unitRef="USD"> 1941000 </us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000635" unitRef="USD"> 585000 </us-gaap:FinitelivedIntangibleAssetsAcquired1>
<AIM:FinitelivedIntangibleAssetsAbandonments contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000637" unitRef="USD"> 14000 </AIM:FinitelivedIntangibleAssetsAbandonments>
<us-gaap:AmortizationOfIntangibleAssets contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact000639" unitRef="USD"> 199000 </us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2023-12-31" decimals="-3" id="Fact000641" unitRef="USD"> 2313000 </us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="AsOf2023-12-31_us-gaap_PatentsMember" id="Fact000643"> P17Y </us-gaap:FiniteLivedIntangibleAssetUsefulLife>
<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="AsOf2023-12-31_us-gaap_TrademarksMember" id="Fact000645"> P10Y </us-gaap:FiniteLivedIntangibleAssetUsefulLife>
<us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000647">
<p id="xdx_89E_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zHnSpfwsAuH" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Amortization of patents and trademarks for each of the next five years is as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B9_zhAkaswPrKwl" style="display: none">Schedule of Amortization of Patents and Trademarks</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td id="xdx_496_20231231_zCKkXJBtsaz9" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="4" style="padding-left: 10pt; font-weight: bold; text-align: left">Year Ending December 31,</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzzOp_zbJLLb14u2z6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2024</td><td style="width: 2%; text-align: left"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">241</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzzOp_zPNQZrxa9Ja1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">232</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANzzOp_zDGbXedYbRol" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2026</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">230</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANzzOp_zCtJZhxKZ7cl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">208</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maFLIANzzOp_zOUaQlCLJmCj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">189</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pn3n3_maFLIANzzOp_zlBjww1Mhkag" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">Thereafter</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,213</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzzOp_zLS4S6CRxsel" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-size: 10pt"><b>Total</b></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,313</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="AsOf2023-12-31" decimals="-3" id="Fact000649" unitRef="USD"> 241000 </us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="AsOf2023-12-31" decimals="-3" id="Fact000651" unitRef="USD"> 232000 </us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="AsOf2023-12-31" decimals="-3" id="Fact000653" unitRef="USD"> 230000 </us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="AsOf2023-12-31" decimals="-3" id="Fact000655" unitRef="USD"> 208000 </us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="AsOf2023-12-31" decimals="-3" id="Fact000657" unitRef="USD"> 189000 </us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="AsOf2023-12-31" decimals="-3" id="Fact000659" unitRef="USD"> 1213000 </us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2023-12-31" decimals="-3" id="Fact000661" unitRef="USD"> 2313000 </us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000663">
<p id="xdx_80C_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zeEijkQZOUYa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>(5) <span id="xdx_827_zSBL5lj9xQkf">Accrued Expenses</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b> </b></span></p> <p id="xdx_89B_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zSIIjs6SKLoi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Accrued expenses at December 31, 2023 and 2022 consist of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8BC_zyhFSMGVUH97" style="display: none">Schedule of Accrued Expenses</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" id="xdx_499_20231231_z2rxv0k69Rv6" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" id="xdx_492_20221231_zn2RaoZy28Qg" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">(in thousands) December 31,</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr id="xdx_409_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALCzYmu_zYBrjBcp2QAf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; color: Black">Compensation</td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">414</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">1</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCzYmu_zKIYB1fK0Ddc" style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left">Professional fees</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">1,352</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">492</td><td style="color: Black; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--AccruedClinicalTrialExpensesCurrent_iI_pn3n3_maALCzYmu_zzqPBPZ4UD2b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: left">Clinical trial expenses</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">184</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">110</td><td style="color: Black; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzYmu_ztQDNe2ckn7c" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Other expenses</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">36</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">203</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzYmu_zbtnnJc115Ec" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">1,986</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">806</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zEU7bP6y9Fl8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b> </b></span></p>
</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000665">
<p id="xdx_89B_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zSIIjs6SKLoi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Accrued expenses at December 31, 2023 and 2022 consist of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8BC_zyhFSMGVUH97" style="display: none">Schedule of Accrued Expenses</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" id="xdx_499_20231231_z2rxv0k69Rv6" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" id="xdx_492_20221231_zn2RaoZy28Qg" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">(in thousands) December 31,</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr id="xdx_409_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALCzYmu_zYBrjBcp2QAf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; color: Black">Compensation</td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">414</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">1</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCzYmu_zKIYB1fK0Ddc" style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left">Professional fees</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">1,352</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">492</td><td style="color: Black; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--AccruedClinicalTrialExpensesCurrent_iI_pn3n3_maALCzYmu_zzqPBPZ4UD2b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: left">Clinical trial expenses</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">184</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">110</td><td style="color: Black; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzYmu_ztQDNe2ckn7c" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Other expenses</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">36</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">203</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzYmu_zbtnnJc115Ec" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">1,986</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">806</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table>
</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2023-12-31" decimals="-3" id="Fact000667" unitRef="USD"> 414000 </us-gaap:EmployeeRelatedLiabilitiesCurrent>
<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="-3" id="Fact000668" unitRef="USD"> 1000 </us-gaap:EmployeeRelatedLiabilitiesCurrent>
<us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2023-12-31" decimals="-3" id="Fact000670" unitRef="USD"> 1352000 </us-gaap:AccruedProfessionalFeesCurrent>
<us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2022-12-31" decimals="-3" id="Fact000671" unitRef="USD"> 492000 </us-gaap:AccruedProfessionalFeesCurrent>
<AIM:AccruedClinicalTrialExpensesCurrent contextRef="AsOf2023-12-31" decimals="-3" id="Fact000673" unitRef="USD"> 184000 </AIM:AccruedClinicalTrialExpensesCurrent>
<AIM:AccruedClinicalTrialExpensesCurrent contextRef="AsOf2022-12-31" decimals="-3" id="Fact000674" unitRef="USD"> 110000 </AIM:AccruedClinicalTrialExpensesCurrent>
<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2023-12-31" decimals="-3" id="Fact000676" unitRef="USD"> 36000 </us-gaap:OtherAccruedLiabilitiesCurrent>
<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="-3" id="Fact000677" unitRef="USD"> 203000 </us-gaap:OtherAccruedLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2023-12-31" decimals="-3" id="Fact000679" unitRef="USD"> 1986000 </us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="-3" id="Fact000680" unitRef="USD"> 806000 </us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000682">
<p id="xdx_803_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zqitzPN2xp8j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>(6) <span id="xdx_823_z4u6BXmAK5W">Stockholders’ Equity</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(a) Preferred Stock</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company is authorized to issue <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--BoardMember_zS1iQPwaahH" title="Preferred stock, shares authorized">5,000,000</span> shares of $<span id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--BoardMember_zyt8J7mVj9tg" title="Preferred stock stated value">0.01</span> par value preferred stock with such designations, rights and preferences as may be determined by the Board. Of our authorized preferred stock, <span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zealkqpR9eDc" title="Preferred stock, shares authorized">4,000,000</span> shares have been designated as Series A Junior Participating Preferred Stock and <span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zvlMIC5enur8" title="Preferred stock, shares authorized">10,000</span> shares have been designated as Series B Convertible Preferred Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Series A Junior Participating Preferred Stock</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On May 10, 2023, the Company filed a Certificate of Increase in Delaware, increasing the number of preferred stock designated as Series A Junior Participating Preferred Stock to <span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230510__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_z74l9b9hkGJ9" title="Preferred stock, shares authorized">4,000,000</span> from <span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230509__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zCjyE5nJ0rU8" title="Preferred stock, shares authorized">250,000</span> shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Series B Convertible Preferred Stock</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company has designated <span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zyUvHgfAa0n9">10,000</span> shares of its preferred stock as Series B Convertible Preferred Stock (the “Preferred Stock”). Each share of Preferred Stock has a par value of $<span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zUZVOl7yMsYl" title="Preferred stock, par value">0.01</span> per share and a stated value equal to $<span id="xdx_900_ecustom--PreferredStockStatedValuePerShare_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zluVtpLH6Osk" title="Preferred stock, stated value">1,000</span> (the “Stated Value”). The shares of Preferred Stock shall initially be issued and maintained in the form of securities held in book-entry form and the Depository Trust Company or its nominee (“DTC”) shall initially be the sole registered holder of the shares of Preferred Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Each share of Preferred Stock shall be convertible, at any time and from time to time from and after the Original Issue Date at the option of the Holder thereof or at any time and from time to time on or after the second anniversary of the Original Issue Date at the option of the Corporation, into that number of shares of Common Stock (subject in each case to the limitations determined by dividing the Stated Value of such share of Preferred Stock by the Conversion Price). The conversion price for the Preferred Stock shall be equal to $<span id="xdx_90C_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20231231_zPphwTZ4MXS9" title="Preferred stock conversion price">0.20</span>, subject to adjustment herein (the “Conversion Price”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Pursuant to a registration statement relating to a rights offering declared effective by the SEC on February 14, 2019, AIM distributed to its holders of common stock and to holders of certain options and redeemable warrants as of February 14, 2019, at no charge, one non-transferable subscription right for each share of common stock held or deemed held on the record date. Each right entitled the holder to purchase one unit, at a subscription price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--AwardTypeAxis__us-gaap--RightsMember_znVBEGKrxhSj" title="Warrant exercise price">1,000</span> per unit, consisting of one share of Series B Convertible Preferred Stock with a face value of $<span id="xdx_907_ecustom--FaceValueOfStock_iI_pp0p0_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--AwardTypeAxis__us-gaap--RightsMember_zQesT79xUSc9" title="Preferred stock face value">1,000</span> (and immediately convertible into common stock at an assumed conversion price of $<span id="xdx_905_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqTl7bQPcnMf" title="Preferred stock conversion price">8.80</span>) and <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zFAs70jaJFbe" title="Number of warrants">114</span> warrants with an assumed exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zRa77juDYnRb" title="Subscription/exercise price">8.80</span>. The redeemable warrants are exercisable for <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zGXFztwsjXVk">five years</span> after the date of issuance. The net proceeds realized from the rights offering were approximately $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfWarrants_pp0p0_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RightsMember_zRJF43tg183l" title="Proceeds from warrants">4,700,000</span>. During the year ended December 31, 2023, <span id="xdx_909_eus-gaap--ConversionOfStockSharesIssued1_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zn2II1ahpKN5">7</span> shares of Series B Convertible Preferred Stock were converted into common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As of December 31, 2023 and 2022, the Company had <span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zP6HJLnaOIZi" title="Preferred stock, shares outstanding">689</span> and <span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zufJWl3Cz0u4" title="Preferred stock, shares outstanding">696</span> shares of Series B Convertible Preferred Stock outstanding, respectively. Holders shall be entitled to receive, and the Company shall pay, dividends on shares of Series B Preferred Stock equal (on an as-if-converted-to-Common-Stock basis) to and in the same form as dividend actually paid on shares of Common Stock when as and if such dividends are paid on shares of the Common Stock. Each such Preferred Share is convertible into <span id="xdx_907_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_zsjCPknBszub" title="Number of shares to be issued on conversion">114</span> shares of common stock. Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, the Holders shall be entitled to receive out of the assets, whether capital or surplus of the Company the same amount that a holder of Common Stock would receive if the Preferred Stock was fully converted. The Series B Convertible Preferred Stock does not carry voting Rights.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(b) Common Stock and Equity Finances</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company has authorized shares of <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231_zKs6QK6ZjIs8" title="Common stock, shares authorized">350,000,000</span> with specific limitations and restrictions on the usage of <span id="xdx_903_ecustom--CommonStockSharesWithLimitationsAndRestrictionsOnUsage_iI_pid_c20231231_zCFCveCaorp9" title="Common stock specific limitations and restrictions on usage">8,000,000</span> of the <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231_zGTsqQZ6xYxa" title="Common stock, shares authorized">350,000,000</span> authorized shares. <span style="background-color: white">As of December 31, 2023 and 2022, there were <span id="xdx_903_eus-gaap--CommonStockSharesIssued_iI_pid_c20231231_zl0Rlmup6df6" title="Common stock, shares issued"><span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20231231_z6db1PxcsX1" title="Common stock, shares outstanding">49,102,484</span></span> and <span id="xdx_906_eus-gaap--CommonStockSharesIssued_iI_pid_c20221231_zEB324dHpD77" title="Common stock, shares issued"><span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20221231_zo4X699gHUUj" title="Common stock, shares outstanding">48,084,287</span></span> shares of Common Stock issued and outstanding, respectively.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Employee Stock Purchase Plan (Not equity compensation)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On July 7, 2020, the Board approved a plan pursuant to which all directors, officers, and employees could purchase from the Company up to an aggregate of $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20200706__20200707__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorsOfficersAndEmployeesMember_zA3rkt9liEhk" title="Common stock shares issued, value">500,000</span> worth of shares at the market price (including subsequent plans, the “Employee Stock Purchase Plan”). Pursuant to NYSE American rules, this plan was effective for a sixty-day period commencing upon the date that the NYSE American approved the Company’s Supplemental Listing Application. The Company created successive new plans following the expiration of the July 7, 2020 plan. The latest plan was approved by the Board in January 2024 and expires in March 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During the year ended December 31, 2023, the Company issued a total of <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zviztUmxoLje" title="Number of shares issued upon transaction">419,285</span> shares of its Common Stock at a price ranging from $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MinimumMember_zdJMaElsXvJ1" title="Shares issued price per share">0.31</span> to $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MaximumMember_zZJhuARTYw22" title="Shares issued price per share">0.67</span> for total proceeds of approximately $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zSPJHE2neJwb" title="Proceeds from issuance of common stock">150,500</span> as part of the employee stock purchase plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During the year ended December 31, 2022, the Company issued a total of <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zfTmenNILks9" title="Number of shares issued upon transaction">86,817</span> shares of its Common Stock at prices ranging from $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MinimumMember_z44dlehfZ2uf" title="Shares issued price per share">0.76</span> to $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MaximumMember_zcYvfoEWRseb" title="Shares issued price per share">1.02</span> for total proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zMIIUdDZAHO5" title="Proceeds from issuance of common stock">80,000</span> as part of the employee stock purchase plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Warrants (Rights offering)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">On September 27, 2019, the Company closed a public offering underwritten by A.G.P./Alliance Global Partners, LLC (the “Offering”) of (i) <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20190926__20190927__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember_zPxn6Z5v7yPa" title="Number of shares issued upon transaction">1,740,550</span> shares of Common Stock; (ii) pre-funded warrants exercisable for <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20190927__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember_z95jjsb0xCgf" title="Warrants issued">7,148,310</span> shares of Common Stock (the “Pre-funded Warrants”), and (iii) warrants to purchase up to an aggregate of <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20190927__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantsMember_zZktK4vOrA5a" title="Number of warrant to purchase shares of common stock">8,888,860</span> shares of Common Stock (the “Warrants”). In conjunction with the Offering, we issued </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">a Representative’s Warrant to purchase up to an aggregate of <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20190927__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeWarrantsMember__srt--RangeAxis__srt--MaximumMember_zcUVBXAOEfFe" title="Number of warrant to purchase shares of common stock">266,665</span> shares of common stock (the “Representative’s Warrant”)<span style="background-color: white">. The shares of Common Stock and Warrants were sold at a combined Offering price of $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20190927__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zG0XCk86BvSl" title="Shares issued price per share">0.90</span>, less underwriting discounts and commissions. Each Warrant sold with the shares of Common Stock represents the right to purchase one share of Common Stock at an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20190927__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z45VysI4Rdh7" title="Warrant exercise price">0.99</span> per share. The Pre-Funded Warrants and Warrants were sold at a combined Offering price of $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20190927__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zQODiBo59fs7" title="Shares issued price per share">0.899</span>, less underwriting discounts and commissions. The Pre-Funded Warrants were sold to purchasers whose purchase of shares of Common Stock in the Offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than <span id="xdx_90B_ecustom--PercentageOfOutstandingStock_iI_pid_dp_uPure_c20190927__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zKDoG8e4n7Nk" title="Percentage of outstanding stock">4.99</span>% of the Company’s outstanding Common Stock immediately following the consummation of the Offering, in lieu of shares of Common Stock. Each Pre-Funded Warrant represents the right to purchase one share of Common Stock at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20190927__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zqDXj99Nqi93" title="Exercise price">0.001</span> per share. The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until the Pre-Funded Warrants are exercised in full. A registration statement on Form S-1, relating to the Offering was filed with the SEC and was declared effective on September 25, 2019, the net proceeds were approximately $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0p0_c20190926__20190927__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember_zZNgiCM0cLbl" title="Proceeds from Issuance or Sale of Equity">7,200,000</span>. During the year ended </span>December 31<span style="background-color: white">, 2020, <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesOther_pp0p0_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_z3g8fsCi3e93" title="Stock issued during period shares other">1,870,000</span> of the Pre-funded Warrants were exercised and <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1TUJZd6f9eb" title="Pre-funded warrants exercised">8,873,960</span> Warrants were exercised. </span>In addition, on March 25, 2020, the Representative’s Warrant was amended to permit exercise of such warrant to commence on March 30, 2020. These warrants were exercised on March 31, 2020 and an aggregate of <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20200331__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeWarrantsMember__srt--RangeAxis__srt--MaximumMember_zBNFf2hF7fXf" title="Warrants exercised aggregate">266,665</span> shares were issued upon exercise of this warrant for gross proceeds of approximately $<span id="xdx_90E_eus-gaap--ProceedsFromWarrantExercises_pp0p0_c20200330__20200331_zt1Btk7f3ku4" title="Warrant gross proceeds">264,000</span> and a $<span id="xdx_907_ecustom--WarrantModifications_pp0p0_c20200330__20200331_z781IO7BCGn9" title="Warrant modification">46,000</span> expense for the warrant modification. No Warrants were exercised during the year ended December 31, 2023 and 2022. As of December 31, 2023 and 2022 there are <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231_zkWxC6X5Uyl1" title="Warrant outstanding"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231_zrwFNaFiUAVi" title="Warrant outstanding">15,000</span></span> Warrants outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Equity Distribution Agreement</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On April 19, 2023, the Company entered into an Equity Distribution Agreement (the “EDA”) with Maxim Group LLC (“Maxim”), pursuant to which the Company may sell, from time to time, shares of its common stock having an aggregate offering price of up to $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20230418__20230419__dei--LegalEntityAxis__custom--MaximGroupLLCMember_zNlgcvJurGw">8,500,000</span> through Maxim, as agent (the “Offering”). Sales under the EDA were registered under the S-3 Shelf Registration Statement. Under the terms of the EDA, Maxim will be entitled to a transaction fee at a fixed rate of <span id="xdx_902_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20230418__20230419__dei--LegalEntityAxis__custom--MaximGroupLLCMember_zMbKWKkSgAB1" title="Transaction fee rate">3.0</span>% of the gross sales price of shares sold under the EDA. During the year ended December 31, 2023, the Company sold <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__dei--LegalEntityAxis__custom--MaximGroupLLCMember_zIliAU2gMc1a" title="Shares sold">598,114</span> shares under the EDA for total gross proceeds of approximately $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230101__20231231__dei--LegalEntityAxis__custom--MaximGroupLLCMember_zCHyKPIRBnx6" title="Gross proceeds from issuance of common stock">344,000</span>, which includes a <span id="xdx_90D_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20230101__20231231__dei--LegalEntityAxis__custom--MaximGroupLLCMember_zTOA1FDdlyr4" title="Transaction fee rate">3.0</span>% fee to Maxim of $<span id="xdx_908_eus-gaap--DebtInstrumentFeeAmount_iI_c20231231__dei--LegalEntityAxis__custom--MaximGroupLLCMember_zxan4REYwBEh">10,326</span>. Subsequent to the year ended December 31, 2023, the Company sold <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20240101__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zDyG2c83P0r1" title="Shares sold">699,568</span> shares under the EDA for total gross proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240101__20240101__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zRQPJ8F7ZeUj" title="Proceeds from issuance of common stock">316,392</span>, which includes a <span id="xdx_903_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20240101__20240101__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBW1BZtSXEI7" title="Transaction fee rate">3.0</span>% fee to Maxim of $<span id="xdx_90D_eus-gaap--DebtInstrumentFeeAmount_iI_c20240101__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zYidNbQUvnb3">9,492</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Rights Plan</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On May 12, 2023, the Company amended and restated its November 14, 2017 Rights Plan with American Stock Transfer & Trust Company as Rights Agent (the “Rights Plan”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(c) Common Stock Options and Warrants</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>(i) Stock Options</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The 2018 Equity Incentive Plan, effective September 12, 2018, authorizes the grant of (i) Incentive Stock Options, (ii) Nonstatutory Stock Options, (iii) Stock Appreciation Rights, (iv) Restricted Stock Awards, (v) Restricted Stock Unit Awards, (vi) Performance Stock Awards, (vii) Performance Cash Awards, and (viii) Other Stock Awards. Initially, a maximum of <span id="xdx_902_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20180912__us-gaap--AwardTypeAxis__custom--EquityIncentivePlanTwoThousandNineMember_zxtEOC1VeTG4" title="Number of common stock reserved for potential issuance">7,000,000</span> shares of common stock is reserved for potential issuance pursuant to awards under the 2018 Equity Incentive Plan. Unless sooner terminated, the 2018 Equity Incentive Plan will continue in effect for a period of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20180912__20180912__us-gaap--AwardTypeAxis__custom--EquityIncentivePlanTwoThousandNineMember_zJTZfbENHDnc">10</span> years from its effective date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Equity Incentive Plans of 2018 are administered by the Board of Directors. The Plans provide for awards to be made to such Officers, other key employees, non-employee Directors, consultants and advisors of the Company and its subsidiaries as the Board may select.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Stock options awarded under the Plans may be exercisable at such times (not later than 10 years after the date of grant) and at such exercise prices (not less than fair market value at the date of grant) as the Board may determine. The Board may provide for options to become immediately exercisable upon a “change in control”, which is defined in the Plans to occur upon any of the following events: (a) the acquisition by any person or group, as beneficial owner, of 20% or more of the outstanding shares or the voting power of the outstanding securities of the Company; (b) either a majority of the Directors of the Company at the annual stockholders meeting has been nominated other than by or at the direction of the incumbent Directors of the Board, or the incumbent Directors cease to constitute a majority of the Company’s Board; (c) the Company’s stockholders approve a merger or other business combination pursuant to which the outstanding common stock of the Company no longer represents more than 50% of the combined entity after the transaction; (d) the Company’s stockholders approve a plan of complete liquidation or an agreement for the sale or disposition of all or substantially all of the Company’s assets; or (e) any other event or circumstance determined by the Company’s Board to affect control of the Company and designated by resolution of the Board as a change in control.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The fair value of each option award is estimated on the date of grant using a Black-Scholes-Merton pricing option valuation model. Expected volatility is based on the historical volatility of the price of the Company’s stock. The risk-free interest rate is based on U.S. Treasury issues with a term equal to the expected life of the option and equity warrant. The Company uses historical data to estimate expected dividend yield, life and forfeiture rates. The expected life of the options and equity warrants was estimated based on historical option and equity warrant holders’ behavior and represents the period of time that options and equity warrants are expected to be outstanding. The fair values of the options granted were estimated based on the following weighted average assumptions:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zwBn9bZOROJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8BE_zRdQc4lhI2ed" style="display: none">Schedule of Options and Equity Estimated Based on Weighted Average Assumptions</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; color: Black; text-align: left">Risk-free interest rate</td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 14%; color: Black; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231_zwsTOtjinuEg" title="Risk-free interest rate">4.37</span></td><td style="width: 1%; color: Black; text-align: left">%</td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 14%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zyu0LDV1Orji" title="Risk-free interest rate">1.74</span>% - <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_z7IM9rf56CHf" title="Risk-free interest rate">3.88</span>%</span></td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left">Expected dividend yield</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20231231_zLRWWWaQR3E9" style="color: Black; text-align: right" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0817">—</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20220101__20221231_zGhPgwxEQY9a" style="color: Black; text-align: right" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0819">—</span></td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: left">Expected life</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zRPHlQrFeOEf" title="Expected life">10</span> years</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_ze6P7e4vBhy7" title="Expected life">10</span> years</span></td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left">Expected volatility</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231_zpSADdjUppo7" title="Expected volatility">99.91</span></td><td style="color: Black; text-align: left">%</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zqFkVRZdLFeg" title="Expected volatility">98.43</span>% - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zbNkTV8pKtak" title="Expected volatility">107.18</span>%</span></td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: left">Weighted average grant date fair value for options issued</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_904_ecustom--WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued_c20230101__20231231_zDcZCd9f8oq8" title="Weighted average grant date fair value for options issued">$0.43 per option for 400,000 options</span></span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90F_ecustom--WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued_c20220101__20221231_zwLGodKu5o01" title="Weighted average grant date fair value for options issued">$0.51 per option for 850,000 options</span></span></td><td style="color: Black; text-align: left"> </td></tr> </table> <p id="xdx_8A1_zpgKNkwD8rIe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The exercise price of all stock options and equity warrants granted was equal to or greater than the fair market value of the underlying common stock on the date of the grant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--EquityIncentivePlanTwoThousandNineMember_z5ECVcr9LKd3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Information regarding the options approved by the Board of Directors under the Equity Plan of 2009 is summarized below. The plan expired on June 24, 2019:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8BA_z2r3OQ5v0nMb" style="display: none">Schedule of Stock Option Activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black; text-align: center"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="color: Black; text-align: center"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center"> </td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Option</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted <br/>Average <br/>Exercise</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center"> </td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Option</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted <br/>Average <br/>Exercise</td><td style="color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black; text-align: center"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 34%; color: Black; text-align: left">Outstanding, beginning of year</td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zyDxeqphjbwl" style="width: 7%; color: Black; text-align: right" title="Number of options outstanding, beginning of year">124,399</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 7%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_902_eus-gaap--SharePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zxwHdtQPhQRl" title="Option price outstanding, beginning of year">13.20</span> – <span id="xdx_902_eus-gaap--SharePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zUvFe764HwR1" title="Option price outstanding, beginning of year">1,003.20</span></span></td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zXR0wPDoayE9" style="width: 7%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">22.23</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_z58yybuTjzag" style="width: 7%; color: Black; text-align: right" title="Number of options outstanding, beginning of year">128,504</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 7%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_900_eus-gaap--SharePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zL37ie7VDOo5" title="Option price outstanding, beginning of year">13.20</span> – <span id="xdx_909_eus-gaap--SharePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zZH7zfDN4kwe" title="Option price outstanding, beginning of year">2,127.84</span></span></td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zZVXpZMZWUk3" style="width: 7%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">25.58</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black">Granted</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zJpxjOdQrXP5" style="color: Black; text-align: right" title="Number of options, granted"><span style="-sec-ix-hidden: xdx2ixbrl0853">—</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantedInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zEiDo8XYt6ji" style="color: Black; text-align: right" title="Option price, granted"><span style="-sec-ix-hidden: xdx2ixbrl0855">—</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_z1vaUNUBJ9Lk" style="color: Black; text-align: right" title="Weighted average exercise price, granted"><span style="-sec-ix-hidden: xdx2ixbrl0857">—</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zXREqcdUViH5" style="color: Black; text-align: right" title="Number of options, granted"><span style="-sec-ix-hidden: xdx2ixbrl0859">—</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantedInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zJouwSlxcz4c" style="color: Black; text-align: right" title="Option price, granted"><span style="-sec-ix-hidden: xdx2ixbrl0861">—</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zQtSE9KhTfWf" style="color: Black; text-align: right" title="Weighted average exercise price, granted"><span style="-sec-ix-hidden: xdx2ixbrl0863">—</span></td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black">Forfeited</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zSz346mvRzqe" style="color: Black; text-align: right" title="Number of options, forfeited">(5,047</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zvrLx2fgS4n" title="Option price, forfeited">9.68</span>-<span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zvOUj8mO8cW9" title="Option price, forfeited">327.36</span></span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zTTIYX7nlGm" style="color: Black; text-align: right" title="Weighted average exercise price, forfeited">57.79</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zVTFyT72V1P7" style="color: Black; text-align: right" title="Number of options, forfeited">(4,105</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zeAPvCW0iP6l" title="Option price, forfeited">16.76</span>-<span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zpMqhGQSPp0h" title="Option price, forfeited">2,127.84</span></span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zcqllAbQ2tF6" style="color: Black; text-align: right" title="Weighted average exercise price, forfeited">129.88</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black">Exercised</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_z18DmVOsWDG4" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0881">—</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zkPHisNO4j4e" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Option price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0883">—</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zEJEklSgmZP7" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0885">—</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zEF8oX7qioI2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0887">—</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zwkacwJmgPY8" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Option price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0889">—</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zAYwZMXI0UG2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0891">—</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Outstanding, end of year</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zoBzU2hbFi5a" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, ending of year">119,352</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_906_eus-gaap--SharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zbJCCgyupPl9" title="Option price exercisable, end of year">13.20</span>-<span id="xdx_902_eus-gaap--SharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zmDKs07uvwPf" title="Option price exercisable, end of year">2,127.84</span></span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zfG1XOAqxnWi" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price outstanding, end of year">20.72</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zvF6i9mV3AVl" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, ending of year">124,399</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90C_eus-gaap--SharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zh6uBgLlzTng" title="Option price exercisable, end of year">13.20</span>-<span id="xdx_90D_eus-gaap--SharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zXu4uzXR0lye" title="Option price exercisable, end of year">1,003.20</span></span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zL1lIOUUh3j8" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price outstanding, end of year">22.23</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left">Exercisable, end of year</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zQtOL6t0A84c" style="color: Black; text-align: right" title="Number of options exercisable, end of year">119,352</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zhq3muq2nUC4" title="Option price exercisable, end of year">13.20</span>-<span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zYqUKFECPByh" title="Option price exercisable, end of year">2,127.84</span></span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"> </td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_z1OAXnd2DIL5" style="color: Black; text-align: right" title="Number of options exercisable, end of year">124,399</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zk7y8OaHVdG3" title="Option price exercisable, end of year">13.20</span>-<span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zCBdKfReAHJh" title="Option price exercisable, end of year">1,003.20</span></span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"> </td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Weighted average remaining contractual life (years)</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; white-space: nowrap; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zuO6mBNBKiS3" title="Weighted average remaining contractual life (years)">4.06</span> years</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"> </td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"> </td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; white-space: nowrap; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zEz3nLpaJO8h" title="Weighted average remaining contractual life (years)">5.98</span> years</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"> </td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"> </td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> </table> <p id="xdx_8AB_zwEfEfkEYN0h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p> <p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--EquityIncentivePlansTwoThousandAndEighteenMember_zAiKbRs8u0ze" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Information regarding the options approved by the Board of Directors under the Equity Plan of 2018 is summarized below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B1_zjBHKIJSnVTc" style="display: none">Schedule of Stock Option Activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black; text-align: center"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="color: Black; text-align: center"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center"> </td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Option</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted <br/>Average <br/>Exercise</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center"> </td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Option</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted <br/>Average <br/>Exercise</td><td style="color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black; text-align: center"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 34%; color: Black; text-align: left">Outstanding, beginning of year</td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zY8TdhJVuvQk" style="width: 7%; color: Black; text-align: right" title="Number of options outstanding, beginning of year">2,474,971</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 7%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_906_eus-gaap--SharePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zVYEt9sxdiZ" title="Option price outstanding, beginning of year">0.31</span>-<span id="xdx_903_eus-gaap--SharePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_z2rNeV89tPai" title="Option price outstanding, beginning of year">9.68</span></span></td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zbMybyjAV6bd" style="width: 7%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">1.72</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zvIdOAMVrKhf" style="width: 7%; color: Black; text-align: right" title="Number of options outstanding, beginning of year">1,650,017</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td style="white-space: nowrap; width: 7%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_906_eus-gaap--SharePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_za8xt9HeolC9" title="Option price outstanding, beginning of year">1.11</span> – <span id="xdx_90D_eus-gaap--SharePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zG0Jrw48ZFRe" title="Option price outstanding, beginning of year">9.68</span></span></td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zTolGtT0cWY7" style="width: 7%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">2.35</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black">Granted</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zvvgWvWDNKf4" style="color: Black; text-align: right" title="Number of options, granted">400,000</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zHwdNuwTBrXe" title="Option price, granted">0.47</span>-<span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zqSZB6vsmL4l" title="Option price, granted">0.47</span></span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_z3Z2NtWcprWa" style="color: Black; text-align: right" title="Weighted average exercise price, granted">0.47</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zoOGxTxPaFf2" style="color: Black; text-align: right" title="Number of options, granted">850,000</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zRwCHfg9H1sf" title="Option price, granted">0.31</span> – <span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zm8tE7cwMMI5" title="Option price, granted">1.71</span></span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zCtFRvKSBhF9" style="color: Black; text-align: right" title="Weighted average exercise price, granted">0.51</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black">Forfeited</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zQU5yoP1BaQe" style="color: Black; text-align: right" title="Number of options, forfeited">(60,829</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zc1uJU6MXwq9" title="Option price, forfeited">0.31</span>-<span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zcSqfq5LYhIg" title="Option price, forfeited">9.68</span></span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zoAUy8QKADD5" style="color: Black; text-align: right" title="Weighted average exercise price, forfeited">1.98</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zafqHYOhNG7k" style="color: Black; text-align: right" title="Number of options, forfeited">(25,046</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_z1UHLlVk9Lck" title="Option price, forfeited">1.85</span> – <span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_znIS51EDLl6h" title="Option price, forfeited">9.68</span></span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zOw8BdlBCRg6" style="color: Black; text-align: right" title="Weighted average exercise price, forfeited">1.86</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black">Exercised</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_za9zosND1Nb8" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0975">—</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_z3YcSiWVvL9b" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Option price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0977">—</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zCrE5j3jPCEd" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0979">—</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zCa1C61l8a2k" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0981">—</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_z8VpDauNgOV4" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Option price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0983">—</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zuAwoTRYyAQg" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0985">—</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Outstanding, end of year</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zKBd7YNedvef" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, ending of year">2,814,142</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_901_eus-gaap--SharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_ziSamlBxMNJ8" title="Option price exercisable, end of year">0.31</span>-<span id="xdx_906_eus-gaap--SharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zDnIoZJDr0G7" title="Option price exercisable, end of year">9.68</span></span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_znS6WrtDV1Hi" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price outstanding, end of year">1.54</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zhuLay5MN263" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, ending of year">2,474,971</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90D_eus-gaap--SharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zIIlppJooD0k" title="Option price exercisable, end of year">0.31</span> – <span id="xdx_901_eus-gaap--SharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zmrKoiA61a5k" title="Option price exercisable, end of year">9.68</span></span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zWr1FaPC9Gyk" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price outstanding, end of year">1.72</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left">Exercisable, end of year</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zWKmTaWD9rXk" style="color: Black; text-align: right" title="Number of options exercisable, end of year">2,397,474</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zUBZQpHHdkQh" title="Option price exercisable, end of year">0.31</span>-<span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zyNfZEZGjY7e" title="Option price exercisable, end of year">327.36</span></span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zCD5NSe1LC96" style="color: Black; text-align: right">4.71</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zV4AA1jdL17j" style="color: Black; text-align: right" title="Number of options exercisable, end of year">1,916,637</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zFNBhjSmkwo6" title="Option price exercisable, end of year">0.41</span> – <span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zfMiYZ3wyc4l" title="Option price exercisable, end of year">9.68</span></span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_ztzNs9InbFV6" style="color: Black; text-align: right">2.22</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: left">Weighted average remaining contractual life (years)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="white-space: nowrap; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zSd2YiyZrKt1" title="Weighted average remaining contractual life (years)">7.96</span> years</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"> </td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"> </td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="white-space: nowrap; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zz081jStHDR4" title="Weighted average remaining contractual life (years)">9.65</span> years</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"> </td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"> </td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Available for future grants</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_z8rTmEuI5Bg2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, beginning of year">1,210,286</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"> </td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"> </td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_z8NQ3MnKjyYg" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, beginning of year">466,120</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"> </td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"> </td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zCt6AGdS0HJb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Stock option activity during the years ended December 31, 2023 and 2022 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z3XyNvJ9gsf9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Vested stock option activity for employees:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B1_zF0PfjjCWiX8" style="display: none">Schedule of Vest Stock Option Activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="color: Black; text-align: center"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Number of</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted Average Exercise</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted <br/>Average <br/>Remaining <br/>Contracted <br/>Term</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Aggregate Intrinsic</td><td style="color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black; text-align: center"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Options</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">(Years)</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Value</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; color: Black">Outstanding December 31, 2021</td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zO1TgIVsrq3b" style="width: 10%; color: Black; text-align: right" title="Number of options outstanding, beginning of year">1,498,798</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 10%; color: Black; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zmuq5cZqvpD1" title="Weighted Average Exercise Price Outstanding, Beginning of Period">4.22</span></td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 10%; color: Black; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zsJ97lMV98Kh" title="Weighted Average Remaining Contracted Term (years) Outstanding">9.11</span></td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zq9gGVhvysT5" style="width: 10%; color: Black; text-align: right" title="Aggregate Intrinsic Value Outstanding, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1033">—</span></td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black">Granted</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zHWslta3k897" style="color: Black; text-align: right" title="Number of options, granted">550,000</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zsjODRHZRBU4" title="Weighted Average Exercise Price, Granted">0.49</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zYRFovyjgKfd" title="Weighted Average Remaining Contracted Term (years) Granted">9.71</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black">Forfeited</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zMZbdMXUmn7h" style="color: Black; text-align: right" title="Number of Options, Forfeited">(28,584</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z8yzOyFJPC1i" title="Weighted Average Exercise Price, Forfeited">17.71</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black">Expired</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zl65lMGPS3Ol" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of Options, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1045">—</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zzTauXEBh8Bf" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1047">—</span></span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black">Outstanding December 31, 2022</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zHCcpauMSbZ" style="color: Black; text-align: right" title="Number of options outstanding, beginning of year">2,020,214</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zacgZgdlDl7j" title="Weighted Average Exercise Price Outstanding, Beginning of Period">3.01</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zN3H21xyxjt4" title="Weighted Average Remaining Contracted Term (years)">8.86</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zvg3m0wkDAXe" style="color: Black; text-align: right" title="Aggregate Intrinsic Value Outstanding, beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1055">—</span></td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black">Granted</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zrdSKYkaXDOa" style="color: Black; text-align: right" title="Number of options, granted">400,000</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zOVWpyGMHwm5" title="Weighted Average Exercise Price, Granted">0.47</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zi6E1SbAFp31" title="Weighted Average Remaining Contracted Term (years) Granted">10.17</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black">Forfeited</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zcQGwKQHoVwf" style="color: Black; text-align: right" title="Number of Options, Forfeited">(7,601</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zapcVRUqDmL7" title="Weighted Average Exercise Price, Forfeited">9.68</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"> </td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black">Expired</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7DeSaNwESe9" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of Options, Expired">(4,175</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zoNz9hltHWEb" title="Weighted Average Exercise Price, Expired">41.61</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; color: Black">Outstanding December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zcNhF6wBaGpl" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of Options Outstanding, Ending of Period">2,408,438</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z6h0jEL4K4Be" title="Weighted Average Exercise Price Outstanding, End of Period">2.50</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zC2GiteBVcEf" title="Weighted Average Remaining Contracted Term (years) Outstanding">8.70</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zGLvweXtYT3d" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate Intrinsic Value Outstanding, Ending of Period"><span style="-sec-ix-hidden: xdx2ixbrl1077">—</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Vested and expected to vest at December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zFy1OWgL3JOh" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of Options, Vested and Expected to Vest">2,041,772</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z0oWA11Q0s1d" title="Weighted Average Exercise Price, Vested and Expected to Vest">1.90</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zV7NaQghpaf4" title="Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest">6.73</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zeCECss9Spk3" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate Intrinsic Value, Vested and Expected to Vest"><span style="-sec-ix-hidden: xdx2ixbrl1085">—</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; color: Black">Exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_ziJBXkFM5CQj" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of Options Exercisable, End of Period">2,041,772</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zTkUx06vDIdk" title="Weighted Average Exercise Price Exercisable, Ending of Period">1.90</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zbU0KvwGWSzh" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period">6.73</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z9fWMvpxLccf" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate Intrinsic Value, Exercisable at End of Period"><span style="-sec-ix-hidden: xdx2ixbrl1093">—</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table> <p id="xdx_8AE_zaPFwFMU6Lmc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The weighted-average grant-date fair value of employee options vested during the year ended December 31, 2023 was $<span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesMember_zDLLW4mKBtch" title="Share-based payment award options vested in period fair value">184,000</span> for <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesMember_zexAY94cljFd" title="Number of options, granted">424,999</span> options at $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesMember_zwhJUHGEuao6" title="Weighted average exercise price, granted">0.43</span> per option and during year ended December 31, 2022 was $<span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesMember_zqKhD2stjHF7" title="Number of options, granted">768,666</span> for <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesMember_z3UmXsez7IE1" title="Number of options, granted">575,000</span> options at $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesMember_zIGmU7JOYkvk">1.34</span> per option.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_898_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zCvDRE2gnWB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Unvested stock option activity for employees:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8BF_znkiS1cgVg4i" style="display: none">Schedule of Unvested Stock Option Activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td colspan="2" style="text-align: center">Number of</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted Average Exercise</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Average Remaining Contracted Term</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Aggregate Intrinsic</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; font-size: 12pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Options</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">(Years)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%; text-align: left"><span style="font-size: 10pt">Unvested December 31, 2021</span></td><td style="width: 2%; text-align: left"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zYPcWmfJ2bFa" style="width: 13%; text-align: right" title="Number of Options Unvested, Beginning of Period">412,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zfTmqmYk7oZi" style="width: 13%; text-align: right" title="Weighted Average Exercise Price Unvested, Beginning of Period">4.15</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zFao3ebbr6Kk" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period">5.85</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_za0d7W3RS2Xc" style="width: 13%; text-align: right" title="Aggregate Intrinsic Value Unvested, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1114">—</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">Granted</span></td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zUmwAfngLDy7" style="text-align: right" title="Number of Options, Granted">550,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zWlXu0GmreYe" style="text-align: right" title="Weighted Average Exercise Price, Granted">0.49</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zFIDIyoHTT51" title="Weighted Average Remaining Contracted Term (years) Granted">9.71</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">Vested</span></td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zUd9hMgV906j" style="text-align: right" title="Number of Options, Vested">(541,590</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zvY5uzFb8gml" style="text-align: right" title="Weighted Average Exercise Price, Vested">1.31</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zIct0KcJzpa" title="Weighted Average Remaining Contracted Term (years) Vested">9.73</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">Forfeited</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zmC8aMjsw6P8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Forfeited">(28,584</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zfvXdF3IyfI8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited">17.71</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">Unvested December 31, 2022</span></td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zJytXXS7WdLg" style="text-align: right" title="Number of Options Unvested, brginning of Period">392,326</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zYqo1XyBaiW8" style="text-align: right" title="Weighted Average Exercise Price Unvested, beginning of Period">0.80</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zzU6tzWxcv9h" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period">8.86</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z52rYMIINNBe" style="text-align: right" title="Aggregate Intrinsic Value Unvested, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1138">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">Granted</span></td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z20vLrXDNmCd" style="text-align: right" title="Number of Options, Granted">400,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z2ibJo58kDtg" style="text-align: right">0.47</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z74w8QEON2Lj" title="Weighted Average Remaining Contracted Term (years) Granted">10.17</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">Vested</span></td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z2Vl6Zu9x53k" style="text-align: right" title="Number of Options, Vested">(413,884</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7xkHbiObAq3" style="text-align: right" title="Weighted Average Exercise Price, Vested">1.90</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zyXuLX3gvPZ2" title="Weighted Average Remaining Contracted Term (years) Vested">6.73</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">Forfeited</span></td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zXha9Elcmyj6" style="text-align: right" title="Number of Options, Forfeited">(7,601</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zxLNQ5Ziljpf" style="text-align: right" title="Weighted Average Exercise Price, Forfeited">9.68</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">Expired</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zweDV8Orlgoa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Expired">(4,175</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z8ut2qIb6Hr7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Expired">41.61</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">Unvested December 31, 2023</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zuhtlgLdSXq6" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Unvested, End of Period">366,666</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zwsYE33HGdii" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Unvested, Ending of Period">2.13</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zijWQVLsXHS3" title="Average Remaining Contractual Term (years) Unvested, End of Period">12.44</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iE_pdp0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zmvRfA3i91T" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Unvested, End of Period"><span style="-sec-ix-hidden: xdx2ixbrl1165">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_zG18YW8IC09l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p> <p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zKEj4qh8kNW8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Vested stock option activity for non-employees:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B7_zsalMMWYrOo9" style="display: none">Schedule of Vest Stock Option Activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="color: Black; text-align: center"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Number of</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted Average Exercise</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted Average Remaining Contracted Term</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Aggregate Intrinsic</td><td style="color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black; text-align: center"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Options</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">(Years)</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Value</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%; color: Black">Outstanding December 31, 2021</td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zeLMRFWVSE3" style="width: 13%; color: Black; text-align: right" title="Number of Options Outstanding, Beginning of Period">279,723</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zjxZzSWuCEzg" style="width: 13%; color: Black; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning of Period">6.12</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 13%; color: Black; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zGT7T885f6n" title="Weighted Average Remaining Contracted Term (years) Outstanding">7.93</span></td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zwTf0HgrbKA4" style="width: 13%; color: Black; text-align: right" title="Aggregate Intrinsic Value Outstanding, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1175">—</span></td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black">Granted</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zHqBdcQNNThg" style="color: Black; text-align: right" title="Number of Options, Granted">300,000</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zDLQRLU0QIA5" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Granted">0.54</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zklP6kdTEUS2" title="Grants in period, weighted average grant date fair value">9.68</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black">Exercised</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zIvMhmMIRAqg" style="color: Black; text-align: right" title="Number of Options, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1183">—</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zabhqOevdvF1" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1185">—</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black">Forfeited</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zFdiQDQxoJOi" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of Options, Forfeited">(568</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMTDeOwOSFy4" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">153.12</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black">Outstanding December 31, 2022</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zfnZbYxoSu4d" style="color: Black; text-align: right" title="Number of Options Outstanding, beginning of Period">579,155</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zGm3M4v0hyO1" style="color: Black; text-align: right" title="Weighted Average Exercise Price Outstanding, beginning of Period">3.09</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zuMxR7aeO8Qh" title="Weighted Average Remaining Contracted Term (years) Outstanding">8.36</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z5GIlJdwHsv1" style="color: Black; text-align: right" title="Aggregate Intrinsic Value Outstanding, beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1196">—</span></td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black">Granted</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zi24FblTlE0h" style="color: Black; text-align: right">360,000</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zwYTkNC4K6Mb" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Granted">0.46</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted_pid_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z0TQxSmD7eFl" title="Grants in period, weighted average grant date fair value">10.04</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black">Exercised</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zYYPNo9CN7h6" style="color: Black; text-align: right" title="Number of Options, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1203">—</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zwJV7OUBpVL6" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1205">—</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black"> Expired</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zXolyBGwaY7l" style="color: Black; text-align: right" title="Number of Options,expired">(653</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExpired_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zrVMvL9EzSG9" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Expired">145.24</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; color: Black">Forfeited</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zCqd3imdscFa" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of Options, Forfeited">(53,447</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z39YSf78win8" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">1.31</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; color: Black">Outstanding December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zezhSipQcXse" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of Options Outstanding, Ending of Period">885,055</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zzDRpEteldth" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted Average Exercise Price Outstanding, End of Period">2.02</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zrKKGIbA2RTb" title="Weighted Average Remaining Contracted Term (years) Outstanding">9.23</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zO67r7VahRxd" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate Intrinsic Value Outstanding, Ending of Period"><span style="-sec-ix-hidden: xdx2ixbrl1220">—</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Vested and expected to vest at December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zJFJeLgHCPgi" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of Options, Vested and Expected to Vest">550,055</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zsVw5JM0Klud" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted Average Exercise Price, Vested and Expected to Vest">2.56</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z3MFGjsRWk45" title="Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest">10.02</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zfSGe30qZ0Se" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate Intrinsic Value, Vested and Expected to Vest"><span style="-sec-ix-hidden: xdx2ixbrl1228">—</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; color: Black">Exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zXLRGkup8nPg" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of Options Exercisable, End of Period">550,055</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zqqDgSxBntta" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted Average Exercise Price Exercisable, Ending of Period">2.56</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zEiXLyYbrHRe" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period">10.02</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zVCTKbz8CYx2" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate Intrinsic Value, Exercisable at End of Period"><span style="-sec-ix-hidden: xdx2ixbrl1236">—</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table> <p id="xdx_8A5_zHocvI0bZukb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The weighted-average grant-date fair value of non-employee options vested during year 2023 was $<span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20230101__20231231__srt--TitleOfIndividualAxis__custom--NonEmployeeMember_znEFRK5NZ8l7" title="Share-based payment award options vested in period fair value">90,000</span> for <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__srt--TitleOfIndividualAxis__custom--NonEmployeeMember_zzSmpvfyg8Q2" title="Number of options, granted">191,666</span> options at $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__srt--TitleOfIndividualAxis__custom--NonEmployeeMember_zSgr1cy7Cd98" title="Weighted average exercise price, granted">0.47</span> per option and during the year 2022 was $<span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20220101__20221231__srt--TitleOfIndividualAxis__custom--NonEmployeeMember_zuhPnyCsCu55" title="Share-based payment award options vested in period fair value">247,166</span> for<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231__srt--TitleOfIndividualAxis__custom--NonEmployeeMember_zvJmne3ZNVc1" title="Number of options, granted"> 229,053</span> options at $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--NonEmployeeMember_zBl8iBiuAg14" title="Weighted average exercise price, granted">1.08</span> per option.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zYm9rSt3FyF" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Unvested stock option activity for non-employees:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8BE_zmTaiMUsaseh" style="display: none">Schedule of Unvested Stock Option Activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Number of</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted Average Exercise</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted <br/>Average <br/>Remaining <br/>Contracted <br/>Term</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Aggregate Intrinsic</td><td style="color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Options</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">(Years)</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Value</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Unvested December 31, 2021</span></td><td style="width: 2%; color: Black; text-align: left"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zo2AVg35ikEl" style="width: 13%; color: Black; text-align: right" title="Number of Options Unvested, Beginning of Period">97,831</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zfYizJKngL4i" style="width: 13%; color: Black; text-align: right" title="Weighted Average Exercise Price Unvested, Beginning of Period">3.89</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 13%; color: Black; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zgRWC1MjHHZh" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period">7.82</span></td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_98A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zOvt2toMtfE1" style="width: 13%; color: Black; text-align: right" title="Aggregate Intrinsic Value Unvested, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1258">—</span></td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Granted</span></td><td style="color: Black; text-align: left"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_ze9MVApUkKzg" style="color: Black; text-align: right" title="Number of Options, Granted">300,000</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zWsa113EBQh8" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Granted">0.54</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zNlL7jztUBwf" title="Average Remaining Contractual Term granted">9.68</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Vested</span></td><td style="color: Black; text-align: left"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zcyYH4K4eujk" style="color: Black; text-align: right" title="Number of Options, Vested">(229,053</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z4OJtleVDkF9" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Vested">0.82</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Forfeited</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMMNRPZaH1Ej" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of Options, Forfeited">(1,989</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Unvested December 31, 2022</span></td><td style="color: Black; text-align: left"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zJoajYJB220i" style="color: Black; text-align: right" title="Number of Options Unvested, brginning of Period">166,789</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zSAo2bkBYYxf" style="color: Black; text-align: right" title="Weighted Average Exercise Price Unvested, beginning of Period">4.05</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zBwgskkI0POc" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period">9.49</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zVAzn6ezY5Jh" style="color: Black; text-align: right" title="Aggregate Intrinsic Value Unvested, beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1278">—</span></td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Granted</span></td><td style="color: Black; text-align: left"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zUEy3RLoUeia" style="color: Black; text-align: right" title="Number of Options, Granted">360,000</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zXKnVXQnIlq" style="color: Black; text-align: right">0.46</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zsKTZ4WdlRX2" title="Average Remaining Contractual Term granted">10.18</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Vested</span></td><td style="color: Black; text-align: left"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zPlkAAN1KSR3" style="color: Black; text-align: right" title="Number of Options, Vested">(137,565</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zum4dS1xfGWe" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Vested">0.47</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z4TOxkGhtMce" title="Average Remaining Contractual Term vested">9.47</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Expired</span></td><td style="color: Black; text-align: left"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zqPaKuMMbZIj" style="color: Black; text-align: right" title="Number of Options, Vested">(776</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zKTko5ejOPf8" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Expired">145.24</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Forfeited</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z3wqyUMV9Egb" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of Options, Forfeited">(53,447</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zS2KlJFe6pR3" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted Average Exercise Price, Forfeited">1.31</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Unvested December 31, 2023</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zdqQIbnp4yV1" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of Options Unvested, End of Period">335,001</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zaDpoYkQy0D8" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted Average Exercise Price Unvested, Ending of Period">1.83</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z0xrtELjI1Ig" title="Average Remaining Contractual Term (years) Unvested, End of Period">10.70</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iE_pdp0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z9z6wdP6hCYd" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate Intrinsic Value Unvested, End of Period"><span style="-sec-ix-hidden: xdx2ixbrl1305">—</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table> <p id="xdx_8A8_z4C2lN2A5n75" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 42pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 42pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Stock-based compensation expense was approximately $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMWuIx6ShLVe" title="Share based compensation expense">243,000 </span>and $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zjGrfLdWeJ5" title="Share based compensation expense">954,000</span> for the years ended December 31, 2023 and 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 42pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 42pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As of December 31, 2023 and 2022, there was $<span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pp0p0_c20231231_zXhQqABm0kwh" title="Unrecognized stock-based compensation cost">294,000</span> and $<span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pp0p0_c20221231_zjMEq1YsxSw2" title="Unrecognized stock-based compensation cost">217,000</span>, respectively, of unrecognized stock-based compensation cost related to options granted under the Equity Incentive Plans. Stock-based compensation related to options granted under the Equity Incentive Plans will be recorded over the vesting period which is typically one year or upon reaching agreed upon Company and/or individual performance milestones being met which is indefinite.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 42pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(ii) Stock Warrants</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Stock warrants are issued as needed by the Board of Directors and have no formal plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The fair value of each warrant award is estimated on the date of grant using a Black-Scholes-Merton pricing option valuation model. Expected volatility is based on the historical volatility of the price of the Company’s stock. The risk-free interest rate is based on U.S. Treasury issues with a term equal to the expected life of the warrant. The Company uses historical data to estimate expected dividend yield, life and forfeiture rates. The expected life of the warrants was estimated based on historical option holder’s behavior and represents the period of time that options are expected to be outstanding. No warrants were granted in 2023 or 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p id="xdx_897_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_zeILQNWJeqal" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Information regarding warrants outstanding and exercisable into shares of common stock is summarized below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B7_z5LMDxbstbGf" style="display: none">Schedule of Warrants Outstanding and Exercisable</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black; text-align: center"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="color: Black; text-align: center"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center"></td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Warrant</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted <br/>Average <br/>Exercise</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center"></td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Warrant</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted <br/>Average <br/>Exercise</td><td style="color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black; text-align: center"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 34%; color: Black; text-align: justify">Outstanding, beginning of year <br/>  <br/></td><td style="width: 1%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqRozs5Y4jkd" style="width: 8%; color: Black; text-align: right" title="Number of options outstanding, beginning of year">226,610</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 1%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 8%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$ <span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zmXSSkkOT8w5" title="Warrant price outstanding, beginning of year">0.99</span>-<span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zpbRlEk5oJtd" title="Warrant price outstanding, beginning of year">132.00</span></span></td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 1%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zahnLtP5LwO2" style="width: 8%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">9.10</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 1%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrmgCjc9Rzvj" style="width: 8%; color: Black; text-align: right" title="Number of options outstanding, beginning of year">294,939</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 1%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 8%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$<span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zyJrDi4sOWgk" title="Warrant price outstanding, beginning of year">0.99</span> – <span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zn0GmmO3P6qd" title="Warrant price outstanding, beginning of year">469.92</span></span></td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 1%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zh5LIcPleKMc" style="width: 8%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">15.19</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black">Granted</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwY5sI38OOzh" style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"><span style="-sec-ix-hidden: xdx2ixbrl1333">—</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLEgVWTRsnak" style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1334">—</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstandingGrantsInPeriod_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zc7yT8hEfSb5" style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"><span style="-sec-ix-hidden: xdx2ixbrl1336">—</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVlIghCmTL7f" style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"><span style="-sec-ix-hidden: xdx2ixbrl1338">—</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkmmxnyXbMd3" style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1339">—</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstandingGrantsInPeriod_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z58kY4rBtdG9" style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"><span style="-sec-ix-hidden: xdx2ixbrl1341">—</span></td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black">Expired</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAwCgD0h9s57" style="color: Black; text-align: right" title="Number of options outstanding, beginning of year">(74,450</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdvdRHtoavji" title="Warrant price, expired">17.05</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZ1pTsT6w837" style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">17.05</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrQH6C4gMbi8" style="color: Black; text-align: right" title="Number of options outstanding, beginning of year">(68,215</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXoTkDQNvH9c" title="Warrant price, expired">469.92</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIgnvUGFmM5g" style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">469.92</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black">Exercised</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwO6JRyXJYlg" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, beginning of year"><span style="-sec-ix-hidden: xdx2ixbrl1355">—</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8XKH76Mu3L1" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1356">—</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4vIQJiOvFfi" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"><span style="-sec-ix-hidden: xdx2ixbrl1358">—</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zszAruL7seU1" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, beginning of year">(114</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zn6j9lU4Wks7" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">8.80</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTEpQNEKrwue" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">8.80</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Outstanding, end of year</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvoaBmP9KhK2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, beginning of year">152,160</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$ <span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_z0BKR7zQaTR9" title="Warrant price outstanding, end of year">0.99</span>-<span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zYSZCmEsGPj3" title="Warrant price outstanding, end of year">8.80</span></span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrRvhpq3yLm8" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">8.03</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zl6cQec3WhGe" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, beginning of year">226,610</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$ <span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zsrEUrBv1Q1h" title="Warrant price outstanding, end of year">0.99</span>-<span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zEF2kNXhsAR3" title="Warrant price outstanding, end of year">132.00</span></span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zA3doCO4NgPj" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">9.10</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; color: Black">Exercisable</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zagMEkNX966k" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, beginning of year">152,160</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$ <span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_z2cMmWZxTZu4" title="Warrant price exercisable, end of year">0.99</span>-<span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zn2YWcIasnj2" title="Warrant price exercisable, end of year">8.80</span></span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyybKuv1rSx7" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">8.03</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqpgrO72ETjj" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, beginning of year">226,610</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$ <span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zjyk7kIgfru" title="Warrant price exercisable, end of year">0.99</span>-<span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z2KaO7qSI7lb" title="Warrant price exercisable, end of year">132.00</span></span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRPxw92JECg8" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">9.10</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black">Weighted average remaining contractual life</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8AuyJMA2PU3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">.75 </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">years</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"> </td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"> </td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQN9lfUrImB4" title="Weighted average remaining contracted term (years) outstanding, ending of year">.94</span> years</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"> </td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"> </td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left">Years exercisable</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9BxMoyx0vGj" title="Years exercisable">2024</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"> </td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"> </td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zo81gQDW6ad6" title="Years exercisable">2023</span>-<span id="xdx_90A_ecustom--WeightedbasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z9dvWViWs0rj" title="Years exercisable">2024</span></span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"> </td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"> </td><td style="color: Black; text-align: left"> </td></tr> </table> <p id="xdx_8A5_zEdcVdPnO2dk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Stock warrants are issued at the discretion of the Board. During the year ended December 31, 2023, there were <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_doxL_c20230101__20231231_zkkhVy30p3Zg" title="Warrants issued::XDX::-"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_doxL_c20230101__20231231_zlawOgcMWi01" title="Warrants exercised::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1406"><span style="-sec-ix-hidden: xdx2ixbrl1408">no</span></span></span></span> warrants issued or exercised. During the year ended December 31, 2022, there were <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_doxL_c20220101__20221231_zaNSjiTXnKtd" title="Warrants issued::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1410">no</span></span> warrants issued and <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_dixL_c20220101__20221231_zHfpY7YXfrz5" title="Warrants exercised::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1412">114</span></span> were exercised.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p>
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2023-12-31_custom_BoardMember" decimals="INF" id="Fact000684" unitRef="Shares"> 5000000 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2023-12-31_custom_BoardMember" decimals="INF" id="Fact000686" unitRef="USDPShares"> 0.01 </us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2023-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember" decimals="INF" id="Fact000688" unitRef="Shares"> 4000000 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember" decimals="INF" id="Fact000690" unitRef="Shares"> 10000 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2023-05-10_custom_SeriesAJuniorParticipatingPreferredStockMember" decimals="INF" id="Fact000692" unitRef="Shares"> 4000000 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2023-05-09_custom_SeriesAJuniorParticipatingPreferredStockMember" decimals="INF" id="Fact000694" unitRef="Shares"> 250000 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember" decimals="INF" id="Fact000695" unitRef="Shares"> 10000 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember" decimals="INF" id="Fact000697" unitRef="USDPShares"> 0.01 </us-gaap:PreferredStockParOrStatedValuePerShare>
<AIM:PreferredStockStatedValuePerShare contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember" decimals="INF" id="Fact000699" unitRef="USDPShares"> 1000 </AIM:PreferredStockStatedValuePerShare>
<us-gaap:PreferredStockConvertibleConversionPrice contextRef="AsOf2023-12-31" decimals="INF" id="Fact000701" unitRef="USDPShares"> 0.20 </us-gaap:PreferredStockConvertibleConversionPrice>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2023-12-31_us-gaap_RightsMember" decimals="INF" id="Fact000703" unitRef="USDPShares"> 1000 </us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<AIM:FaceValueOfStock contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_RightsMember" decimals="0" id="Fact000705" unitRef="USD"> 1000 </AIM:FaceValueOfStock>
<us-gaap:PreferredStockConvertibleConversionPrice contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" decimals="INF" id="Fact000707" unitRef="USDPShares"> 8.80 </us-gaap:PreferredStockConvertibleConversionPrice>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2023-12-31_us-gaap_WarrantMember" decimals="INF" id="Fact000709" unitRef="Shares"> 114 </us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2023-12-31_us-gaap_WarrantMember" decimals="INF" id="Fact000711" unitRef="USDPShares"> 8.80 </us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2023-12-31_us-gaap_WarrantMember" id="Fact000712"> P5Y </us-gaap:WarrantsAndRightsOutstandingTerm>
<us-gaap:ProceedsFromIssuanceOfWarrants contextRef="From2023-01-012023-12-31_us-gaap_RightsMember" decimals="0" id="Fact000714" unitRef="USD"> 4700000 </us-gaap:ProceedsFromIssuanceOfWarrants>
<us-gaap:ConversionOfStockSharesIssued1 contextRef="From2023-01-012023-12-31_custom_SeriesBConvertiblePreferredStockMember" decimals="INF" id="Fact000715" unitRef="Shares"> 7 </us-gaap:ConversionOfStockSharesIssued1>
<us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember" decimals="INF" id="Fact000717" unitRef="Shares"> 689 </us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember" decimals="INF" id="Fact000719" unitRef="Shares"> 696 </us-gaap:PreferredStockSharesOutstanding>
<us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember" decimals="INF" id="Fact000721" unitRef="Shares"> 114 </us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
<us-gaap:CommonStockSharesAuthorized contextRef="AsOf2023-12-31" decimals="INF" id="Fact000723" unitRef="Shares"> 350000000 </us-gaap:CommonStockSharesAuthorized>
<AIM:CommonStockSharesWithLimitationsAndRestrictionsOnUsage contextRef="AsOf2023-12-31" decimals="INF" id="Fact000725" unitRef="Shares"> 8000000 </AIM:CommonStockSharesWithLimitationsAndRestrictionsOnUsage>
<us-gaap:CommonStockSharesAuthorized contextRef="AsOf2023-12-31" decimals="INF" id="Fact000727" unitRef="Shares"> 350000000 </us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued contextRef="AsOf2023-12-31" decimals="INF" id="Fact000729" unitRef="Shares"> 49102484 </us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="AsOf2023-12-31" decimals="INF" id="Fact000731" unitRef="Shares"> 49102484 </us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesIssued contextRef="AsOf2022-12-31" decimals="INF" id="Fact000733" unitRef="Shares"> 48084287 </us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="INF" id="Fact000735" unitRef="Shares"> 48084287 </us-gaap:CommonStockSharesOutstanding>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2020-07-062020-07-07_custom_DirectorsOfficersAndEmployeesMember" decimals="0" id="Fact000737" unitRef="USD"> 500000 </us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember289842265" decimals="INF" id="Fact000739" unitRef="Shares"> 419285 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:SharesIssuedPricePerShare contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_srt_MinimumMember" decimals="INF" id="Fact000741" unitRef="USDPShares"> 0.31 </us-gaap:SharesIssuedPricePerShare>
<us-gaap:SharesIssuedPricePerShare contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_srt_MaximumMember" decimals="INF" id="Fact000743" unitRef="USDPShares"> 0.67 </us-gaap:SharesIssuedPricePerShare>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember289842265" decimals="0" id="Fact000745" unitRef="USD"> 150500 </us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember289842296" decimals="INF" id="Fact000747" unitRef="Shares"> 86817 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:SharesIssuedPricePerShare contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_srt_MinimumMember" decimals="INF" id="Fact000749" unitRef="USDPShares"> 0.76 </us-gaap:SharesIssuedPricePerShare>
<us-gaap:SharesIssuedPricePerShare contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_srt_MaximumMember" decimals="INF" id="Fact000751" unitRef="USDPShares"> 1.02 </us-gaap:SharesIssuedPricePerShare>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember289842296" decimals="0" id="Fact000753" unitRef="USD"> 80000 </us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2019-09-262019-09-27_custom_AllianceGlobalPartnersLLCMember" decimals="INF" id="Fact000755" unitRef="Shares"> 1740550 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2019-09-27_custom_AllianceGlobalPartnersLLCMember" decimals="INF" id="Fact000757" unitRef="Shares"> 7148310 </us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="AsOf2019-09-27_custom_AllianceGlobalPartnersLLCMember_custom_WarrantsMember" decimals="INF" id="Fact000759" unitRef="Shares"> 8888860 </us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="AsOf2019-09-27_custom_AllianceGlobalPartnersLLCMember_custom_RepresentativeWarrantsMember_srt_MaximumMember" decimals="INF" id="Fact000761" unitRef="Shares"> 266665 </us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
<us-gaap:SharesIssuedPricePerShare contextRef="AsOf2019-09-27_custom_AllianceGlobalPartnersLLCMember_custom_PreFundedWarrantsMember" decimals="INF" id="Fact000763" unitRef="USDPShares"> 0.90 </us-gaap:SharesIssuedPricePerShare>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2019-09-27_us-gaap_WarrantMember" decimals="INF" id="Fact000765" unitRef="USDPShares"> 0.99 </us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:SharesIssuedPricePerShare contextRef="AsOf2019-09-27_custom_PreFundedWarrantsMember" decimals="INF" id="Fact000767" unitRef="USDPShares"> 0.899 </us-gaap:SharesIssuedPricePerShare>
<AIM:PercentageOfOutstandingStock contextRef="AsOf2019-09-27_custom_PreFundedWarrantsMember" decimals="INF" id="Fact000769" unitRef="Pure"> 0.0499 </AIM:PercentageOfOutstandingStock>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2019-09-27_custom_PreFundedWarrantsMember" decimals="INF" id="Fact000771" unitRef="USDPShares"> 0.001 </us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="From2019-09-262019-09-27_custom_AllianceGlobalPartnersLLCMember" decimals="0" id="Fact000773" unitRef="USD"> 7200000 </us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
<us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2020-01-012020-12-31_custom_PreFundedWarrantsMember" decimals="0" id="Fact000775" unitRef="Shares"> 1870000 </us-gaap:StockIssuedDuringPeriodSharesOther>
<us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember" decimals="INF" id="Fact000777" unitRef="Shares"> 8873960 </us-gaap:StockIssuedDuringPeriodSharesOther>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="AsOf2020-03-31_custom_AllianceGlobalPartnersLLCMember_custom_RepresentativeWarrantsMember_srt_MaximumMember" decimals="INF" id="Fact000779" unitRef="Shares"> 266665 </us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
<us-gaap:ProceedsFromWarrantExercises contextRef="From2020-03-302020-03-31" decimals="0" id="Fact000781" unitRef="USD"> 264000 </us-gaap:ProceedsFromWarrantExercises>
<AIM:WarrantModifications contextRef="From2020-03-302020-03-31" decimals="0" id="Fact000783" unitRef="USD"> 46000 </AIM:WarrantModifications>
<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2023-12-31" decimals="INF" id="Fact000785" unitRef="Shares"> 15000 </us-gaap:ClassOfWarrantOrRightOutstanding>
<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2022-12-31" decimals="INF" id="Fact000787" unitRef="Shares"> 15000 </us-gaap:ClassOfWarrantOrRightOutstanding>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2023-04-182023-04-19_custom_MaximGroupLLCMember" decimals="0" id="Fact000788" unitRef="USD"> 8500000 </us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction contextRef="From2023-04-182023-04-19_custom_MaximGroupLLCMember" decimals="INF" id="Fact000790" unitRef="Pure"> 0.030 </us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2023-01-012023-12-31_custom_MaximGroupLLCMember" decimals="INF" id="Fact000792" unitRef="Shares"> 598114 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2023-01-012023-12-31_custom_MaximGroupLLCMember" decimals="0" id="Fact000794" unitRef="USD"> 344000 </us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction contextRef="From2023-01-012023-12-31_custom_MaximGroupLLCMember" decimals="INF" id="Fact000796" unitRef="Pure"> 0.030 </us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
<us-gaap:DebtInstrumentFeeAmount contextRef="AsOf2023-12-31_custom_MaximGroupLLCMember" decimals="0" id="Fact000797" unitRef="USD"> 10326 </us-gaap:DebtInstrumentFeeAmount>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2024-01-012024-01-01_custom_MaximGroupLLCMember_us-gaap_SubsequentEventMember" decimals="INF" id="Fact000799" unitRef="Shares"> 699568 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2024-01-012024-01-01_custom_MaximGroupLLCMember_us-gaap_SubsequentEventMember" decimals="0" id="Fact000801" unitRef="USD"> 316392 </us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction contextRef="From2024-01-012024-01-01_custom_MaximGroupLLCMember_us-gaap_SubsequentEventMember" decimals="INF" id="Fact000803" unitRef="Pure"> 0.030 </us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
<us-gaap:DebtInstrumentFeeAmount contextRef="AsOf2024-01-01_custom_MaximGroupLLCMember_us-gaap_SubsequentEventMember" decimals="0" id="Fact000804" unitRef="USD"> 9492 </us-gaap:DebtInstrumentFeeAmount>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="AsOf2018-09-12_custom_EquityIncentivePlanTwoThousandNineMember" decimals="INF" id="Fact000806" unitRef="Shares"> 7000000 </us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2018-09-122018-09-12_custom_EquityIncentivePlanTwoThousandNineMember" id="Fact000807"> P10Y </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000809">
<p id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zwBn9bZOROJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8BE_zRdQc4lhI2ed" style="display: none">Schedule of Options and Equity Estimated Based on Weighted Average Assumptions</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; color: Black; text-align: left">Risk-free interest rate</td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 14%; color: Black; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231_zwsTOtjinuEg" title="Risk-free interest rate">4.37</span></td><td style="width: 1%; color: Black; text-align: left">%</td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 14%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zyu0LDV1Orji" title="Risk-free interest rate">1.74</span>% - <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_z7IM9rf56CHf" title="Risk-free interest rate">3.88</span>%</span></td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left">Expected dividend yield</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20231231_zLRWWWaQR3E9" style="color: Black; text-align: right" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0817">—</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20220101__20221231_zGhPgwxEQY9a" style="color: Black; text-align: right" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0819">—</span></td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: left">Expected life</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zRPHlQrFeOEf" title="Expected life">10</span> years</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_ze6P7e4vBhy7" title="Expected life">10</span> years</span></td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left">Expected volatility</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231_zpSADdjUppo7" title="Expected volatility">99.91</span></td><td style="color: Black; text-align: left">%</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zqFkVRZdLFeg" title="Expected volatility">98.43</span>% - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zbNkTV8pKtak" title="Expected volatility">107.18</span>%</span></td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: left">Weighted average grant date fair value for options issued</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_904_ecustom--WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued_c20230101__20231231_zDcZCd9f8oq8" title="Weighted average grant date fair value for options issued">$0.43 per option for 400,000 options</span></span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90F_ecustom--WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued_c20220101__20221231_zwLGodKu5o01" title="Weighted average grant date fair value for options issued">$0.51 per option for 850,000 options</span></span></td><td style="color: Black; text-align: left"> </td></tr> </table>
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2023-01-01to2023-12-31" decimals="INF" id="Fact000811" unitRef="Pure"> 0.0437 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2022-01-012022-12-31_srt_MinimumMember" decimals="INF" id="Fact000813" unitRef="Pure"> 0.0174 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2022-01-012022-12-31_srt_MaximumMember" decimals="INF" id="Fact000815" unitRef="Pure"> 0.0388 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2023-01-01to2023-12-31" id="Fact000821"> P10Y </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2022-01-012022-12-31" id="Fact000823"> P10Y </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2023-01-01to2023-12-31" decimals="INF" id="Fact000825" unitRef="Pure"> 0.9991 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2022-01-012022-12-31_srt_MinimumMember" decimals="INF" id="Fact000827" unitRef="Pure"> 0.9843 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2022-01-012022-12-31_srt_MaximumMember" decimals="INF" id="Fact000829" unitRef="Pure"> 1.0718 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<AIM:WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued contextRef="From2023-01-01to2023-12-31" id="Fact000831"> $0.43 per option for 400,000 options </AIM:WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued>
<AIM:WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued contextRef="From2022-01-012022-12-31" id="Fact000833"> $0.51 per option for 850,000 options </AIM:WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlanTwoThousandNineMember" id="Fact000835">
<p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--EquityIncentivePlanTwoThousandNineMember_z5ECVcr9LKd3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Information regarding the options approved by the Board of Directors under the Equity Plan of 2009 is summarized below. The plan expired on June 24, 2019:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8BA_z2r3OQ5v0nMb" style="display: none">Schedule of Stock Option Activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black; text-align: center"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="color: Black; text-align: center"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center"> </td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Option</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted <br/>Average <br/>Exercise</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center"> </td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Option</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted <br/>Average <br/>Exercise</td><td style="color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black; text-align: center"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 34%; color: Black; text-align: left">Outstanding, beginning of year</td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zyDxeqphjbwl" style="width: 7%; color: Black; text-align: right" title="Number of options outstanding, beginning of year">124,399</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 7%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_902_eus-gaap--SharePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zxwHdtQPhQRl" title="Option price outstanding, beginning of year">13.20</span> – <span id="xdx_902_eus-gaap--SharePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zUvFe764HwR1" title="Option price outstanding, beginning of year">1,003.20</span></span></td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zXR0wPDoayE9" style="width: 7%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">22.23</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_z58yybuTjzag" style="width: 7%; color: Black; text-align: right" title="Number of options outstanding, beginning of year">128,504</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 7%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_900_eus-gaap--SharePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zL37ie7VDOo5" title="Option price outstanding, beginning of year">13.20</span> – <span id="xdx_909_eus-gaap--SharePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zZH7zfDN4kwe" title="Option price outstanding, beginning of year">2,127.84</span></span></td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zZVXpZMZWUk3" style="width: 7%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">25.58</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black">Granted</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zJpxjOdQrXP5" style="color: Black; text-align: right" title="Number of options, granted"><span style="-sec-ix-hidden: xdx2ixbrl0853">—</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantedInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zEiDo8XYt6ji" style="color: Black; text-align: right" title="Option price, granted"><span style="-sec-ix-hidden: xdx2ixbrl0855">—</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_z1vaUNUBJ9Lk" style="color: Black; text-align: right" title="Weighted average exercise price, granted"><span style="-sec-ix-hidden: xdx2ixbrl0857">—</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zXREqcdUViH5" style="color: Black; text-align: right" title="Number of options, granted"><span style="-sec-ix-hidden: xdx2ixbrl0859">—</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantedInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zJouwSlxcz4c" style="color: Black; text-align: right" title="Option price, granted"><span style="-sec-ix-hidden: xdx2ixbrl0861">—</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zQtSE9KhTfWf" style="color: Black; text-align: right" title="Weighted average exercise price, granted"><span style="-sec-ix-hidden: xdx2ixbrl0863">—</span></td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black">Forfeited</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zSz346mvRzqe" style="color: Black; text-align: right" title="Number of options, forfeited">(5,047</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zvrLx2fgS4n" title="Option price, forfeited">9.68</span>-<span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zvOUj8mO8cW9" title="Option price, forfeited">327.36</span></span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zTTIYX7nlGm" style="color: Black; text-align: right" title="Weighted average exercise price, forfeited">57.79</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zVTFyT72V1P7" style="color: Black; text-align: right" title="Number of options, forfeited">(4,105</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zeAPvCW0iP6l" title="Option price, forfeited">16.76</span>-<span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zpMqhGQSPp0h" title="Option price, forfeited">2,127.84</span></span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zcqllAbQ2tF6" style="color: Black; text-align: right" title="Weighted average exercise price, forfeited">129.88</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black">Exercised</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_z18DmVOsWDG4" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0881">—</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zkPHisNO4j4e" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Option price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0883">—</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zEJEklSgmZP7" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0885">—</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zEF8oX7qioI2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0887">—</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zwkacwJmgPY8" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Option price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0889">—</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zAYwZMXI0UG2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0891">—</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Outstanding, end of year</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zoBzU2hbFi5a" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, ending of year">119,352</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_906_eus-gaap--SharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zbJCCgyupPl9" title="Option price exercisable, end of year">13.20</span>-<span id="xdx_902_eus-gaap--SharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zmDKs07uvwPf" title="Option price exercisable, end of year">2,127.84</span></span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zfG1XOAqxnWi" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price outstanding, end of year">20.72</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zvF6i9mV3AVl" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, ending of year">124,399</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90C_eus-gaap--SharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zh6uBgLlzTng" title="Option price exercisable, end of year">13.20</span>-<span id="xdx_90D_eus-gaap--SharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zXu4uzXR0lye" title="Option price exercisable, end of year">1,003.20</span></span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zL1lIOUUh3j8" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price outstanding, end of year">22.23</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left">Exercisable, end of year</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zQtOL6t0A84c" style="color: Black; text-align: right" title="Number of options exercisable, end of year">119,352</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zhq3muq2nUC4" title="Option price exercisable, end of year">13.20</span>-<span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zYqUKFECPByh" title="Option price exercisable, end of year">2,127.84</span></span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"> </td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_z1OAXnd2DIL5" style="color: Black; text-align: right" title="Number of options exercisable, end of year">124,399</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zk7y8OaHVdG3" title="Option price exercisable, end of year">13.20</span>-<span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zCBdKfReAHJh" title="Option price exercisable, end of year">1,003.20</span></span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"> </td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Weighted average remaining contractual life (years)</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; white-space: nowrap; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zuO6mBNBKiS3" title="Weighted average remaining contractual life (years)">4.06</span> years</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"> </td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"> </td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; white-space: nowrap; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zEz3nLpaJO8h" title="Weighted average remaining contractual life (years)">5.98</span> years</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"> </td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"> </td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> </table>
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2009Member" decimals="INF" id="Fact000837" unitRef="Shares"> 124399 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:SharePrice contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2009Member_srt_MinimumMember" decimals="INF" id="Fact000839" unitRef="USDPShares"> 13.20 </us-gaap:SharePrice>
<us-gaap:SharePrice contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2009Member_srt_MaximumMember" decimals="INF" id="Fact000841" unitRef="USDPShares"> 1003.20 </us-gaap:SharePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2009Member" decimals="INF" id="Fact000843" unitRef="USDPShares"> 22.23 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2021-12-31_custom_EquityIncentivePlans2009Member" decimals="INF" id="Fact000845" unitRef="Shares"> 128504 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:SharePrice contextRef="AsOf2021-12-31_custom_EquityIncentivePlans2009Member_srt_MinimumMember" decimals="INF" id="Fact000847" unitRef="USDPShares"> 13.20 </us-gaap:SharePrice>
<us-gaap:SharePrice contextRef="AsOf2021-12-31_custom_EquityIncentivePlans2009Member_srt_MaximumMember" decimals="INF" id="Fact000849" unitRef="USDPShares"> 2127.84 </us-gaap:SharePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2021-12-31_custom_EquityIncentivePlans2009Member" decimals="INF" id="Fact000851" unitRef="USDPShares"> 25.58 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2009Member" decimals="INF" id="Fact000865" unitRef="Shares"> 5047 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2009Member_srt_MinimumMember" decimals="INF" id="Fact000867" unitRef="USDPShares"> 9.68 </AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2009Member_srt_MaximumMember" decimals="INF" id="Fact000869" unitRef="USDPShares"> 327.36 </AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2009Member" decimals="INF" id="Fact000871" unitRef="USDPShares"> 57.79 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2009Member" decimals="INF" id="Fact000873" unitRef="Shares"> 4105 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2009Member_srt_MinimumMember" decimals="INF" id="Fact000875" unitRef="USDPShares"> 16.76 </AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2009Member_srt_MaximumMember" decimals="INF" id="Fact000877" unitRef="USDPShares"> 2127.84 </AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2009Member" decimals="INF" id="Fact000879" unitRef="USDPShares"> 129.88 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2009Member" decimals="INF" id="Fact000893" unitRef="Shares"> 119352 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:SharePrice contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2009Member_srt_MinimumMember" decimals="INF" id="Fact000895" unitRef="USDPShares"> 13.20 </us-gaap:SharePrice>
<us-gaap:SharePrice contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2009Member_srt_MaximumMember" decimals="INF" id="Fact000897" unitRef="USDPShares"> 2127.84 </us-gaap:SharePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2009Member" decimals="INF" id="Fact000899" unitRef="USDPShares"> 20.72 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2009Member" decimals="INF" id="Fact000901" unitRef="Shares"> 124399 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:SharePrice contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2009Member_srt_MinimumMember" decimals="INF" id="Fact000903" unitRef="USDPShares"> 13.20 </us-gaap:SharePrice>
<us-gaap:SharePrice contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2009Member_srt_MaximumMember" decimals="INF" id="Fact000905" unitRef="USDPShares"> 1003.20 </us-gaap:SharePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2009Member" decimals="INF" id="Fact000907" unitRef="USDPShares"> 22.23 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2009Member" decimals="INF" id="Fact000909" unitRef="Shares"> 119352 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2009Member_srt_MinimumMember" decimals="INF" id="Fact000911" unitRef="USDPShares"> 13.20 </AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2009Member_srt_MaximumMember" decimals="INF" id="Fact000913" unitRef="USDPShares"> 2127.84 </AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2009Member" decimals="INF" id="Fact000915" unitRef="Shares"> 124399 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2009Member_srt_MinimumMember" decimals="INF" id="Fact000917" unitRef="USDPShares"> 13.20 </AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2009Member_srt_MaximumMember" decimals="INF" id="Fact000919" unitRef="USDPShares"> 1003.20 </AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2009Member" id="Fact000921"> P4Y21D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2009Member" id="Fact000923"> P5Y11M23D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlansTwoThousandAndEighteenMember" id="Fact000925">
<p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--EquityIncentivePlansTwoThousandAndEighteenMember_zAiKbRs8u0ze" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Information regarding the options approved by the Board of Directors under the Equity Plan of 2018 is summarized below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B1_zjBHKIJSnVTc" style="display: none">Schedule of Stock Option Activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black; text-align: center"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="color: Black; text-align: center"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center"> </td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Option</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted <br/>Average <br/>Exercise</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center"> </td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Option</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted <br/>Average <br/>Exercise</td><td style="color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black; text-align: center"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 34%; color: Black; text-align: left">Outstanding, beginning of year</td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zY8TdhJVuvQk" style="width: 7%; color: Black; text-align: right" title="Number of options outstanding, beginning of year">2,474,971</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 7%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_906_eus-gaap--SharePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zVYEt9sxdiZ" title="Option price outstanding, beginning of year">0.31</span>-<span id="xdx_903_eus-gaap--SharePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_z2rNeV89tPai" title="Option price outstanding, beginning of year">9.68</span></span></td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zbMybyjAV6bd" style="width: 7%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">1.72</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zvIdOAMVrKhf" style="width: 7%; color: Black; text-align: right" title="Number of options outstanding, beginning of year">1,650,017</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td style="white-space: nowrap; width: 7%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_906_eus-gaap--SharePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_za8xt9HeolC9" title="Option price outstanding, beginning of year">1.11</span> – <span id="xdx_90D_eus-gaap--SharePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zG0Jrw48ZFRe" title="Option price outstanding, beginning of year">9.68</span></span></td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zTolGtT0cWY7" style="width: 7%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">2.35</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black">Granted</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zvvgWvWDNKf4" style="color: Black; text-align: right" title="Number of options, granted">400,000</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zHwdNuwTBrXe" title="Option price, granted">0.47</span>-<span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zqSZB6vsmL4l" title="Option price, granted">0.47</span></span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_z3Z2NtWcprWa" style="color: Black; text-align: right" title="Weighted average exercise price, granted">0.47</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zoOGxTxPaFf2" style="color: Black; text-align: right" title="Number of options, granted">850,000</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zRwCHfg9H1sf" title="Option price, granted">0.31</span> – <span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zm8tE7cwMMI5" title="Option price, granted">1.71</span></span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zCtFRvKSBhF9" style="color: Black; text-align: right" title="Weighted average exercise price, granted">0.51</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black">Forfeited</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zQU5yoP1BaQe" style="color: Black; text-align: right" title="Number of options, forfeited">(60,829</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zc1uJU6MXwq9" title="Option price, forfeited">0.31</span>-<span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zcSqfq5LYhIg" title="Option price, forfeited">9.68</span></span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zoAUy8QKADD5" style="color: Black; text-align: right" title="Weighted average exercise price, forfeited">1.98</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zafqHYOhNG7k" style="color: Black; text-align: right" title="Number of options, forfeited">(25,046</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_z1UHLlVk9Lck" title="Option price, forfeited">1.85</span> – <span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_znIS51EDLl6h" title="Option price, forfeited">9.68</span></span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zOw8BdlBCRg6" style="color: Black; text-align: right" title="Weighted average exercise price, forfeited">1.86</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black">Exercised</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_za9zosND1Nb8" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0975">—</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_z3YcSiWVvL9b" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Option price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0977">—</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zCrE5j3jPCEd" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0979">—</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zCa1C61l8a2k" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0981">—</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_z8VpDauNgOV4" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Option price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0983">—</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zuAwoTRYyAQg" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0985">—</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Outstanding, end of year</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zKBd7YNedvef" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, ending of year">2,814,142</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_901_eus-gaap--SharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_ziSamlBxMNJ8" title="Option price exercisable, end of year">0.31</span>-<span id="xdx_906_eus-gaap--SharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zDnIoZJDr0G7" title="Option price exercisable, end of year">9.68</span></span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_znS6WrtDV1Hi" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price outstanding, end of year">1.54</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zhuLay5MN263" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, ending of year">2,474,971</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90D_eus-gaap--SharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zIIlppJooD0k" title="Option price exercisable, end of year">0.31</span> – <span id="xdx_901_eus-gaap--SharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zmrKoiA61a5k" title="Option price exercisable, end of year">9.68</span></span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zWr1FaPC9Gyk" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price outstanding, end of year">1.72</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left">Exercisable, end of year</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zWKmTaWD9rXk" style="color: Black; text-align: right" title="Number of options exercisable, end of year">2,397,474</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zUBZQpHHdkQh" title="Option price exercisable, end of year">0.31</span>-<span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zyNfZEZGjY7e" title="Option price exercisable, end of year">327.36</span></span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zCD5NSe1LC96" style="color: Black; text-align: right">4.71</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zV4AA1jdL17j" style="color: Black; text-align: right" title="Number of options exercisable, end of year">1,916,637</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zFNBhjSmkwo6" title="Option price exercisable, end of year">0.41</span> – <span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zfMiYZ3wyc4l" title="Option price exercisable, end of year">9.68</span></span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_ztzNs9InbFV6" style="color: Black; text-align: right">2.22</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: left">Weighted average remaining contractual life (years)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="white-space: nowrap; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zSd2YiyZrKt1" title="Weighted average remaining contractual life (years)">7.96</span> years</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"> </td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"> </td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="white-space: nowrap; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zz081jStHDR4" title="Weighted average remaining contractual life (years)">9.65</span> years</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"> </td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"> </td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Available for future grants</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_z8rTmEuI5Bg2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, beginning of year">1,210,286</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"> </td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"> </td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_z8NQ3MnKjyYg" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, beginning of year">466,120</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"> </td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"> </td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> </table>
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2018Member" decimals="INF" id="Fact000927" unitRef="Shares"> 2474971 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:SharePrice contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2018Member_srt_MinimumMember" decimals="INF" id="Fact000929" unitRef="USDPShares"> 0.31 </us-gaap:SharePrice>
<us-gaap:SharePrice contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2018Member_srt_MaximumMember" decimals="INF" id="Fact000931" unitRef="USDPShares"> 9.68 </us-gaap:SharePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2018Member" decimals="INF" id="Fact000933" unitRef="USDPShares"> 1.72 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2021-12-31_custom_EquityIncentivePlans2018Member" decimals="INF" id="Fact000935" unitRef="Shares"> 1650017 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:SharePrice contextRef="AsOf2021-12-31_custom_EquityIncentivePlans2018Member_srt_MinimumMember" decimals="INF" id="Fact000937" unitRef="USDPShares"> 1.11 </us-gaap:SharePrice>
<us-gaap:SharePrice contextRef="AsOf2021-12-31_custom_EquityIncentivePlans2018Member_srt_MaximumMember" decimals="INF" id="Fact000939" unitRef="USDPShares"> 9.68 </us-gaap:SharePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2021-12-31_custom_EquityIncentivePlans2018Member" decimals="INF" id="Fact000941" unitRef="USDPShares"> 2.35 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2018Member" decimals="INF" id="Fact000943" unitRef="Shares"> 400000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2018Member_srt_MinimumMember" decimals="INF" id="Fact000945" unitRef="USDPShares"> 0.47 </AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2018Member_srt_MaximumMember" decimals="INF" id="Fact000947" unitRef="USDPShares"> 0.47 </AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2018Member" decimals="INF" id="Fact000949" unitRef="USDPShares"> 0.47 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2018Member" decimals="INF" id="Fact000951" unitRef="Shares"> 850000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2018Member_srt_MinimumMember" decimals="INF" id="Fact000953" unitRef="USDPShares"> 0.31 </AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2018Member_srt_MaximumMember" decimals="INF" id="Fact000955" unitRef="USDPShares"> 1.71 </AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2018Member" decimals="INF" id="Fact000957" unitRef="USDPShares"> 0.51 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2018Member" decimals="INF" id="Fact000959" unitRef="Shares"> 60829 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2018Member_srt_MinimumMember" decimals="INF" id="Fact000961" unitRef="USDPShares"> 0.31 </AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2018Member_srt_MaximumMember" decimals="INF" id="Fact000963" unitRef="USDPShares"> 9.68 </AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2018Member" decimals="INF" id="Fact000965" unitRef="USDPShares"> 1.98 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2018Member" decimals="INF" id="Fact000967" unitRef="Shares"> 25046 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2018Member_srt_MinimumMember" decimals="INF" id="Fact000969" unitRef="USDPShares"> 1.85 </AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2018Member_srt_MaximumMember" decimals="INF" id="Fact000971" unitRef="USDPShares"> 9.68 </AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2018Member" decimals="INF" id="Fact000973" unitRef="USDPShares"> 1.86 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2018Member" decimals="INF" id="Fact000987" unitRef="Shares"> 2814142 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:SharePrice contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2018Member_srt_MinimumMember" decimals="INF" id="Fact000989" unitRef="USDPShares"> 0.31 </us-gaap:SharePrice>
<us-gaap:SharePrice contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2018Member_srt_MaximumMember" decimals="INF" id="Fact000991" unitRef="USDPShares"> 9.68 </us-gaap:SharePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2018Member" decimals="INF" id="Fact000993" unitRef="USDPShares"> 1.54 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2018Member" decimals="INF" id="Fact000995" unitRef="Shares"> 2474971 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:SharePrice contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2018Member_srt_MinimumMember" decimals="INF" id="Fact000997" unitRef="USDPShares"> 0.31 </us-gaap:SharePrice>
<us-gaap:SharePrice contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2018Member_srt_MaximumMember" decimals="INF" id="Fact000999" unitRef="USDPShares"> 9.68 </us-gaap:SharePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2018Member" decimals="INF" id="Fact001001" unitRef="USDPShares"> 1.72 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2018Member" decimals="INF" id="Fact001003" unitRef="Shares"> 2397474 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2018Member_srt_MinimumMember" decimals="INF" id="Fact001005" unitRef="USDPShares"> 0.31 </AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2018Member_srt_MaximumMember" decimals="INF" id="Fact001007" unitRef="USDPShares"> 327.36 </AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2018Member" decimals="INF" id="Fact001008" unitRef="USDPShares"> 4.71 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2018Member" decimals="INF" id="Fact001010" unitRef="Shares"> 1916637 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2018Member_srt_MinimumMember" decimals="INF" id="Fact001012" unitRef="USDPShares"> 0.41 </AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2018Member_srt_MaximumMember" decimals="INF" id="Fact001014" unitRef="USDPShares"> 9.68 </AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2018Member" decimals="INF" id="Fact001015" unitRef="USDPShares"> 2.22 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2018Member" id="Fact001017"> P7Y11M15D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2018Member" id="Fact001019"> P9Y7M24D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2018Member" decimals="INF" id="Fact001021" unitRef="Shares"> 1210286 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2018Member" decimals="INF" id="Fact001023" unitRef="Shares"> 466120 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001025">
<p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z3XyNvJ9gsf9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Vested stock option activity for employees:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B1_zF0PfjjCWiX8" style="display: none">Schedule of Vest Stock Option Activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="color: Black; text-align: center"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Number of</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted Average Exercise</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted <br/>Average <br/>Remaining <br/>Contracted <br/>Term</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Aggregate Intrinsic</td><td style="color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black; text-align: center"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Options</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">(Years)</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Value</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; color: Black">Outstanding December 31, 2021</td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zO1TgIVsrq3b" style="width: 10%; color: Black; text-align: right" title="Number of options outstanding, beginning of year">1,498,798</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 10%; color: Black; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zmuq5cZqvpD1" title="Weighted Average Exercise Price Outstanding, Beginning of Period">4.22</span></td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 10%; color: Black; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zsJ97lMV98Kh" title="Weighted Average Remaining Contracted Term (years) Outstanding">9.11</span></td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zq9gGVhvysT5" style="width: 10%; color: Black; text-align: right" title="Aggregate Intrinsic Value Outstanding, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1033">—</span></td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black">Granted</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zHWslta3k897" style="color: Black; text-align: right" title="Number of options, granted">550,000</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zsjODRHZRBU4" title="Weighted Average Exercise Price, Granted">0.49</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zYRFovyjgKfd" title="Weighted Average Remaining Contracted Term (years) Granted">9.71</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black">Forfeited</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zMZbdMXUmn7h" style="color: Black; text-align: right" title="Number of Options, Forfeited">(28,584</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z8yzOyFJPC1i" title="Weighted Average Exercise Price, Forfeited">17.71</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black">Expired</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zl65lMGPS3Ol" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of Options, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1045">—</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zzTauXEBh8Bf" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1047">—</span></span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black">Outstanding December 31, 2022</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zHCcpauMSbZ" style="color: Black; text-align: right" title="Number of options outstanding, beginning of year">2,020,214</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zacgZgdlDl7j" title="Weighted Average Exercise Price Outstanding, Beginning of Period">3.01</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zN3H21xyxjt4" title="Weighted Average Remaining Contracted Term (years)">8.86</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zvg3m0wkDAXe" style="color: Black; text-align: right" title="Aggregate Intrinsic Value Outstanding, beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1055">—</span></td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black">Granted</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zrdSKYkaXDOa" style="color: Black; text-align: right" title="Number of options, granted">400,000</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zOVWpyGMHwm5" title="Weighted Average Exercise Price, Granted">0.47</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zi6E1SbAFp31" title="Weighted Average Remaining Contracted Term (years) Granted">10.17</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black">Forfeited</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zcQGwKQHoVwf" style="color: Black; text-align: right" title="Number of Options, Forfeited">(7,601</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zapcVRUqDmL7" title="Weighted Average Exercise Price, Forfeited">9.68</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"> </td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black">Expired</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7DeSaNwESe9" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of Options, Expired">(4,175</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zoNz9hltHWEb" title="Weighted Average Exercise Price, Expired">41.61</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; color: Black">Outstanding December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zcNhF6wBaGpl" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of Options Outstanding, Ending of Period">2,408,438</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z6h0jEL4K4Be" title="Weighted Average Exercise Price Outstanding, End of Period">2.50</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zC2GiteBVcEf" title="Weighted Average Remaining Contracted Term (years) Outstanding">8.70</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zGLvweXtYT3d" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate Intrinsic Value Outstanding, Ending of Period"><span style="-sec-ix-hidden: xdx2ixbrl1077">—</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Vested and expected to vest at December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zFy1OWgL3JOh" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of Options, Vested and Expected to Vest">2,041,772</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z0oWA11Q0s1d" title="Weighted Average Exercise Price, Vested and Expected to Vest">1.90</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zV7NaQghpaf4" title="Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest">6.73</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zeCECss9Spk3" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate Intrinsic Value, Vested and Expected to Vest"><span style="-sec-ix-hidden: xdx2ixbrl1085">—</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; color: Black">Exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_ziJBXkFM5CQj" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of Options Exercisable, End of Period">2,041,772</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zTkUx06vDIdk" title="Weighted Average Exercise Price Exercisable, Ending of Period">1.90</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zbU0KvwGWSzh" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period">6.73</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z9fWMvpxLccf" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate Intrinsic Value, Exercisable at End of Period"><span style="-sec-ix-hidden: xdx2ixbrl1093">—</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table>
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2021-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" decimals="INF" id="Fact001027" unitRef="Shares"> 1498798 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2021-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" decimals="INF" id="Fact001029" unitRef="USDPShares"> 4.22 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001031"> P9Y1M9D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" decimals="INF" id="Fact001035" unitRef="Shares"> 550000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" decimals="INF" id="Fact001037" unitRef="USDPShares"> 0.49 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001039"> P9Y8M15D </AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" decimals="INF" id="Fact001041" unitRef="Shares"> 28584 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" decimals="INF" id="Fact001043" unitRef="USDPShares"> 17.71 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" decimals="INF" id="Fact001049" unitRef="Shares"> 2020214 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" decimals="INF" id="Fact001051" unitRef="USDPShares"> 3.01 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001053"> P8Y10M9D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" decimals="INF" id="Fact001057" unitRef="Shares"> 400000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" decimals="INF" id="Fact001059" unitRef="USDPShares"> 0.47 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2 contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001061"> P10Y2M1D </AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" decimals="INF" id="Fact001063" unitRef="Shares"> 7601 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" decimals="INF" id="Fact001065" unitRef="USDPShares"> 9.68 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" decimals="INF" id="Fact001067" unitRef="Shares"> 4175 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" decimals="INF" id="Fact001069" unitRef="USDPShares"> 41.61 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" decimals="INF" id="Fact001071" unitRef="Shares"> 2408438 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" decimals="INF" id="Fact001073" unitRef="USDPShares"> 2.50 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001075"> P8Y8M12D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" decimals="INF" id="Fact001079" unitRef="Shares"> 2041772 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" decimals="INF" id="Fact001081" unitRef="USDPShares"> 1.90 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001083"> P6Y8M23D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" decimals="INF" id="Fact001087" unitRef="Shares"> 2041772 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" decimals="INF" id="Fact001089" unitRef="USDPShares"> 1.90 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001091"> P6Y8M23D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2023-01-012023-12-31_custom_EmployeesMember" decimals="0" id="Fact001095" unitRef="USD"> 184000 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2023-01-012023-12-31_custom_EmployeesMember" decimals="INF" id="Fact001097" unitRef="Shares"> 424999 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2023-01-012023-12-31_custom_EmployeesMember" decimals="INF" id="Fact001099" unitRef="USDPShares"> 0.43 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2022-01-012022-12-31_custom_EmployeesMember" decimals="0" id="Fact001101" unitRef="USD"> 768666 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2022-01-012022-12-31_custom_EmployeesMember" decimals="INF" id="Fact001103" unitRef="Shares"> 575000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2022-01-012022-12-31_custom_EmployeesMember" decimals="INF" id="Fact001104" unitRef="USDPShares"> 1.34 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001106">
<p id="xdx_898_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zCvDRE2gnWB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Unvested stock option activity for employees:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8BF_znkiS1cgVg4i" style="display: none">Schedule of Unvested Stock Option Activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td colspan="2" style="text-align: center">Number of</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted Average Exercise</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Average Remaining Contracted Term</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Aggregate Intrinsic</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; font-size: 12pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Options</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">(Years)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%; text-align: left"><span style="font-size: 10pt">Unvested December 31, 2021</span></td><td style="width: 2%; text-align: left"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zYPcWmfJ2bFa" style="width: 13%; text-align: right" title="Number of Options Unvested, Beginning of Period">412,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zfTmqmYk7oZi" style="width: 13%; text-align: right" title="Weighted Average Exercise Price Unvested, Beginning of Period">4.15</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zFao3ebbr6Kk" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period">5.85</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_za0d7W3RS2Xc" style="width: 13%; text-align: right" title="Aggregate Intrinsic Value Unvested, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1114">—</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">Granted</span></td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zUmwAfngLDy7" style="text-align: right" title="Number of Options, Granted">550,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zWlXu0GmreYe" style="text-align: right" title="Weighted Average Exercise Price, Granted">0.49</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zFIDIyoHTT51" title="Weighted Average Remaining Contracted Term (years) Granted">9.71</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">Vested</span></td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zUd9hMgV906j" style="text-align: right" title="Number of Options, Vested">(541,590</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zvY5uzFb8gml" style="text-align: right" title="Weighted Average Exercise Price, Vested">1.31</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zIct0KcJzpa" title="Weighted Average Remaining Contracted Term (years) Vested">9.73</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">Forfeited</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zmC8aMjsw6P8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Forfeited">(28,584</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zfvXdF3IyfI8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited">17.71</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">Unvested December 31, 2022</span></td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zJytXXS7WdLg" style="text-align: right" title="Number of Options Unvested, brginning of Period">392,326</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zYqo1XyBaiW8" style="text-align: right" title="Weighted Average Exercise Price Unvested, beginning of Period">0.80</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zzU6tzWxcv9h" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period">8.86</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z52rYMIINNBe" style="text-align: right" title="Aggregate Intrinsic Value Unvested, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1138">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">Granted</span></td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z20vLrXDNmCd" style="text-align: right" title="Number of Options, Granted">400,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z2ibJo58kDtg" style="text-align: right">0.47</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z74w8QEON2Lj" title="Weighted Average Remaining Contracted Term (years) Granted">10.17</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">Vested</span></td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z2Vl6Zu9x53k" style="text-align: right" title="Number of Options, Vested">(413,884</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7xkHbiObAq3" style="text-align: right" title="Weighted Average Exercise Price, Vested">1.90</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zyXuLX3gvPZ2" title="Weighted Average Remaining Contracted Term (years) Vested">6.73</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">Forfeited</span></td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zXha9Elcmyj6" style="text-align: right" title="Number of Options, Forfeited">(7,601</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zxLNQ5Ziljpf" style="text-align: right" title="Weighted Average Exercise Price, Forfeited">9.68</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">Expired</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zweDV8Orlgoa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Expired">(4,175</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z8ut2qIb6Hr7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Expired">41.61</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">Unvested December 31, 2023</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zuhtlgLdSXq6" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Unvested, End of Period">366,666</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zwsYE33HGdii" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Unvested, Ending of Period">2.13</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zijWQVLsXHS3" title="Average Remaining Contractual Term (years) Unvested, End of Period">12.44</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iE_pdp0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zmvRfA3i91T" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Unvested, End of Period"><span style="-sec-ix-hidden: xdx2ixbrl1165">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="AsOf2021-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" decimals="INF" id="Fact001108" unitRef="Shares"> 412500 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2021-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" decimals="INF" id="Fact001110" unitRef="USDPShares"> 4.15 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
<AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm contextRef="From2021-01-012021-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001112"> P5Y10M6D </AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" decimals="INF" id="Fact001116" unitRef="Shares"> 550000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" decimals="INF" id="Fact001118" unitRef="USDPShares"> 0.49 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001120"> P9Y8M15D </AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" decimals="INF" id="Fact001122" unitRef="Shares"> 541590 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" decimals="INF" id="Fact001124" unitRef="USDPShares"> 1.31 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
<AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001126"> P9Y8M23D </AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" decimals="INF" id="Fact001128" unitRef="Shares"> 28584 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" decimals="INF" id="Fact001130" unitRef="USDPShares"> 17.71 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="AsOf2022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" decimals="INF" id="Fact001132" unitRef="Shares"> 392326 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" decimals="INF" id="Fact001134" unitRef="USDPShares"> 0.80 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
<AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001136"> P8Y10M9D </AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" decimals="INF" id="Fact001140" unitRef="Shares"> 400000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" decimals="INF" id="Fact001141" unitRef="USDPShares"> 0.47 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001143"> P10Y2M1D </AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" decimals="INF" id="Fact001145" unitRef="Shares"> 413884 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" decimals="INF" id="Fact001147" unitRef="USDPShares"> 1.90 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
<AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001149"> P6Y8M23D </AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" decimals="INF" id="Fact001151" unitRef="Shares"> 7601 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" decimals="INF" id="Fact001153" unitRef="USDPShares"> 9.68 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
<AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" decimals="INF" id="Fact001155" unitRef="Shares"> 4175 </AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares>
<AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" decimals="INF" id="Fact001157" unitRef="USDPShares"> 41.61 </AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" decimals="INF" id="Fact001159" unitRef="Shares"> 366666 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" decimals="INF" id="Fact001161" unitRef="USDPShares"> 2.13 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
<AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001163"> P12Y5M8D </AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001167">
<p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zKEj4qh8kNW8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Vested stock option activity for non-employees:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B7_zsalMMWYrOo9" style="display: none">Schedule of Vest Stock Option Activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="color: Black; text-align: center"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Number of</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted Average Exercise</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted Average Remaining Contracted Term</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Aggregate Intrinsic</td><td style="color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black; text-align: center"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Options</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">(Years)</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Value</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%; color: Black">Outstanding December 31, 2021</td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zeLMRFWVSE3" style="width: 13%; color: Black; text-align: right" title="Number of Options Outstanding, Beginning of Period">279,723</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zjxZzSWuCEzg" style="width: 13%; color: Black; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning of Period">6.12</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 13%; color: Black; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zGT7T885f6n" title="Weighted Average Remaining Contracted Term (years) Outstanding">7.93</span></td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zwTf0HgrbKA4" style="width: 13%; color: Black; text-align: right" title="Aggregate Intrinsic Value Outstanding, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1175">—</span></td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black">Granted</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zHqBdcQNNThg" style="color: Black; text-align: right" title="Number of Options, Granted">300,000</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zDLQRLU0QIA5" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Granted">0.54</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zklP6kdTEUS2" title="Grants in period, weighted average grant date fair value">9.68</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black">Exercised</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zIvMhmMIRAqg" style="color: Black; text-align: right" title="Number of Options, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1183">—</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zabhqOevdvF1" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1185">—</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black">Forfeited</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zFdiQDQxoJOi" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of Options, Forfeited">(568</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMTDeOwOSFy4" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">153.12</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black">Outstanding December 31, 2022</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zfnZbYxoSu4d" style="color: Black; text-align: right" title="Number of Options Outstanding, beginning of Period">579,155</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zGm3M4v0hyO1" style="color: Black; text-align: right" title="Weighted Average Exercise Price Outstanding, beginning of Period">3.09</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zuMxR7aeO8Qh" title="Weighted Average Remaining Contracted Term (years) Outstanding">8.36</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z5GIlJdwHsv1" style="color: Black; text-align: right" title="Aggregate Intrinsic Value Outstanding, beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1196">—</span></td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black">Granted</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zi24FblTlE0h" style="color: Black; text-align: right">360,000</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zwYTkNC4K6Mb" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Granted">0.46</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted_pid_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z0TQxSmD7eFl" title="Grants in period, weighted average grant date fair value">10.04</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black">Exercised</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zYYPNo9CN7h6" style="color: Black; text-align: right" title="Number of Options, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1203">—</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zwJV7OUBpVL6" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1205">—</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black"> Expired</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zXolyBGwaY7l" style="color: Black; text-align: right" title="Number of Options,expired">(653</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExpired_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zrVMvL9EzSG9" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Expired">145.24</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; color: Black">Forfeited</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zCqd3imdscFa" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of Options, Forfeited">(53,447</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z39YSf78win8" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">1.31</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; color: Black">Outstanding December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zezhSipQcXse" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of Options Outstanding, Ending of Period">885,055</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zzDRpEteldth" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted Average Exercise Price Outstanding, End of Period">2.02</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zrKKGIbA2RTb" title="Weighted Average Remaining Contracted Term (years) Outstanding">9.23</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zO67r7VahRxd" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate Intrinsic Value Outstanding, Ending of Period"><span style="-sec-ix-hidden: xdx2ixbrl1220">—</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Vested and expected to vest at December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zJFJeLgHCPgi" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of Options, Vested and Expected to Vest">550,055</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zsVw5JM0Klud" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted Average Exercise Price, Vested and Expected to Vest">2.56</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z3MFGjsRWk45" title="Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest">10.02</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zfSGe30qZ0Se" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate Intrinsic Value, Vested and Expected to Vest"><span style="-sec-ix-hidden: xdx2ixbrl1228">—</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; color: Black">Exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zXLRGkup8nPg" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of Options Exercisable, End of Period">550,055</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zqqDgSxBntta" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted Average Exercise Price Exercisable, Ending of Period">2.56</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zEiXLyYbrHRe" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period">10.02</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zVCTKbz8CYx2" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate Intrinsic Value, Exercisable at End of Period"><span style="-sec-ix-hidden: xdx2ixbrl1236">—</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table>
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2021-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" decimals="INF" id="Fact001169" unitRef="Shares"> 279723 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2021-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" decimals="INF" id="Fact001171" unitRef="USDPShares"> 6.12 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001173"> P7Y11M4D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" decimals="INF" id="Fact001177" unitRef="Shares"> 300000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" decimals="INF" id="Fact001179" unitRef="USDPShares"> 0.54 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001181"> P9Y8M4D </AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" decimals="INF" id="Fact001187" unitRef="Shares"> 568 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" decimals="INF" id="Fact001188" unitRef="USDPShares"> 153.12 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" decimals="INF" id="Fact001190" unitRef="Shares"> 579155 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" decimals="INF" id="Fact001192" unitRef="USDPShares"> 3.09 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001194"> P8Y4M9D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" decimals="INF" id="Fact001197" unitRef="Shares"> 360000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" decimals="INF" id="Fact001199" unitRef="USDPShares"> 0.46 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001201"> P10Y14D </AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" decimals="INF" id="Fact001207" unitRef="Shares"> 653 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
<AIM:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExpired contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" decimals="INF" id="Fact001209" unitRef="USDPShares"> 145.24 </AIM:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExpired>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" decimals="INF" id="Fact001211" unitRef="Shares"> 53447 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" decimals="INF" id="Fact001212" unitRef="USDPShares"> 1.31 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" decimals="INF" id="Fact001214" unitRef="Shares"> 885055 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" decimals="INF" id="Fact001216" unitRef="USDPShares"> 2.02 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001218"> P9Y2M23D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" decimals="INF" id="Fact001222" unitRef="Shares"> 550055 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" decimals="INF" id="Fact001224" unitRef="USDPShares"> 2.56 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001226"> P10Y7D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" decimals="INF" id="Fact001230" unitRef="Shares"> 550055 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" decimals="INF" id="Fact001232" unitRef="USDPShares"> 2.56 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001234"> P10Y7D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2023-01-012023-12-31_custom_NonEmployeeMember" decimals="0" id="Fact001238" unitRef="USD"> 90000 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2023-01-012023-12-31_custom_NonEmployeeMember" decimals="INF" id="Fact001240" unitRef="Shares"> 191666 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2023-01-012023-12-31_custom_NonEmployeeMember" decimals="INF" id="Fact001242" unitRef="USDPShares"> 0.47 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2022-01-012022-12-31_custom_NonEmployeeMember" decimals="0" id="Fact001244" unitRef="USD"> 247166 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2022-01-012022-12-31_custom_NonEmployeeMember" decimals="INF" id="Fact001246" unitRef="Shares"> 229053 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2022-01-012022-12-31_custom_NonEmployeeMember" decimals="INF" id="Fact001248" unitRef="USDPShares"> 1.08 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001250">
<p id="xdx_896_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zYm9rSt3FyF" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Unvested stock option activity for non-employees:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8BE_zmTaiMUsaseh" style="display: none">Schedule of Unvested Stock Option Activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Number of</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted Average Exercise</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted <br/>Average <br/>Remaining <br/>Contracted <br/>Term</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Aggregate Intrinsic</td><td style="color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Options</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">(Years)</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Value</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Unvested December 31, 2021</span></td><td style="width: 2%; color: Black; text-align: left"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zo2AVg35ikEl" style="width: 13%; color: Black; text-align: right" title="Number of Options Unvested, Beginning of Period">97,831</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zfYizJKngL4i" style="width: 13%; color: Black; text-align: right" title="Weighted Average Exercise Price Unvested, Beginning of Period">3.89</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 13%; color: Black; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zgRWC1MjHHZh" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period">7.82</span></td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 2%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_98A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zOvt2toMtfE1" style="width: 13%; color: Black; text-align: right" title="Aggregate Intrinsic Value Unvested, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1258">—</span></td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Granted</span></td><td style="color: Black; text-align: left"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_ze9MVApUkKzg" style="color: Black; text-align: right" title="Number of Options, Granted">300,000</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zWsa113EBQh8" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Granted">0.54</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zNlL7jztUBwf" title="Average Remaining Contractual Term granted">9.68</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Vested</span></td><td style="color: Black; text-align: left"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zcyYH4K4eujk" style="color: Black; text-align: right" title="Number of Options, Vested">(229,053</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z4OJtleVDkF9" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Vested">0.82</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Forfeited</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMMNRPZaH1Ej" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of Options, Forfeited">(1,989</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Unvested December 31, 2022</span></td><td style="color: Black; text-align: left"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zJoajYJB220i" style="color: Black; text-align: right" title="Number of Options Unvested, brginning of Period">166,789</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zSAo2bkBYYxf" style="color: Black; text-align: right" title="Weighted Average Exercise Price Unvested, beginning of Period">4.05</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zBwgskkI0POc" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period">9.49</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zVAzn6ezY5Jh" style="color: Black; text-align: right" title="Aggregate Intrinsic Value Unvested, beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1278">—</span></td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Granted</span></td><td style="color: Black; text-align: left"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zUEy3RLoUeia" style="color: Black; text-align: right" title="Number of Options, Granted">360,000</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zXKnVXQnIlq" style="color: Black; text-align: right">0.46</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zsKTZ4WdlRX2" title="Average Remaining Contractual Term granted">10.18</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Vested</span></td><td style="color: Black; text-align: left"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zPlkAAN1KSR3" style="color: Black; text-align: right" title="Number of Options, Vested">(137,565</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zum4dS1xfGWe" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Vested">0.47</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z4TOxkGhtMce" title="Average Remaining Contractual Term vested">9.47</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Expired</span></td><td style="color: Black; text-align: left"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zqPaKuMMbZIj" style="color: Black; text-align: right" title="Number of Options, Vested">(776</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zKTko5ejOPf8" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Expired">145.24</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right">—</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Forfeited</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z3wqyUMV9Egb" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of Options, Forfeited">(53,447</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zS2KlJFe6pR3" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted Average Exercise Price, Forfeited">1.31</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">—</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Unvested December 31, 2023</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zdqQIbnp4yV1" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of Options Unvested, End of Period">335,001</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zaDpoYkQy0D8" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted Average Exercise Price Unvested, Ending of Period">1.83</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z0xrtELjI1Ig" title="Average Remaining Contractual Term (years) Unvested, End of Period">10.70</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iE_pdp0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z9z6wdP6hCYd" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate Intrinsic Value Unvested, End of Period"><span style="-sec-ix-hidden: xdx2ixbrl1305">—</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> </table>
</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="AsOf2021-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" decimals="INF" id="Fact001252" unitRef="Shares"> 97831 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2021-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" decimals="INF" id="Fact001254" unitRef="USDPShares"> 3.89 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
<AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm contextRef="From2021-01-012021-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001256"> P7Y9M25D </AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" decimals="INF" id="Fact001260" unitRef="Shares"> 300000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" decimals="INF" id="Fact001262" unitRef="USDPShares"> 0.54 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001264"> P9Y8M4D </AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" decimals="INF" id="Fact001266" unitRef="Shares"> 229053 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" decimals="INF" id="Fact001268" unitRef="USDPShares"> 0.82 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" decimals="INF" id="Fact001270" unitRef="Shares"> 1989 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="AsOf2022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" decimals="INF" id="Fact001272" unitRef="Shares"> 166789 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" decimals="INF" id="Fact001274" unitRef="USDPShares"> 4.05 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
<AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001276"> P9Y5M26D </AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" decimals="INF" id="Fact001280" unitRef="Shares"> 360000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" decimals="INF" id="Fact001281" unitRef="USDPShares"> 0.46 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001283"> P10Y2M4D </AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" decimals="INF" id="Fact001285" unitRef="Shares"> 137565 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" decimals="INF" id="Fact001287" unitRef="USDPShares"> 0.47 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
<AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001289"> P9Y5M19D </AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm>
<AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" decimals="INF" id="Fact001291" unitRef="Shares"> 776 </AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares>
<AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" decimals="INF" id="Fact001293" unitRef="USDPShares"> 145.24 </AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" decimals="INF" id="Fact001295" unitRef="Shares"> 53447 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" decimals="INF" id="Fact001297" unitRef="USDPShares"> 1.31 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" decimals="INF" id="Fact001299" unitRef="Shares"> 335001 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" decimals="INF" id="Fact001301" unitRef="USDPShares"> 1.83 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
<AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001303"> P10Y8M12D </AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm>
<us-gaap:ShareBasedCompensation contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" decimals="0" id="Fact001307" unitRef="USD"> 243000 </us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" decimals="0" id="Fact001309" unitRef="USD"> 954000 </us-gaap:ShareBasedCompensation>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2023-12-31" decimals="0" id="Fact001311" unitRef="USD"> 294000 </us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2022-12-31" decimals="0" id="Fact001313" unitRef="USD"> 217000 </us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001315">
<p id="xdx_897_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_zeILQNWJeqal" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Information regarding warrants outstanding and exercisable into shares of common stock is summarized below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B7_z5LMDxbstbGf" style="display: none">Schedule of Warrants Outstanding and Exercisable</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black; text-align: center"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="color: Black; text-align: center"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center"></td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Warrant</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted <br/>Average <br/>Exercise</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center"></td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Warrant</td><td style="color: Black"> </td><td style="color: Black"> </td> <td colspan="2" style="color: Black; text-align: center">Weighted <br/>Average <br/>Exercise</td><td style="color: Black"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; color: Black; text-align: center"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 34%; color: Black; text-align: justify">Outstanding, beginning of year <br/>  <br/></td><td style="width: 1%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqRozs5Y4jkd" style="width: 8%; color: Black; text-align: right" title="Number of options outstanding, beginning of year">226,610</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 1%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 8%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$ <span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zmXSSkkOT8w5" title="Warrant price outstanding, beginning of year">0.99</span>-<span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zpbRlEk5oJtd" title="Warrant price outstanding, beginning of year">132.00</span></span></td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 1%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zahnLtP5LwO2" style="width: 8%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">9.10</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 1%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrmgCjc9Rzvj" style="width: 8%; color: Black; text-align: right" title="Number of options outstanding, beginning of year">294,939</td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 1%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 8%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$<span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zyJrDi4sOWgk" title="Warrant price outstanding, beginning of year">0.99</span> – <span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zn0GmmO3P6qd" title="Warrant price outstanding, beginning of year">469.92</span></span></td><td style="width: 1%; color: Black; text-align: left"> </td><td style="width: 1%; color: Black"> </td> <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zh5LIcPleKMc" style="width: 8%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">15.19</td><td style="width: 1%; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black">Granted</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwY5sI38OOzh" style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"><span style="-sec-ix-hidden: xdx2ixbrl1333">—</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLEgVWTRsnak" style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1334">—</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstandingGrantsInPeriod_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zc7yT8hEfSb5" style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"><span style="-sec-ix-hidden: xdx2ixbrl1336">—</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVlIghCmTL7f" style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"><span style="-sec-ix-hidden: xdx2ixbrl1338">—</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkmmxnyXbMd3" style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1339">—</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstandingGrantsInPeriod_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z58kY4rBtdG9" style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"><span style="-sec-ix-hidden: xdx2ixbrl1341">—</span></td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black">Expired</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAwCgD0h9s57" style="color: Black; text-align: right" title="Number of options outstanding, beginning of year">(74,450</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdvdRHtoavji" title="Warrant price, expired">17.05</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZ1pTsT6w837" style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">17.05</td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrQH6C4gMbi8" style="color: Black; text-align: right" title="Number of options outstanding, beginning of year">(68,215</td><td style="color: Black; text-align: left">)</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXoTkDQNvH9c" title="Warrant price, expired">469.92</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIgnvUGFmM5g" style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">469.92</td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; color: Black">Exercised</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwO6JRyXJYlg" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, beginning of year"><span style="-sec-ix-hidden: xdx2ixbrl1355">—</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8XKH76Mu3L1" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1356">—</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4vIQJiOvFfi" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"><span style="-sec-ix-hidden: xdx2ixbrl1358">—</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zszAruL7seU1" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, beginning of year">(114</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zn6j9lU4Wks7" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">8.80</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTEpQNEKrwue" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">8.80</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Outstanding, end of year</td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvoaBmP9KhK2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, beginning of year">152,160</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$ <span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_z0BKR7zQaTR9" title="Warrant price outstanding, end of year">0.99</span>-<span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zYSZCmEsGPj3" title="Warrant price outstanding, end of year">8.80</span></span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrRvhpq3yLm8" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">8.03</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zl6cQec3WhGe" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, beginning of year">226,610</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$ <span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zsrEUrBv1Q1h" title="Warrant price outstanding, end of year">0.99</span>-<span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zEF2kNXhsAR3" title="Warrant price outstanding, end of year">132.00</span></span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 1.5pt; color: Black"> </td> <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zA3doCO4NgPj" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">9.10</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; color: Black">Exercisable</td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zagMEkNX966k" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, beginning of year">152,160</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$ <span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_z2cMmWZxTZu4" title="Warrant price exercisable, end of year">0.99</span>-<span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zn2YWcIasnj2" title="Warrant price exercisable, end of year">8.80</span></span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyybKuv1rSx7" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">8.03</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqpgrO72ETjj" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, beginning of year">226,610</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$ <span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zjyk7kIgfru" title="Warrant price exercisable, end of year">0.99</span>-<span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z2KaO7qSI7lb" title="Warrant price exercisable, end of year">132.00</span></span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td><td style="padding-bottom: 2.5pt; color: Black"> </td> <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRPxw92JECg8" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">9.10</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: Black">Weighted average remaining contractual life</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8AuyJMA2PU3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">.75 </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">years</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"> </td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"> </td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQN9lfUrImB4" title="Weighted average remaining contracted term (years) outstanding, ending of year">.94</span> years</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"> </td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"> </td><td style="color: Black; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: Black; text-align: left">Years exercisable</td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9BxMoyx0vGj" title="Years exercisable">2024</span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"> </td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"> </td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zo81gQDW6ad6" title="Years exercisable">2023</span>-<span id="xdx_90A_ecustom--WeightedbasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z9dvWViWs0rj" title="Years exercisable">2024</span></span></td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right"> </td><td style="color: Black; text-align: left"> </td><td style="color: Black"> </td> <td style="color: Black; text-align: left"> </td><td style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"> </td><td style="color: Black; text-align: left"> </td></tr> </table>
</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="AsOf2022-12-31_us-gaap_WarrantMember" decimals="INF" id="Fact001317" unitRef="Shares"> 226610 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber contextRef="AsOf2022-12-31_us-gaap_WarrantMember_srt_MinimumMember" decimals="INF" id="Fact001319" unitRef="USDPShares"> 0.99 </AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber contextRef="AsOf2022-12-31_us-gaap_WarrantMember_srt_MaximumMember" decimals="INF" id="Fact001321" unitRef="USDPShares"> 132.00 </AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding contextRef="AsOf2022-12-31_us-gaap_WarrantMember" decimals="INF" id="Fact001323" unitRef="USDPShares"> 9.10 </AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="AsOf2021-12-31_us-gaap_WarrantMember" decimals="INF" id="Fact001325" unitRef="Shares"> 294939 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber contextRef="AsOf2021-12-31_us-gaap_WarrantMember_srt_MinimumMember" decimals="INF" id="Fact001327" unitRef="USDPShares"> 0.99 </AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber contextRef="AsOf2021-12-31_us-gaap_WarrantMember_srt_MaximumMember" decimals="INF" id="Fact001329" unitRef="USDPShares"> 469.92 </AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding contextRef="AsOf2021-12-31_us-gaap_WarrantMember" decimals="INF" id="Fact001331" unitRef="USDPShares"> 15.19 </AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" decimals="INF" id="Fact001343" unitRef="Shares"> 74450 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" decimals="INF" id="Fact001345" unitRef="USDPShares"> 17.05 </AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" decimals="INF" id="Fact001347" unitRef="USDPShares"> 17.05 </AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" decimals="INF" id="Fact001349" unitRef="Shares"> 68215 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" decimals="INF" id="Fact001351" unitRef="USDPShares"> 469.92 </AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" decimals="INF" id="Fact001353" unitRef="USDPShares"> 469.92 </AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" decimals="INF" id="Fact001360" unitRef="Shares"> 114 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" decimals="INF" id="Fact001361" unitRef="USDPShares"> 8.80 </AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" decimals="INF" id="Fact001363" unitRef="USDPShares"> 8.80 </AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="AsOf2023-12-31_us-gaap_WarrantMember289844531" decimals="INF" id="Fact001365" unitRef="Shares"> 152160 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber contextRef="AsOf2023-12-31_us-gaap_WarrantMember_srt_MinimumMember" decimals="INF" id="Fact001367" unitRef="USDPShares"> 0.99 </AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber contextRef="AsOf2023-12-31_us-gaap_WarrantMember_srt_MaximumMember" decimals="INF" id="Fact001369" unitRef="USDPShares"> 8.80 </AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding contextRef="AsOf2023-12-31_us-gaap_WarrantMember289844531" decimals="INF" id="Fact001371" unitRef="USDPShares"> 8.03 </AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="AsOf2022-12-31_us-gaap_WarrantMember" decimals="INF" id="Fact001373" unitRef="Shares"> 226610 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber contextRef="AsOf2022-12-31_us-gaap_WarrantMember_srt_MinimumMember" decimals="INF" id="Fact001375" unitRef="USDPShares"> 0.99 </AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber contextRef="AsOf2022-12-31_us-gaap_WarrantMember_srt_MaximumMember" decimals="INF" id="Fact001377" unitRef="USDPShares"> 132.00 </AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding contextRef="AsOf2022-12-31_us-gaap_WarrantMember" decimals="INF" id="Fact001379" unitRef="USDPShares"> 9.10 </AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" decimals="INF" id="Fact001381" unitRef="Shares"> 152160 </AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice contextRef="AsOf2023-12-31_us-gaap_WarrantMember_srt_MinimumMember" decimals="INF" id="Fact001383" unitRef="USDPShares"> 0.99 </AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice contextRef="AsOf2023-12-31_us-gaap_WarrantMember_srt_MaximumMember" decimals="INF" id="Fact001385" unitRef="USDPShares"> 8.80 </AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" decimals="INF" id="Fact001387" unitRef="USDPShares"> 8.03 </AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" decimals="INF" id="Fact001389" unitRef="Shares"> 226610 </AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice contextRef="AsOf2022-12-31_us-gaap_WarrantMember_srt_MinimumMember" decimals="INF" id="Fact001391" unitRef="USDPShares"> 0.99 </AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice contextRef="AsOf2022-12-31_us-gaap_WarrantMember_srt_MaximumMember" decimals="INF" id="Fact001393" unitRef="USDPShares"> 132.00 </AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" decimals="INF" id="Fact001395" unitRef="USDPShares"> 9.10 </AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="Fact001396"> P0Y9M </AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber>
<AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" id="Fact001398"> P0Y11M8D </AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber>
<AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="Fact001400"> 2024 </AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear>
<AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_srt_MinimumMember" id="Fact001402"> 2023 </AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear>
<AIM:WeightedbasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_srt_MaximumMember" id="Fact001404"> 2024 </AIM:WeightedbasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear>
<us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001414">
<p id="xdx_802_eus-gaap--SegmentReportingDisclosureTextBlock_zJJslBquIkL7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>(7) <span id="xdx_82D_zREfYxgxL3z4">Segment and Related Information</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company operates in <span id="xdx_909_eus-gaap--NumberOfOperatingSegments_dc_uInteger_c20230101__20231231_zc5D3JCz9mj5" title="Number of segment">one</span> segment, which performs research and development activities related to Ampligen and other drugs under development. The Company’s revenues for the two-year period ended December 31, 2023, were earned in the United States. All assets are maintained in the United States of America.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p>
</us-gaap:SegmentReportingDisclosureTextBlock>
<us-gaap:NumberOfOperatingSegments contextRef="From2023-01-01to2023-12-31" decimals="INF" id="Fact001416" unitRef="Integer"> 1 </us-gaap:NumberOfOperatingSegments>
<AIM:ResearchConsultingAndSupplyAgreementsTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001418">
<p id="xdx_805_ecustom--ResearchConsultingAndSupplyAgreementsTextBlock_z4fLtYbN7Vll" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>(8) <span id="xdx_822_zEJLf0INZyc8">Research, Consulting and Supply Agreements</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company has entered into research, consulting and supply agreements with third party service providers to perform research and development activities on therapeutics, including clinical trials. The identification of research and development costs involves reviewing open contracts and purchase orders, communicating with applicable company and third-party personnel to identify services that have been performed, and corroborating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual expenses. The Company expenses these research and development costs when incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During the year ended December 31, 2023, research and development expenses were comprised of: clinical studies ($<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__srt--ProductOrServiceAxis__custom--ClinicalStudiesMember_zyjDnZGFgh62" title="Research and development expense">6,014,000</span>), manufacturing and engineering ($<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__srt--ProductOrServiceAxis__custom--ManufacturingAndEngineeringMember_zfI5Va6rI0d5" title="Research and development expense">3,220,000</span>), quality control ($<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__srt--ProductOrServiceAxis__custom--QualityControlMember_zj6NBYEJsDr9" title="Research and development expense">1,271,000</span>) and regulatory ($<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__srt--ProductOrServiceAxis__custom--RegulatoryMember_z6SeNVOYYyG5" title="Research and development expense">434,000</span>).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span>During the year ended December 31, 2022, research and development expenses were comprised of: clinical studies ($<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__srt--ProductOrServiceAxis__custom--ClinicalStudiesMember_zyuQ9B3Ls66h" title="Research and development expense">4,070,000</span>), manufacturing and engineering ($<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__srt--ProductOrServiceAxis__custom--ManufacturingAndEngineeringMember_zrzfkeFObV29" title="Research and development expense">1,241,000</span>), quality control ($<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__srt--ProductOrServiceAxis__custom--QualityControlMember_zGzSy0BCHlT8" title="Research and development expense">1,236,000</span>) and regulatory ($<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__srt--ProductOrServiceAxis__custom--RegulatoryMember_zwhviG7susAi" title="Research and development expense">443,000</span>).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The following summarizes the most substantial of our contracts relating to research, consulting, and supply costs for AIM as they related to research and development costs during the year ended December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Amarex Clinical Research LLC</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Amarex is the principal administrator of several of AIM’s largest clinical studies. AIM has multiple contracts with Amarex Clinical Research LLC (“Amarex”). During the year ended December 31, 2023 and 2022, the Company incurred approximately $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zjsKeSbwVgt3" title="Research and development expense">4,290,000</span> and $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zoTYVGpzRIHh" title="Research and development expense">2,272,000</span>, respectively, related to these ongoing agreements:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Pancreatic Cancer - In April 2022, AIM executed a work order with Amarex pursuant to which Amarex is managing a Phase 2 clinical trial in locally advanced pancreatic cancer patients designated AMP-270. Per the work order, AIM anticipates that Amarex’s management of the study will cost approximately $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c20220401__20220430__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zj0b7yetqVHi" title="Research and development expense excluding acquired in process cost">8,400,000</span>. This estimate includes pass-through costs of approximately $<span id="xdx_904_eus-gaap--DevelopmentCosts_c20220401__20220430__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_z6E238Oy8zCa" title="Development cost">1,000,000</span> and excludes certain third-party and investigator costs and escalations necessary for study completion. AIM anticipates that the study will take approximately <span id="xdx_904_ecustom--ResearchAndDevelopmentExpenseCostEstimatedLives_dtY_c20220401__20220430__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zvzpsBBUJNJ6" title="Estimated lives">4.6</span> years to complete.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">○</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During the year ended December 31, 2023, the Company incurred approximately $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--PancreaticCancerMember_zEogaZmww6xe" title="Research and development expense">600,000</span> related to this agreement.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">○</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the year ended December 31, 2022, the Company incurred approximately $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--PancreaticCancerMember_zRA9HhWySi2b" title="Research and development expense">1,691,000</span> related to this agreement.</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Post-COVID Conditions - In September 2022, AIM executed a work order with Amarex, pursuant to which Amarex is managing a Phase 2 trial in patients with Post-COVID Conditions. AIM is sponsoring the study. AIM anticipates that the study will cost approximately $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c20220901__20220930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_z3OtcXkdCxH5">6,400,000</span>, which includes pass through costs of approximately $<span id="xdx_90C_eus-gaap--DevelopmentCosts_c20220901__20220930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_z68nU02VjkCg" title="Development cost">125,000</span>, investigator costs estimated at about $<span id="xdx_900_eus-gaap--CostMaintenance_c20220901__20220930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zwAikhPsTji7" title="Invigilators cost">4,400,000</span>, and excludes certain other third-party costs and escalations. During 2023, the original work order increased to approximately $<span id="xdx_904_eus-gaap--DevelopmentCosts_c20230101__20231231__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zN5anhmwgnI8" title="Development cost">6,600,000</span> for the addition of patient reported outcome (PRO) electronic questionnaires (devices/tablets for patients to complete); services associated with the ePRO system and additional safety monitoring services as well as changes to study documentation (such as protocol amendments) which resulted in additional IND submissions to FDA. This study was effectively concluded in 2023.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">○</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During the year ended December 31, 2023, the Company incurred approximately $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--PostCOVIDMember_zX4oZsJX0Xcg" title="Research and development expense">3,690,000</span> related to this agreement.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">○</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the year ended December 31, 2022, the Company incurred approximately $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--PostCOVIDMember_zBWSLzE4RDt" title="Research and development expense">581,000</span> related to this agreement.</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Jubilant HollisterStier</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Jubilant HollisterStier (“Jubilant”) is AIM’s authorized CMO for Ampligen for the approval in Argentina. In 2017, the Company entered into an agreement with Jubilant pursuant to which Jubilant will manufacture batches of Ampligen® for the Company. Since the 2017 engagement of Jubilant, two lots of Ampligen consisting of more than <span id="xdx_90F_ecustom--UnitsManufactured_uInteger_c20170101__20171231__dei--LegalEntityAxis__custom--JubilantHollisterStierMember_zJaL14ANND35" title="Number of units manufactured">16,000</span> units were manufactured and released in the year 2018. The first lot was designated for human use in the United States in the cost recovery CFS program and for expanded oncology clinical trials. The second lot has been designated for these programs in addition to commercial distribution in Argentina for the treatment of CFS. Jubilant manufactured additional two lots of Ampligen in December 2019 and January 2020. In March 2023, the Company ordered an additional <span id="xdx_904_ecustom--NumberOfVials_uInteger_c20230101__20230331__dei--LegalEntityAxis__custom--JubilantHollisterStierMember_zpL9XLWaZCf5" title="Additional number of vials">27,900</span> vials from Jubilant at a cost of approximately $<span id="xdx_90E_eus-gaap--InventoryWorkInProcessAndRawMaterials_iI_c20230331__dei--LegalEntityAxis__custom--JubilantHollisterStierMember_zCBLLFuNAPH9" title="Inventory work in process and raw materials">1,432,000</span>. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">○</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During the year ended December 31, 2023, the Company incurred approximately $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__dei--LegalEntityAxis__custom--JubilantHollisterStierMember__us-gaap--TypeOfArrangementAxis__custom--ResearchConsultingAndSupplyAgreementsMember_zfI7t5QWlnMa" title="Research and development expense">1,432,000</span> related to this agreement.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">○</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the year ended December 31, 2022, the Company incurred approximately $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--JubilantHollisterStierMember__us-gaap--TypeOfArrangementAxis__custom--ResearchConsultingAndSupplyAgreementsMember_zCKeu8FivXJ" title="Research and development expense">79,000</span> related to this agreement.</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Sterling Pharma Solutions</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In 2022, the Company entered into a Master Service Agreement and a Quality Agreement with Sterling Pharma Solutions (“Sterling”) for the manufacture of the Company’s Poly I and Poly C12U polynucleotides and transfer of associated test methods at Sterling’s Dudley, UK location to produce the polymer precursors to manufacture the drug Ampligen.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">○</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During the year ended December 31, 2023, the Company incurred approximately $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__dei--LegalEntityAxis__custom--PharmaSolutionsMember__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAgreementAndQualityAgreementMember_zKzuIfnLYHIk" title="Research and development expense">363,000</span> related to this agreement.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">○</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the year ended December 31, 2022, the Company did not incur any expense related to this agreement.</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Erasmus</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In December 2022, the Company entered into a joint clinical study agreement with Erasmus University Medical Center Rotterdam to conduct a Phase II study: Combining anti-PD-L1 immune checkpoint inhibitor durvalumab with TLR-3 agonist rintatolimod in patients with metastatic pancreatic ductal adenocarcinoma for therapy efficacy. This is a study in collaboration with AstraZeneca. AIM’s limited responsibilities are limited to providing Ampligen. Additionally, AIM agreed to provide a grant of $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20221201__20221231__dei--LegalEntityAxis__custom--ErasmusMember__us-gaap--TypeOfArrangementAxis__custom--JointClinicalStudyAgreementMember_zrZLNisgBPx" title="Research and development expense">200,000</span> for the study.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">○</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During the year ended December 31, 2023, the Company incurred approximately $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__dei--LegalEntityAxis__custom--ErasmusMember__us-gaap--TypeOfArrangementAxis__custom--JjointClinicalStudyAgreementMember_zbzGQ71Oq9Yg" title="Research and development expense">100,000</span> pursuant to the Grant Agreement.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">○</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the year ended December 31, 2022, the Company did not incur any expense related to this agreement.</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Azenova Sales International</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2023, the Company entered into a consulting agreement with Azenova, LLC whereas Azenova will provide business development services for AIM’s Ampligen product for solid tumors for a 12 month term that is extendable upon the agreement of the parties. In exchange for its services, Azenova will receive a fixed monthly retainer of $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_c20231031__dei--LegalEntityAxis__custom--AzenovaSalesInternationalMember_zDtRuFC8pDte" title="Stock options, aggregate intrinsic value">30,000</span> per month in addition to <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20231031__dei--LegalEntityAxis__custom--AzenovaSalesInternationalMember_zoUQauZAXSz5" title="Stock options, vested">360,000</span> stock options that vest monthly.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">○</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2023, the Company incurred approximately $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__dei--LegalEntityAxis__custom--AzenovaSalesInternationalMember_zwr8JgvdTSQa" title="Research and development expense">75,000</span> related to this agreement.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">○</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the year ended December 31, 2022, the Company did not incur any expense related to this agreement.</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Alcami</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In September 2023, the Company entered into an agreement with Alcami Corporation to perform an extractables study for a primary packaging component. The agreement called for fixed costs of approximately $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20230901__20230930__dei--LegalEntityAxis__custom--AlcamiMember_zF5WPVvD5UFa" title="Research and development expense">30,000</span> upon completion of the study and issue of the final report, along with solvent costs, and pass through items to be billed on a per activity basis. The final bill for the initial study was received in December 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">○</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2023, the Company incurred approximately $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__dei--LegalEntityAxis__custom--AlcamiMember_zjgWBiPtStJ3" title="Research and development expense">65,000</span> of lab services from Alcami.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">○</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the year ended December 31, 2022, the Company incurred approximately $<span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--AlcamiMember_zKyWKv2prIx3" title="Research and development expense">18,000</span> of lab services from Alcami.</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</AIM:ResearchConsultingAndSupplyAgreementsTextBlock>
<us-gaap:ResearchAndDevelopmentExpense contextRef="From2023-01-012023-12-31_custom_ClinicalStudiesMember" decimals="0" id="Fact001420" unitRef="USD"> 6014000 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="From2023-01-012023-12-31_custom_ManufacturingAndEngineeringMember" decimals="0" id="Fact001422" unitRef="USD"> 3220000 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="From2023-01-012023-12-31_custom_QualityControlMember" decimals="0" id="Fact001424" unitRef="USD"> 1271000 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="From2023-01-012023-12-31_custom_RegulatoryMember" decimals="0" id="Fact001426" unitRef="USD"> 434000 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="From2022-01-012022-12-31_custom_ClinicalStudiesMember" decimals="0" id="Fact001428" unitRef="USD"> 4070000 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="From2022-01-012022-12-31_custom_ManufacturingAndEngineeringMember" decimals="0" id="Fact001430" unitRef="USD"> 1241000 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="From2022-01-012022-12-31_custom_QualityControlMember" decimals="0" id="Fact001432" unitRef="USD"> 1236000 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="From2022-01-012022-12-31_custom_RegulatoryMember" decimals="0" id="Fact001434" unitRef="USD"> 443000 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="From2023-01-012023-12-31_custom_AmarexClinicalResearchLLCMember" decimals="0" id="Fact001436" unitRef="USD"> 4290000 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="From2022-01-012022-12-31_custom_AmarexClinicalResearchLLCMember" decimals="0" id="Fact001438" unitRef="USD"> 2272000 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="From2022-04-012022-04-30_custom_AmarexClinicalResearchLLCMember" decimals="0" id="Fact001440" unitRef="USD"> 8400000 </us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
<us-gaap:DevelopmentCosts contextRef="From2022-04-012022-04-30_custom_AmarexClinicalResearchLLCMember" decimals="0" id="Fact001442" unitRef="USD"> 1000000 </us-gaap:DevelopmentCosts>
<AIM:ResearchAndDevelopmentExpenseCostEstimatedLives contextRef="From2022-04-012022-04-30_custom_AmarexClinicalResearchLLCMember" id="Fact001444"> P4Y7M6D </AIM:ResearchAndDevelopmentExpenseCostEstimatedLives>
<us-gaap:ResearchAndDevelopmentExpense contextRef="From2023-01-012023-12-31_custom_AmarexClinicalResearchLLCMember_custom_PancreaticCancerMember" decimals="0" id="Fact001446" unitRef="USD"> 600000 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="From2022-01-012022-12-31_custom_AmarexClinicalResearchLLCMember_custom_PancreaticCancerMember" decimals="0" id="Fact001448" unitRef="USD"> 1691000 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="From2022-09-012022-09-30_custom_AmarexClinicalResearchLLCMember" decimals="0" id="Fact001449" unitRef="USD"> 6400000 </us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
<us-gaap:DevelopmentCosts contextRef="From2022-09-012022-09-30_custom_AmarexClinicalResearchLLCMember" decimals="0" id="Fact001451" unitRef="USD"> 125000 </us-gaap:DevelopmentCosts>
<us-gaap:CostMaintenance contextRef="From2022-09-012022-09-30_custom_AmarexClinicalResearchLLCMember" decimals="0" id="Fact001453" unitRef="USD"> 4400000 </us-gaap:CostMaintenance>
<us-gaap:DevelopmentCosts contextRef="From2023-01-012023-12-31_custom_AmarexClinicalResearchLLCMember" decimals="0" id="Fact001455" unitRef="USD"> 6600000 </us-gaap:DevelopmentCosts>
<us-gaap:ResearchAndDevelopmentExpense contextRef="From2023-01-012023-12-31_custom_AmarexClinicalResearchLLCMember_custom_PostCOVIDMember" decimals="0" id="Fact001457" unitRef="USD"> 3690000 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="From2022-01-012022-12-31_custom_AmarexClinicalResearchLLCMember_custom_PostCOVIDMember" decimals="0" id="Fact001459" unitRef="USD"> 581000 </us-gaap:ResearchAndDevelopmentExpense>
<AIM:UnitsManufactured contextRef="From2017-01-012017-12-31_custom_JubilantHollisterStierMember" decimals="INF" id="Fact001461" unitRef="Integer"> 16000 </AIM:UnitsManufactured>
<AIM:NumberOfVials contextRef="From2023-01-012023-03-31_custom_JubilantHollisterStierMember" decimals="INF" id="Fact001463" unitRef="Integer"> 27900 </AIM:NumberOfVials>
<us-gaap:InventoryWorkInProcessAndRawMaterials contextRef="AsOf2023-03-31_custom_JubilantHollisterStierMember" decimals="0" id="Fact001465" unitRef="USD"> 1432000 </us-gaap:InventoryWorkInProcessAndRawMaterials>
<us-gaap:ResearchAndDevelopmentExpense contextRef="From2023-01-012023-12-31_custom_JubilantHollisterStierMember_custom_ResearchConsultingAndSupplyAgreementsMember" decimals="0" id="Fact001467" unitRef="USD"> 1432000 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="From2022-01-012022-12-31_custom_JubilantHollisterStierMember_custom_ResearchConsultingAndSupplyAgreementsMember" decimals="0" id="Fact001469" unitRef="USD"> 79000 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="From2023-01-012023-12-31_custom_PharmaSolutionsMember_custom_MasterServiceAgreementAndQualityAgreementMember" decimals="0" id="Fact001471" unitRef="USD"> 363000 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="From2022-12-012022-12-31_custom_ErasmusMember_custom_JointClinicalStudyAgreementMember" decimals="0" id="Fact001473" unitRef="USD"> 200000 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="From2023-01-012023-12-31_custom_ErasmusMember_custom_JjointClinicalStudyAgreementMember" decimals="0" id="Fact001475" unitRef="USD"> 100000 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="AsOf2023-10-31_custom_AzenovaSalesInternationalMember" decimals="0" id="Fact001477" unitRef="USD"> 30000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2023-10-31_custom_AzenovaSalesInternationalMember" decimals="INF" id="Fact001479" unitRef="Shares"> 360000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
<us-gaap:ResearchAndDevelopmentExpense contextRef="From2023-01-012023-12-31_custom_AzenovaSalesInternationalMember" decimals="0" id="Fact001481" unitRef="USD"> 75000 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="From2023-09-012023-09-30_custom_AlcamiMember" decimals="0" id="Fact001483" unitRef="USD"> 30000 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="From2023-01-012023-12-31_custom_AlcamiMember" decimals="0" id="Fact001485" unitRef="USD"> 65000 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="From2022-01-012022-12-31_custom_AlcamiMember" decimals="0" id="Fact001487" unitRef="USD"> 18000 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001489">
<p id="xdx_80F_eus-gaap--CompensationAndEmployeeBenefitPlansTextBlock_z41Ccz5PSXFj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(9) <span id="xdx_827_zYskLrLHgAXi">401(k) Plan</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIM has a defined contribution plan, entitled the AIM ImmunoTech Employees 401(k) Plan and Trust Agreement (the “401(k) Plan”). AIM’s full-time employees are eligible to participate in the 401(k) Plan following 61 days of employment. Subject to certain limitations imposed by federal tax laws, participants are eligible to contribute up to <span id="xdx_90A_eus-gaap--DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_dp_uPure_c20230101__20231231__us-gaap--RetirementPlanNameAxis__custom--FourZeroOnekPlanMember_zux9xhht0cd7" title="Percentage of maximum annual contribution per employee, as percentage of their annual salary">15</span>% of their salary (including bonuses and/or commissions) per annum. Participants’ contributions to the 401(k) Plan may be matched by us at a rate determined annually by the Board.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each participant immediately vests in his or her deferred salary contributions as well as the Company’s safe harbor contributions. A <span id="xdx_903_eus-gaap--DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_pid_dp_uPure_c20230101__20231231_zPmL7gjec7M6" title="Deferred compensation arrangementl, cash awards granted, percentage">6</span>% safe harbor matching contribution by us was reinstated effective January 1, 2021. For the year ended December 31, 2023 and 2022, the Company’s matching contributions were approximately $<span id="xdx_90F_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_c20230101__20231231_zDzlD8umTTua" title="Contribution amount">162,000</span> and $<span id="xdx_903_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_c20220101__20221231_zWVac5329b" title="Contribution amount">122,000</span>, respectively</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
<us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent contextRef="From2023-01-012023-12-31_custom_FourZeroOnekPlanMember" decimals="INF" id="Fact001491" unitRef="Pure"> 0.15 </us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
<us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage contextRef="From2023-01-01to2023-12-31" decimals="INF" id="Fact001493" unitRef="Pure"> 0.06 </us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage>
<us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact001495" unitRef="USD"> 162000 </us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
<us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="From2022-01-012022-12-31" decimals="0" id="Fact001497" unitRef="USD"> 122000 </us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
<AIM:EmploymentAgreementsTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001499">
<p id="xdx_80E_ecustom--EmploymentAgreementsTextBlock_z3dZg3hif1Cj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(10) <span id="xdx_829_zMyC1KKbWmIl">Employment Agreements</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company had contractual agreements with Named Executive Officers (“NEO”) in 2023, and 2022. The aggregate annual base compensation for these NEO under their respective contractual agreements for 2023 and 2022 was $<span id="xdx_902_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentContractualAgreementsMember__srt--TitleOfIndividualAxis__custom--NamedExecutiveOfficersMember_zj0ShGkuJnL1" title="Employee benefits and share-based compensation">1,275,000</span> and $<span id="xdx_900_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentContractualAgreementsMember__srt--TitleOfIndividualAxis__custom--NamedExecutiveOfficersMember_zaEP2bBxhiGd" title="Employee benefits and share-based compensation">1,275,000</span>, respectively. In addition, certain of these Officers were entitled to receive performance bonuses of up to <span id="xdx_90C_eus-gaap--RevenueRemainingPerformanceObligationPercentage_iI_pid_dp_uPure_c20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentContractualAgreementsMember__srt--TitleOfIndividualAxis__custom--NamedExecutiveOfficersMember_zAWrRcxlY5Ya" title="Revenue, remaining performance obligation, percentage">25</span>% or <span id="xdx_902_eus-gaap--RevenueRemainingPerformanceObligationPercentage_iI_pid_dp_uPure_c20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentContractualAgreementsMember__srt--TitleOfIndividualAxis__custom--NamedExecutiveOfficersMember_ziu4G3VqCNwd" title="Revenue, remaining performance obligation, percentage">20</span>% of their respective annual base salary, at the sole discretion of the Compensation Committee of the Board of Directors. For the years ended December 31, 2023 and 2022, Officers’ bonuses were $<span id="xdx_903_ecustom--Bonus_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentContractualAgreementsMember__srt--TitleOfIndividualAxis__custom--NamedExecutiveOfficersMember_zEMZSOc8AYE5">450,000</span>, to be deferred and paid in 2024 and $<span id="xdx_90B_ecustom--Bonus_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentContractualAgreementsMember__srt--TitleOfIndividualAxis__custom--NamedExecutiveOfficersMember_z1JvkmqZRr9h">450,000</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2023, equity was granted as a form of compensation to these Officers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a. </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company granted <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--ThomasKEquelsMember_zLuhZd8cUGIg" title="Number of options, granted">300,000</span> <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--ThomasKEquelsMember_z5g6mpgvgvc3" title="Options term::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl1513">ten-year</span></span> options to purchase common stock with an exercise price of $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--ThomasKEquelsMember_z5z5Hbpc0Nte" title="Stock options exercise price per share">0.47</span> per share to vest in <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--ThomasKEquelsMember_zP3lUqpy1hlg">one year</span> to Thomas K. Equels, Chief Executive Officer. </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b. </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company granted <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--PeterRodinoMember_zC6zjeGF8sLe" title="Number of options, granted">100,000</span> <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--PeterRodinoMember_zwzTNS7Bj5Xe" title="Options term::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl1520">ten-year</span></span> options to purchase common stock with an exercise price of $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--PeterRodinoMember_zTrS2M1Re0Ai" title="Stock options exercise price per share">0.47</span> per share which vest in <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--PeterRodinoMember_ztOxwIqUCeed" title="Vesting period">one year</span> to Peter Rodino, Chief Operating Officer and General Counsel.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recorded stock compensation expense of approximately $<span id="xdx_900_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EquelsandRodinoMember_zf8vnYpJe6ol" title="Stock compensation expense">14,000</span> during the year ended December 31, 2023 with regard to these issuances to Officers Equels and Rodino.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2022, equity was granted as a form of compensation to these Officers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c. </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company granted <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--ThomasKEquelsMember_z6KkeQwFNM9l" title="Number of options, granted">300,000</span> <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--ThomasKEquelsMember_zkTwRI3bRFRj" title="Options term::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl1530">ten-year</span></span> options to purchase common stock with an exercise price of $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--ThomasKEquelsMember_zlND1tOnooGc" title="Stock options exercise price per share">0.41</span> per share to vest in <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--ThomasKEquelsMember_zLAigI8Ixqb6">one year</span> to Thomas K. Equels, Chief Executive Officer. </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d. </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company granted <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--PeterRodinoMember_zqR0Vn4Va4Ni" title="Number of options, granted">150,000</span><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--PeterRodinoMember_zCXKUdCehaDe" title="Options term::XDX::P10Y"> <span style="-sec-ix-hidden: xdx2ixbrl1537">ten-year</span></span> options to purchase common stock with exercise price of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--PeterRodinoMember__srt--RangeAxis__srt--MinimumMember_zVGM4kglJob6" title="Stock options exercise price per share">0.41</span> to $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--PeterRodinoMember__srt--RangeAxis__srt--MaximumMember_z0pDSSJI41T5" title="Stock options exercise price per share">0.70</span> per share which vest in <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--PeterRodinoMember_zW8O62SfRcNh" title="Vesting period">one year</span> to Peter Rodino, Chief Operating Officer and General Counsel.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e. </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company granted <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--EllenLintalMember_zF2JjGbqRn9h">50,000</span> <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--EllenLintalMember_z9axaCjww9u9" title="::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl1545">ten-year</span></span> options to purchase common stock with an exercise price of $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--EllenLintalMember_z3sSALWeLDHh">0.70</span> per share which vest in <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--EllenLintalMember_ztrwY3O2VUSk">one year</span> to Ellen Lintal, former Chief Financial Officer.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recorded stock compensation expense of approximately $<span id="xdx_90B_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EquelsRodinoAndFormerOfficerLintalMember_zy4Yu23qvXD1" title="Stock compensation expense">107,000</span> during the year ended December 31, 2023 with regard to these issuances to Officers Equels, Rodino, and former Officer Lintal.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</AIM:EmploymentAgreementsTextBlock>
<us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="From2023-01-012023-12-31_custom_EmploymentContractualAgreementsMember_custom_NamedExecutiveOfficersMember" decimals="0" id="Fact001501" unitRef="USD"> 1275000 </us-gaap:EmployeeBenefitsAndShareBasedCompensation>
<us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="From2022-01-012022-12-31_custom_EmploymentContractualAgreementsMember_custom_NamedExecutiveOfficersMember" decimals="0" id="Fact001503" unitRef="USD"> 1275000 </us-gaap:EmployeeBenefitsAndShareBasedCompensation>
<us-gaap:RevenueRemainingPerformanceObligationPercentage contextRef="AsOf2023-12-31_custom_EmploymentContractualAgreementsMember_custom_NamedExecutiveOfficersMember" decimals="INF" id="Fact001505" unitRef="Pure"> 0.25 </us-gaap:RevenueRemainingPerformanceObligationPercentage>
<us-gaap:RevenueRemainingPerformanceObligationPercentage contextRef="AsOf2022-12-31_custom_EmploymentContractualAgreementsMember_custom_NamedExecutiveOfficersMember" decimals="INF" id="Fact001507" unitRef="Pure"> 0.20 </us-gaap:RevenueRemainingPerformanceObligationPercentage>
<AIM:Bonus contextRef="From2023-01-012023-12-31_custom_EmploymentContractualAgreementsMember_custom_NamedExecutiveOfficersMember" decimals="0" id="Fact001508" unitRef="USD"> 450000 </AIM:Bonus>
<AIM:Bonus contextRef="From2022-01-012022-12-31_custom_EmploymentContractualAgreementsMember_custom_NamedExecutiveOfficersMember" decimals="0" id="Fact001509" unitRef="USD"> 450000 </AIM:Bonus>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_ThomasKEquelsMember" decimals="INF" id="Fact001511" unitRef="Shares"> 300000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_ThomasKEquelsMember" decimals="INF" id="Fact001515" unitRef="USDPShares"> 0.47 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_ThomasKEquelsMember" id="Fact001516"> P1Y </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_PeterRodinoMember" decimals="INF" id="Fact001518" unitRef="Shares"> 100000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_PeterRodinoMember" decimals="INF" id="Fact001522" unitRef="USDPShares"> 0.47 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_PeterRodinoMember" id="Fact001524"> P1Y </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="From2023-01-012023-12-31_custom_EquelsandRodinoMember" decimals="0" id="Fact001526" unitRef="USD"> 14000 </us-gaap:EmployeeBenefitsAndShareBasedCompensation>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_ThomasKEquelsMember" decimals="INF" id="Fact001528" unitRef="Shares"> 300000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_ThomasKEquelsMember" decimals="INF" id="Fact001532" unitRef="USDPShares"> 0.41 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_ThomasKEquelsMember" id="Fact001533"> P1Y </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_PeterRodinoMember" decimals="INF" id="Fact001535" unitRef="Shares"> 150000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_PeterRodinoMember_srt_MinimumMember" decimals="INF" id="Fact001539" unitRef="USDPShares"> 0.41 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_PeterRodinoMember_srt_MaximumMember" decimals="INF" id="Fact001541" unitRef="USDPShares"> 0.70 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_PeterRodinoMember" id="Fact001543"> P1Y </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_EllenLintalMember" decimals="INF" id="Fact001544" unitRef="Shares"> 50000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_EllenLintalMember" decimals="INF" id="Fact001546" unitRef="USDPShares"> 0.70 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_EllenLintalMember" id="Fact001547"> P1Y </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="From2023-01-012023-12-31_custom_EquelsRodinoAndFormerOfficerLintalMember" decimals="0" id="Fact001549" unitRef="USD"> 107000 </us-gaap:EmployeeBenefitsAndShareBasedCompensation>
<us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001551">
<p id="xdx_803_eus-gaap--LesseeOperatingLeasesTextBlock_zQOOVYpaB976" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(11) <span id="xdx_829_zlz5v5PdPTu6">Leases</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company leases office and lab facilities and other equipment under non-cancellable operating leases with initial terms typically ranging from <span id="xdx_90A_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember_zVaiRjTuXbg8" title="Operating lease term">1</span> to <span id="xdx_90A_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember_zeNDPYLL2htc" title="Operating lease term">5</span> years, expiring at various dates during 2024 through 2027, and requiring monthly payments ranging from less than $<span id="xdx_903_eus-gaap--OperatingLeasePayments_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zPaGW6A9yk8l" title="Operating lease Payment">1,000</span> to $<span id="xdx_905_eus-gaap--OperatingLeasePayments_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_ziPjjkhnYaY2" title="Operating lease Payment">17,000</span>. Certain leases include additional renewal options ranging from <span id="xdx_901_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember_zYHnZjDWxwf3" title="Operating lease term">1</span> to <span id="xdx_905_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember_zlgXnWxMrNn7" title="Operating lease term">5</span> years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p id="xdx_89F_ecustom--ScheduleOfOperatingLeaseTableTextBlock_z2R0fdzjTYpd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> <p id="xdx_8A2_z85JlF1Xgu1h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIM has classified all of its leases as operating leases.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023 and 2022, the balance of the right of use assets was $<span id="xdx_90E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20231231_zbMGwrMOU9uc" title="Right of use asset">697,000</span> and $<span id="xdx_904_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20221231_zdRwzGCHavDc" title="Right of use asset">829,000</span>, respectively, and the corresponding operating lease liability balance was $<span id="xdx_90D_eus-gaap--OperatingLeaseLiability_iI_c20231231_z1GBWvCTxGS2" title="Lease liability">718,000</span> and $<span id="xdx_907_eus-gaap--OperatingLeaseLiability_iI_c20221231_z4bM4Ll48O9g" title="Lease liability">837,000</span>, respectively. Right of use assets are recorded net of accumulated amortization of $<span id="xdx_907_ecustom--OperationLeaseRightOfUseAssetAccumulatedAmortization_iI_c20231231_zJhI6zUqL3P8" title="Accumulated amortization">363,000</span> and $<span id="xdx_90A_ecustom--OperationLeaseRightOfUseAssetAccumulatedAmortization_iI_c20221231_zLjp2IYKIKjg" title="Accumulated amortization">158,000</span> as of December 31, 2023 and 2022, respectively. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--LeaseCostTableTextBlock_z347Q1dQ6oSf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIM recognized rent expense associated with these leases are follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span>   <span id="xdx_8BF_zGZL5uejvTRh" style="display: none">Schedule of AIM Recognized Rent Expense Associated with Operating Lease</span> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20230101__20231231_zOpJDHWcVJ16" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20220101__20221231_zHCAqJ15Tuz3" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40A_eus-gaap--LeaseCostAbstract_iB_zqjVluk5je56" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Lease costs:</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OperatingLeaseCost_maLCzBan_zrUS37aqDnY8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Operating lease costs</td> <td style="width: 2%; text-align: left"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">288</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">128</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ShortTermLeaseCost_maLCzBan_z0oaYLfb69V" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Short-term and variable lease costs</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">335</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">211</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LeaseCost_iT_mtLCzBan_zHnIVoksKHL5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: justify">Total lease costs</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">623</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">339</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Classification of lease costs</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OperatingLeaseCost_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z5rTSLGM7Tnj" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: justify">Research & development</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">498</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">220</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--OperatingLeaseCost_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zJVt6hY4kXC8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">General and administrative</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">125</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">119</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OperatingLeaseCost_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zVRkgMAIalx1" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Lease cost </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">125</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">119</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LeaseCost_iT_zGcpqXYxXvwj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total lease costs</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">623</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">339</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_zvy3LB7wwUQ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s leases have remaining lease terms between <span id="xdx_904_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtM_c20231231__srt--RangeAxis__srt--MinimumMember_zATfJuQh90Y8" title="Operating lease, remaining lease term">3</span> and <span id="xdx_905_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtM_c20231231__srt--RangeAxis__srt--MaximumMember_zmpjeMDRy71c" title="Operating lease, remaining lease term">44</span> months. As of December 31, 2023 and 2022, the weighted-average remaining term was <span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20231231_zDINuqx6mOY4" title="Weighted average remaining lease term">41</span> and <span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20221231_zbLzyoyha2G3" title="Weighted average remaining lease term">43</span> months, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s weighted average incremental borrowing rate for its leases was <span id="xdx_90A_eus-gaap--DebtWeightedAverageInterestRate_iI_pid_dp_uPure_c20231231_zbCfGO82WmBh" title="Weighted average incremental borrowing rate"><span id="xdx_90B_eus-gaap--DebtWeightedAverageInterestRate_iI_pid_dp_uPure_c20221231_z0MPgINDETAf" title="Weighted average incremental borrowing rate">10</span></span>% as of December 31, 2023 and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zAMUZzGqHFyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future minimum payments as of December 31, 2023, are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B0_zbWNcHMSJbZg" style="display: none">Schedule of Operating Lease Future Payments</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 40%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center">Year Ending December 31, (in thousands)</td><td> </td> <td colspan="2" id="xdx_494_20231231_zcJjykldx2C"> </td><td> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maOLLzSP3_zow9nISDSi32" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 61%; text-align: justify">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 35%; text-align: right">279</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maOLLzSP3_zspBNmYAFgze" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">229</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maOLLzSP3_zacWzTUp42Ef" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">200</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maOLLzSP3_zsWcEBYzPYp7" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">133</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_pn3n3_maOLLzSP3_zdEIthtFppgd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Thereafter</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1627">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_maOLLzSP3_ziCYDT3WeYNk" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Less imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(123</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_mtOLLzSP3_zT2MBhLj3nr" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">718</td><td style="padding-bottom: 2.5pt; text-align: justify"> </td></tr> </table> <p id="xdx_8A3_zZYGeQSguPLd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
</us-gaap:LesseeOperatingLeasesTextBlock>
<us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="AsOf2023-12-31_srt_MinimumMember" id="Fact001553"> P1Y </us-gaap:LesseeOperatingLeaseRenewalTerm>
<us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="AsOf2023-12-31_srt_MaximumMember" id="Fact001555"> P5Y </us-gaap:LesseeOperatingLeaseRenewalTerm>
<us-gaap:OperatingLeasePayments contextRef="From2023-01-012023-12-31_srt_MinimumMember" decimals="0" id="Fact001557" unitRef="USD"> 1000 </us-gaap:OperatingLeasePayments>
<us-gaap:OperatingLeasePayments contextRef="From2023-01-012023-12-31_srt_MaximumMember" decimals="0" id="Fact001559" unitRef="USD"> 17000 </us-gaap:OperatingLeasePayments>
<us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="AsOf2023-12-31_srt_MinimumMember" id="Fact001561"> P1Y </us-gaap:LesseeOperatingLeaseRenewalTerm>
<us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="AsOf2023-12-31_srt_MaximumMember" id="Fact001563"> P5Y </us-gaap:LesseeOperatingLeaseRenewalTerm>
<AIM:ScheduleOfOperatingLeaseTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001565">
<p id="xdx_89F_ecustom--ScheduleOfOperatingLeaseTableTextBlock_z2R0fdzjTYpd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>
</AIM:ScheduleOfOperatingLeaseTableTextBlock>
<us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2023-12-31" decimals="0" id="Fact001567" unitRef="USD"> 697000 </us-gaap:OperatingLeaseRightOfUseAsset>
<us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-12-31" decimals="0" id="Fact001569" unitRef="USD"> 829000 </us-gaap:OperatingLeaseRightOfUseAsset>
<us-gaap:OperatingLeaseLiability contextRef="AsOf2023-12-31" decimals="0" id="Fact001571" unitRef="USD"> 718000 </us-gaap:OperatingLeaseLiability>
<us-gaap:OperatingLeaseLiability contextRef="AsOf2022-12-31" decimals="0" id="Fact001573" unitRef="USD"> 837000 </us-gaap:OperatingLeaseLiability>
<AIM:OperationLeaseRightOfUseAssetAccumulatedAmortization contextRef="AsOf2023-12-31" decimals="0" id="Fact001575" unitRef="USD"> 363000 </AIM:OperationLeaseRightOfUseAssetAccumulatedAmortization>
<AIM:OperationLeaseRightOfUseAssetAccumulatedAmortization contextRef="AsOf2022-12-31" decimals="0" id="Fact001577" unitRef="USD"> 158000 </AIM:OperationLeaseRightOfUseAssetAccumulatedAmortization>
<us-gaap:LeaseCostTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001579">
<p id="xdx_890_eus-gaap--LeaseCostTableTextBlock_z347Q1dQ6oSf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIM recognized rent expense associated with these leases are follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span>   <span id="xdx_8BF_zGZL5uejvTRh" style="display: none">Schedule of AIM Recognized Rent Expense Associated with Operating Lease</span> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20230101__20231231_zOpJDHWcVJ16" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20220101__20221231_zHCAqJ15Tuz3" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40A_eus-gaap--LeaseCostAbstract_iB_zqjVluk5je56" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Lease costs:</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OperatingLeaseCost_maLCzBan_zrUS37aqDnY8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Operating lease costs</td> <td style="width: 2%; text-align: left"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">288</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">128</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ShortTermLeaseCost_maLCzBan_z0oaYLfb69V" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Short-term and variable lease costs</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">335</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">211</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LeaseCost_iT_mtLCzBan_zHnIVoksKHL5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: justify">Total lease costs</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">623</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">339</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Classification of lease costs</td> <td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OperatingLeaseCost_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z5rTSLGM7Tnj" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: justify">Research & development</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">498</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">220</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--OperatingLeaseCost_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zJVt6hY4kXC8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">General and administrative</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">125</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">119</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OperatingLeaseCost_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zVRkgMAIalx1" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Lease cost </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">125</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">119</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td> <td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LeaseCost_iT_zGcpqXYxXvwj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total lease costs</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">623</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">339</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
</us-gaap:LeaseCostTableTextBlock>
<us-gaap:OperatingLeaseCost contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact001584" unitRef="USD"> 288 </us-gaap:OperatingLeaseCost>
<us-gaap:OperatingLeaseCost contextRef="From2022-01-012022-12-31" decimals="0" id="Fact001585" unitRef="USD"> 128 </us-gaap:OperatingLeaseCost>
<us-gaap:ShortTermLeaseCost contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact001587" unitRef="USD"> 335 </us-gaap:ShortTermLeaseCost>
<us-gaap:ShortTermLeaseCost contextRef="From2022-01-012022-12-31" decimals="0" id="Fact001588" unitRef="USD"> 211 </us-gaap:ShortTermLeaseCost>
<us-gaap:LeaseCost contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact001590" unitRef="USD"> 623 </us-gaap:LeaseCost>
<us-gaap:LeaseCost contextRef="From2022-01-012022-12-31" decimals="0" id="Fact001591" unitRef="USD"> 339 </us-gaap:LeaseCost>
<us-gaap:OperatingLeaseCost contextRef="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="0" id="Fact001593" unitRef="USD"> 498 </us-gaap:OperatingLeaseCost>
<us-gaap:OperatingLeaseCost contextRef="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="0" id="Fact001594" unitRef="USD"> 220 </us-gaap:OperatingLeaseCost>
<us-gaap:OperatingLeaseCost contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="0" id="Fact001596" unitRef="USD"> 125 </us-gaap:OperatingLeaseCost>
<us-gaap:OperatingLeaseCost contextRef="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="0" id="Fact001597" unitRef="USD"> 119 </us-gaap:OperatingLeaseCost>
<us-gaap:OperatingLeaseCost contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="0" id="Fact001599" unitRef="USD"> 125 </us-gaap:OperatingLeaseCost>
<us-gaap:OperatingLeaseCost contextRef="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="0" id="Fact001600" unitRef="USD"> 119 </us-gaap:OperatingLeaseCost>
<us-gaap:LeaseCost contextRef="From2023-01-01to2023-12-31" decimals="0" id="Fact001602" unitRef="USD"> 623 </us-gaap:LeaseCost>
<us-gaap:LeaseCost contextRef="From2022-01-012022-12-31" decimals="0" id="Fact001603" unitRef="USD"> 339 </us-gaap:LeaseCost>
<us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="AsOf2023-12-31_srt_MinimumMember" id="Fact001605"> P3M </us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
<us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="AsOf2023-12-31_srt_MaximumMember" id="Fact001607"> P44M </us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
<us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2023-12-31" id="Fact001609"> P41M </us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
<us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2022-12-31" id="Fact001611"> P43M </us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
<us-gaap:DebtWeightedAverageInterestRate contextRef="AsOf2023-12-31" decimals="INF" id="Fact001613" unitRef="Pure"> 0.10 </us-gaap:DebtWeightedAverageInterestRate>
<us-gaap:DebtWeightedAverageInterestRate contextRef="AsOf2022-12-31" decimals="INF" id="Fact001615" unitRef="Pure"> 0.10 </us-gaap:DebtWeightedAverageInterestRate>
<us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001617">
<p id="xdx_891_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zAMUZzGqHFyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future minimum payments as of December 31, 2023, are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B0_zbWNcHMSJbZg" style="display: none">Schedule of Operating Lease Future Payments</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 40%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center">Year Ending December 31, (in thousands)</td><td> </td> <td colspan="2" id="xdx_494_20231231_zcJjykldx2C"> </td><td> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maOLLzSP3_zow9nISDSi32" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 61%; text-align: justify">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 35%; text-align: right">279</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maOLLzSP3_zspBNmYAFgze" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">229</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maOLLzSP3_zacWzTUp42Ef" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">200</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maOLLzSP3_zsWcEBYzPYp7" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">133</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_pn3n3_maOLLzSP3_zdEIthtFppgd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Thereafter</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1627">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_maOLLzSP3_ziCYDT3WeYNk" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Less imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(123</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_mtOLLzSP3_zT2MBhLj3nr" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">718</td><td style="padding-bottom: 2.5pt; text-align: justify"> </td></tr> </table>
</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2023-12-31" decimals="-3" id="Fact001619" unitRef="USD"> 279000 </us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2023-12-31" decimals="-3" id="Fact001621" unitRef="USD"> 229000 </us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="AsOf2023-12-31" decimals="-3" id="Fact001623" unitRef="USD"> 200000 </us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="AsOf2023-12-31" decimals="-3" id="Fact001625" unitRef="USD"> 133000 </us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
<us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2023-12-31" decimals="-3" id="Fact001629" unitRef="USD"> 123000 </us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
<us-gaap:OperatingLeaseLiability contextRef="AsOf2023-12-31" decimals="-3" id="Fact001631" unitRef="USD"> 718000 </us-gaap:OperatingLeaseLiability>
<us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001633">
<p id="xdx_80F_eus-gaap--IncomeTaxDisclosureTextBlock_zrklqGUSkgpf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(12) <span id="xdx_827_zvlAk2Kg9xT7">Income Taxes (FASB ASC 740 Income Taxes)</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company applies the provisions of FASB ASC 740-10 Uncertainty in Income Taxes. As a result of the implementation, there has been no material change to the Company’s tax positions as they have not paid any corporate income taxes due to operating losses. With the exception of net operating losses and research and development credits generated in New Jersey, all tax benefits will likely not be recognized due to the substantial net operating loss carryforwards which will most likely not be realized prior to expiration.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">As of December 31, 2023, the Company has approximately $<span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zL6twwVY9lF2" title="Operating loss carryforwards">166,300,000</span> of Federal net operating loss carryforwards (expiring in the years 2023 through 2038), and $<span id="xdx_90D_ecustom--OperatingLossCarryforwardsWithNoExpirationDate_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zEauPMWJIJW4" title="Operating loss carry forwards with no expiration date">103,300,000</span> of Federal net operating loss carryforwards with no expiration date, both of which have been limited by Internal Revenue Code Section 382, available to offset future federal taxable income. The Company has approximately $<span id="xdx_90D_eus-gaap--OperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--NewJerseyDivisionOfTaxationMember_z6XxYw8iV7C5" title="Operating loss carryforwards">28,800,000</span> of New Jersey state net operating loss carryforwards (expiring in 2044). The Company has approximately $<span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zdUMO0kEmCag" title="Operating loss carryforwards">82,500,000</span> of Florida state net operating loss carryforwards with no expiration date to offset future Florida taxable income. The Company has approximately $<span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_c20231231__srt--StatementGeographicalAxis__country--BE_zG6U1zZnlsSc" title="Operating loss carryforwards">3,600,000</span> of Belgium net operating loss carryforwards with no expiration date to offset future taxable income In December 2023, the Company effectively sold $<span id="xdx_90D_eus-gaap--OperatingLossCarryforwards_iI_c20231231__srt--StatementGeographicalAxis__stpr--NJ_zMjFiyczoPS9" title="Operating loss carryforwards">14,156,000</span> of its New Jersey state net operating loss carryforward and $<span id="xdx_90B_eus-gaap--IncomeTaxReconciliationTaxCredits_c20230101__20231231__srt--StatementGeographicalAxis__stpr--NJ_zcApvIcqtUC4" title="Effective income tax rate reconciliation, tax credit, amount">38,600</span> in R&D credits for the year 2022 for approximately $<span id="xdx_905_eus-gaap--IncomeTaxReconciliationTaxCredits_pp0p0_c20220101__20221231__srt--StatementGeographicalAxis__stpr--NJ_zEMfLp5M7ibk" title="Effective income tax rate reconciliation, tax credit, amount">1,313,000</span>. The utilization of certain state net operating loss carryforwards may be subject to annual limitations. With no tax due for the foreseeable future, the Company has determined that a policy to determine the accounting for interest or penalties related to the payment of tax is not necessary at this time.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the Tax Reform Act of 1986, the utilization of a corporation’s net operating loss carryforward is limited following a greater than 50% change in ownership. As noted above, due to the Company’s prior and current equity transactions, some of the Company’s net operating loss carryforwards are subject to an annual limitation generally determined by multiplying the value of the Company on the date of the ownership change by the federal long-term tax-exempt rate. Any unused annual limitation may be carried forward to future years for the balance of the net operating loss carryforward period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred income taxes reflect the net tax effects of temporary differences between carrying amounts of assets and liabilities for financial reporting purposes and the carrying amounts used for income tax purposes. In assessing the realizability of deferred tax assets, Management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences representing net future deductible amounts become deductible. With the exception of net operating losses generated in New Jersey which can be surrendered for 80% of their value, due to the uncertainty of the Company’s ability to realize the benefit of the deferred tax asset, the remainder of our deferred tax assets are fully offset by a valuation allowance at December 31, 2023 and 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zKGiWrm15ang" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of the net deferred tax assets and liabilities as of December 31, 2023 and 2022, which include the correction of an immaterial deferred tax error of approximately $<span id="xdx_908_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iI_pn5n6_c20221231__srt--RestatementAxis__srt--RestatementAdjustmentMember_z9hjvJsKXZy4" title="Deferred tax">1.4</span> million in the stock compensation component and the corresponding valuation allowance for the same amount as of December 31, 2022, consist of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B9_zLYR9HsUI8Bi" style="display: none">Schedule of Components of Net Deferred Tax Assets and Liabilities</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20231231_zQizh4fUHDyf" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20221231_zzMXzulSyTS3" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="text-align: center">(in thousands)</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: justify">Deferred tax assets:</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGz4fF_zB9lf9LWXyi5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Net operating losses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">25,114</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">19,674</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_maDTAGz4fF_zV5Om2Fyq4f9" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Research and Development costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,517</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,647</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--DeferredTaxAssetsAmortizationAndDepreciation_iI_pn3n3_maDTAGz4fF_zl6vRunZmmY9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Amortization & depreciation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,791</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,342</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn3n3_maDTAGz4fF_zdK4YaDglam8" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">R&D credits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,376</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">744</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_maDTAGz4fF_zJgnBkSZlTKk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">137</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">77</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--DeferredTaxAssetsRightOfUseAssets_iI_pn3n3_maDTAGz4fF_zF5P7tqSWyT8" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Right of use asset</p></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGz4fF_zk6eNAaNVGm4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Stock compensation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,479</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,472</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGz4fF_maDTALNzkn6_zA3rlcq0Axhl" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Total deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">38,420</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31,958</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTALNzkn6_zBxfBSX6VBS7" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Less: Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(36,816</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(30,840</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNzkn6_zpwwp20T4oY5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Deferred tax assets, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,604</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,118</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_zeUFKzIwyEv4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax assets are included within other assets in the accompanying Consolidated Balance Sheets. The benefits of deferred tax assets are included within the gain from sale of income tax operating losses in the accompanying Consolidated Statements of Operations and Comprehensive Loss. The Company’s deferred tax asset estimates the projected sale of 2023 and 2022 New Jersey state operating losses to be sold in the subsequent year, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rate Reconciliation</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zZ3JfXDPGIw5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reconciliation between the effective tax rate on income from continuing operations and the statutory tax rate is as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B1_zluv3XFKo1Aj" style="display: none">Schedule of Effective Tax Rate and Statutory Tax Rate</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Pre Tax Book Loss</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--IncomeTaxReconciliationTaxExemptIncome_pn3n3_c20230101__20231231_zUk0H7uzSRJb" style="width: 16%; text-align: right" title="Pre Tax Book Loss">(28,962</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Federal Rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maETR001_c20230101__20231231_znu4O9r1ncFb" style="text-align: right" title="Federal Rate">(6,082</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maETR002_c20230101__20231231_z0BQdbFnmgqa" style="text-align: right" title="Federal Rate">21.0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State Taxes</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_pn3n3_maETR001_c20230101__20231231_zCZxcFyxAGzg" style="text-align: right" title="State Taxes">(2,244</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maETR002_c20230101__20231231_zPImplBdhmRk" style="text-align: right" title="State Taxes">7.75</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other Perms</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_pn3n3_maETR001_c20230101__20231231_z6e5LDis58Za" style="text-align: right" title="Other Perms">(83</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_maETR002_c20230101__20231231_zEh9cf06xrO5" style="text-align: right" title="Other Perms">0.29</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>RTP</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--IncomeTaxReconciliationForeignIncomeRTP_pn3n3_maETR001_c20230101__20231231_zPwOrZmSpQu3" style="text-align: right" title="RTP">(8</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--EffectiveIncomeTaxRateReconciliationRTPPercentage_pid_dp_uPure_maETR002_c20230101__20231231_z0n8SGqv0Gsc" style="text-align: right" title="RTP">0.03</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Income Tax Income</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_pn3n3_maETR001_c20230101__20231231_z6ZOb67rMmA5" style="text-align: right" title="Income Tax Income">(479</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_pid_dp_uPure_maETR002_c20230101__20231231_zgZVHoTKxwyc" style="text-align: right" title="Income Tax Income">1.65</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>State Rate Change</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--IncomeTaxReconciliationTaxContingenciesStateAndLocal_pn3n3_maETR001_c20230101__20231231_zOyuWYbHXo67" style="text-align: right" title="State Rate Change">618</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal_pid_dp_uPure_maETR002_c20230101__20231231_zailtWVZsBfc" style="text-align: right" title="State Rate Change">-2.13</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>R&D</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_iN_pn3n3_di_maETR001_c20230101__20231231_zr2krjEZgE06" style="text-align: right" title="R&D">(272</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_pid_dp_uPure_maETR002_c20230101__20231231_zTvgnMlejgce" style="text-align: right" title="R&D">0.94</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>State NOL</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--IncomeTaxReconciliationNondeductibleStateNetOperatingLoss_pn3n3_maETR001_c20230101__20231231_zAOC9dhg9GI3" style="text-align: right" title="State NOL"><span style="-sec-ix-hidden: xdx2ixbrl1717">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--EffectiveIncomeTaxRateReconciliationNondeductibleStateNetOperatingLossPercentage_pid_dp_uPure_maETR002_c20230101__20231231_zAmrjfO7TxRf" style="text-align: right" title="State NOL">0.00</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>NJ NOL True Up</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--IncomeTaxReconciliationNondeductibleNewJerseyStateNetOperatingLoss_pn3n3_maETR001_c20230101__20231231_zYOisKRm787" style="text-align: right" title="NJ NOL True Up">1,123</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--EffectiveIncomeTaxRateReconciliationNondeductibleNewJerseyStateNetOperatingLossPercentage_pid_dp_uPure_maETR002_c20230101__20231231_zcFqvOOxl0Hg" style="text-align: right" title="NJ NOL True Up">-3.88</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Stock Compensation True Up</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_pn3n3_maETR001_c20230101__20231231_z5uJr9GZg3Q6" style="text-align: right" title="Stock Compensation True Up">(1,347</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_uPure_maETR002_c20230101__20231231_ziNmP9CO1Bli" style="text-align: right" title="Stock Compensation True Up">4.65</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Fixed Assets True Up</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--IncomeTaxReconciliationNondeductibleExpenseFixedAssets_pn3n3_maETR001_c20230101__20231231_zd65WviK2WLe" style="text-align: right" title="Fixed Assets True Up">925</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFixedAssets_pid_dp_uPure_maETR002_c20230101__20231231_zKM1twI8vXO6" style="text-align: right" title="Fixed Assets True Up">-3.19</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Other</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--IncomeTaxReconciliationOtherAdjustments_pn3n3_maETR001_c20230101__20231231_zEF2kURlkc33" style="text-align: right" title="Other">(22</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--EffectiveIncomeTaxRateReconciliationOther_pid_dp_uPure_maETR002_c20230101__20231231_zdXp5XMKqZ4c" style="text-align: right" title="Other">0.08</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">NOL Refund VA True Up</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_ecustom--IncomeTaxReconciliationNetOperatingLossRefundValuationAllowance_pn3n3_maETR001_c20230101__20231231_zHNGbba5HNbg" style="border-bottom: Black 1.5pt solid; text-align: right" title="NOL Refund VA True Up">486</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_ecustom--EffectiveIncomeTaxRateReconciliationNetOperatingLossRefundValuationAllowancePercentage_pid_dp_uPure_maETR002_c20230101__20231231_z5nEMEpYqbR2" style="border-bottom: Black 1.5pt solid; text-align: right" title="NOL Refund VA True Up">-1.68</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right" title="Other"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right" title="Statutory Other"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Valuation Allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_maETR001_c20230101__20231231_z5zuuPmopnO4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Valuation Allowance">7,385</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateValuationAllowance_pid_dp_uPure_maETR002_c20230101__20231231_zT30nw9ITP5i" style="border-bottom: Black 1.5pt solid; text-align: right" title="Statutory Valuation Allowance">-25.50</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtETR001_c20230101__20231231_zoFjKVU71yQh" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl1745">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtETR002_c20230101__20231231_zkYkQzPqUIXk" style="border-bottom: Black 2.5pt double; text-align: right" title="Statutory Total">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table> <p id="xdx_8AD_zyVBat4fM2Ea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</us-gaap:IncomeTaxDisclosureTextBlock>
<us-gaap:OperatingLossCarryforwards contextRef="AsOf2023-12-31_us-gaap_DomesticCountryMember" decimals="0" id="Fact001635" unitRef="USD"> 166300000 </us-gaap:OperatingLossCarryforwards>
<AIM:OperatingLossCarryforwardsWithNoExpirationDate contextRef="AsOf2023-12-31_us-gaap_DomesticCountryMember" decimals="0" id="Fact001637" unitRef="USD"> 103300000 </AIM:OperatingLossCarryforwardsWithNoExpirationDate>
<us-gaap:OperatingLossCarryforwards contextRef="AsOf2023-12-31_us-gaap_NewJerseyDivisionOfTaxationMember" decimals="0" id="Fact001639" unitRef="USD"> 28800000 </us-gaap:OperatingLossCarryforwards>
<us-gaap:OperatingLossCarryforwards contextRef="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember" decimals="0" id="Fact001641" unitRef="USD"> 82500000 </us-gaap:OperatingLossCarryforwards>
<us-gaap:OperatingLossCarryforwards contextRef="AsOf2023-12-31_country_BE" decimals="0" id="Fact001643" unitRef="USD"> 3600000 </us-gaap:OperatingLossCarryforwards>
<us-gaap:OperatingLossCarryforwards contextRef="AsOf2023-12-31_stpr_NJ" decimals="0" id="Fact001645" unitRef="USD"> 14156000 </us-gaap:OperatingLossCarryforwards>
<us-gaap:IncomeTaxReconciliationTaxCredits contextRef="From2023-01-012023-12-31_stpr_NJ" decimals="0" id="Fact001647" unitRef="USD"> 38600 </us-gaap:IncomeTaxReconciliationTaxCredits>
<us-gaap:IncomeTaxReconciliationTaxCredits contextRef="From2022-01-012022-12-31_stpr_NJ" decimals="0" id="Fact001649" unitRef="USD"> 1313000 </us-gaap:IncomeTaxReconciliationTaxCredits>
<us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001651">
<p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zKGiWrm15ang" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of the net deferred tax assets and liabilities as of December 31, 2023 and 2022, which include the correction of an immaterial deferred tax error of approximately $<span id="xdx_908_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iI_pn5n6_c20221231__srt--RestatementAxis__srt--RestatementAdjustmentMember_z9hjvJsKXZy4" title="Deferred tax">1.4</span> million in the stock compensation component and the corresponding valuation allowance for the same amount as of December 31, 2022, consist of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B9_zLYR9HsUI8Bi" style="display: none">Schedule of Components of Net Deferred Tax Assets and Liabilities</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20231231_zQizh4fUHDyf" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20221231_zzMXzulSyTS3" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="text-align: center">(in thousands)</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: justify">Deferred tax assets:</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGz4fF_zB9lf9LWXyi5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Net operating losses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">25,114</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">19,674</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_maDTAGz4fF_zV5Om2Fyq4f9" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Research and Development costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,517</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,647</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--DeferredTaxAssetsAmortizationAndDepreciation_iI_pn3n3_maDTAGz4fF_zl6vRunZmmY9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Amortization & depreciation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,791</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,342</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn3n3_maDTAGz4fF_zdK4YaDglam8" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">R&D credits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,376</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">744</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_maDTAGz4fF_zJgnBkSZlTKk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">137</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">77</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--DeferredTaxAssetsRightOfUseAssets_iI_pn3n3_maDTAGz4fF_zF5P7tqSWyT8" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Right of use asset</p></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGz4fF_zk6eNAaNVGm4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Stock compensation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,479</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,472</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGz4fF_maDTALNzkn6_zA3rlcq0Axhl" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Total deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">38,420</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31,958</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTALNzkn6_zBxfBSX6VBS7" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Less: Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(36,816</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(30,840</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNzkn6_zpwwp20T4oY5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Deferred tax assets, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,604</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,118</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
<us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="AsOf2022-12-31_srt_RestatementAdjustmentMember" decimals="-5" id="Fact001653" unitRef="USD"> 1400000 </us-gaap:DeferredTaxAssetsLiabilitiesNet>
<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2023-12-31" decimals="-3" id="Fact001655" unitRef="USD"> 25114000 </us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2022-12-31" decimals="-3" id="Fact001656" unitRef="USD"> 19674000 </us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
<us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2023-12-31" decimals="-3" id="Fact001658" unitRef="USD"> 3517000 </us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
<us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2022-12-31" decimals="-3" id="Fact001659" unitRef="USD"> 7647000 </us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
<AIM:DeferredTaxAssetsAmortizationAndDepreciation contextRef="AsOf2023-12-31" decimals="-3" id="Fact001661" unitRef="USD"> 6791000 </AIM:DeferredTaxAssetsAmortizationAndDepreciation>
<AIM:DeferredTaxAssetsAmortizationAndDepreciation contextRef="AsOf2022-12-31" decimals="-3" id="Fact001662" unitRef="USD"> 2342000 </AIM:DeferredTaxAssetsAmortizationAndDepreciation>
<us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="AsOf2023-12-31" decimals="-3" id="Fact001664" unitRef="USD"> 1376000 </us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
<us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="AsOf2022-12-31" decimals="-3" id="Fact001665" unitRef="USD"> 744000 </us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
<us-gaap:DeferredTaxAssetsOther contextRef="AsOf2023-12-31" decimals="-3" id="Fact001667" unitRef="USD"> 137000 </us-gaap:DeferredTaxAssetsOther>
<us-gaap:DeferredTaxAssetsOther contextRef="AsOf2022-12-31" decimals="-3" id="Fact001668" unitRef="USD"> 77000 </us-gaap:DeferredTaxAssetsOther>
<AIM:DeferredTaxAssetsRightOfUseAssets contextRef="AsOf2023-12-31" decimals="-3" id="Fact001670" unitRef="USD"> 6000 </AIM:DeferredTaxAssetsRightOfUseAssets>
<AIM:DeferredTaxAssetsRightOfUseAssets contextRef="AsOf2022-12-31" decimals="-3" id="Fact001671" unitRef="USD"> 2000 </AIM:DeferredTaxAssetsRightOfUseAssets>
<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2023-12-31" decimals="-3" id="Fact001673" unitRef="USD"> 1479000 </us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2022-12-31" decimals="-3" id="Fact001674" unitRef="USD"> 1472000 </us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
<us-gaap:DeferredTaxAssetsGross contextRef="AsOf2023-12-31" decimals="-3" id="Fact001676" unitRef="USD"> 38420000 </us-gaap:DeferredTaxAssetsGross>
<us-gaap:DeferredTaxAssetsGross contextRef="AsOf2022-12-31" decimals="-3" id="Fact001677" unitRef="USD"> 31958000 </us-gaap:DeferredTaxAssetsGross>
<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2023-12-31" decimals="-3" id="Fact001679" unitRef="USD"> 36816000 </us-gaap:DeferredTaxAssetsValuationAllowance>
<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2022-12-31" decimals="-3" id="Fact001680" unitRef="USD"> 30840000 </us-gaap:DeferredTaxAssetsValuationAllowance>
<us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="AsOf2023-12-31" decimals="-3" id="Fact001682" unitRef="USD"> 1604000 </us-gaap:DeferredTaxAssetsLiabilitiesNet>
<us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="AsOf2022-12-31" decimals="-3" id="Fact001683" unitRef="USD"> 1118000 </us-gaap:DeferredTaxAssetsLiabilitiesNet>
<us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001685">
<p id="xdx_89B_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zZ3JfXDPGIw5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reconciliation between the effective tax rate on income from continuing operations and the statutory tax rate is as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B1_zluv3XFKo1Aj" style="display: none">Schedule of Effective Tax Rate and Statutory Tax Rate</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Pre Tax Book Loss</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--IncomeTaxReconciliationTaxExemptIncome_pn3n3_c20230101__20231231_zUk0H7uzSRJb" style="width: 16%; text-align: right" title="Pre Tax Book Loss">(28,962</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Federal Rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maETR001_c20230101__20231231_znu4O9r1ncFb" style="text-align: right" title="Federal Rate">(6,082</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maETR002_c20230101__20231231_z0BQdbFnmgqa" style="text-align: right" title="Federal Rate">21.0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State Taxes</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_pn3n3_maETR001_c20230101__20231231_zCZxcFyxAGzg" style="text-align: right" title="State Taxes">(2,244</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maETR002_c20230101__20231231_zPImplBdhmRk" style="text-align: right" title="State Taxes">7.75</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other Perms</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_pn3n3_maETR001_c20230101__20231231_z6e5LDis58Za" style="text-align: right" title="Other Perms">(83</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_maETR002_c20230101__20231231_zEh9cf06xrO5" style="text-align: right" title="Other Perms">0.29</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>RTP</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--IncomeTaxReconciliationForeignIncomeRTP_pn3n3_maETR001_c20230101__20231231_zPwOrZmSpQu3" style="text-align: right" title="RTP">(8</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--EffectiveIncomeTaxRateReconciliationRTPPercentage_pid_dp_uPure_maETR002_c20230101__20231231_z0n8SGqv0Gsc" style="text-align: right" title="RTP">0.03</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Income Tax Income</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_pn3n3_maETR001_c20230101__20231231_z6ZOb67rMmA5" style="text-align: right" title="Income Tax Income">(479</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_pid_dp_uPure_maETR002_c20230101__20231231_zgZVHoTKxwyc" style="text-align: right" title="Income Tax Income">1.65</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>State Rate Change</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--IncomeTaxReconciliationTaxContingenciesStateAndLocal_pn3n3_maETR001_c20230101__20231231_zOyuWYbHXo67" style="text-align: right" title="State Rate Change">618</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal_pid_dp_uPure_maETR002_c20230101__20231231_zailtWVZsBfc" style="text-align: right" title="State Rate Change">-2.13</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>R&D</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_iN_pn3n3_di_maETR001_c20230101__20231231_zr2krjEZgE06" style="text-align: right" title="R&D">(272</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_pid_dp_uPure_maETR002_c20230101__20231231_zTvgnMlejgce" style="text-align: right" title="R&D">0.94</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>State NOL</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--IncomeTaxReconciliationNondeductibleStateNetOperatingLoss_pn3n3_maETR001_c20230101__20231231_zAOC9dhg9GI3" style="text-align: right" title="State NOL"><span style="-sec-ix-hidden: xdx2ixbrl1717">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--EffectiveIncomeTaxRateReconciliationNondeductibleStateNetOperatingLossPercentage_pid_dp_uPure_maETR002_c20230101__20231231_zAmrjfO7TxRf" style="text-align: right" title="State NOL">0.00</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>NJ NOL True Up</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--IncomeTaxReconciliationNondeductibleNewJerseyStateNetOperatingLoss_pn3n3_maETR001_c20230101__20231231_zYOisKRm787" style="text-align: right" title="NJ NOL True Up">1,123</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--EffectiveIncomeTaxRateReconciliationNondeductibleNewJerseyStateNetOperatingLossPercentage_pid_dp_uPure_maETR002_c20230101__20231231_zcFqvOOxl0Hg" style="text-align: right" title="NJ NOL True Up">-3.88</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Stock Compensation True Up</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_pn3n3_maETR001_c20230101__20231231_z5uJr9GZg3Q6" style="text-align: right" title="Stock Compensation True Up">(1,347</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_uPure_maETR002_c20230101__20231231_ziNmP9CO1Bli" style="text-align: right" title="Stock Compensation True Up">4.65</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Fixed Assets True Up</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--IncomeTaxReconciliationNondeductibleExpenseFixedAssets_pn3n3_maETR001_c20230101__20231231_zd65WviK2WLe" style="text-align: right" title="Fixed Assets True Up">925</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFixedAssets_pid_dp_uPure_maETR002_c20230101__20231231_zKM1twI8vXO6" style="text-align: right" title="Fixed Assets True Up">-3.19</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Other</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--IncomeTaxReconciliationOtherAdjustments_pn3n3_maETR001_c20230101__20231231_zEF2kURlkc33" style="text-align: right" title="Other">(22</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--EffectiveIncomeTaxRateReconciliationOther_pid_dp_uPure_maETR002_c20230101__20231231_zdXp5XMKqZ4c" style="text-align: right" title="Other">0.08</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">NOL Refund VA True Up</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_ecustom--IncomeTaxReconciliationNetOperatingLossRefundValuationAllowance_pn3n3_maETR001_c20230101__20231231_zHNGbba5HNbg" style="border-bottom: Black 1.5pt solid; text-align: right" title="NOL Refund VA True Up">486</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_ecustom--EffectiveIncomeTaxRateReconciliationNetOperatingLossRefundValuationAllowancePercentage_pid_dp_uPure_maETR002_c20230101__20231231_z5nEMEpYqbR2" style="border-bottom: Black 1.5pt solid; text-align: right" title="NOL Refund VA True Up">-1.68</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right" title="Other"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right" title="Statutory Other"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Valuation Allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_maETR001_c20230101__20231231_z5zuuPmopnO4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Valuation Allowance">7,385</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateValuationAllowance_pid_dp_uPure_maETR002_c20230101__20231231_zT30nw9ITP5i" style="border-bottom: Black 1.5pt solid; text-align: right" title="Statutory Valuation Allowance">-25.50</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtETR001_c20230101__20231231_zoFjKVU71yQh" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl1745">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtETR002_c20230101__20231231_zkYkQzPqUIXk" style="border-bottom: Black 2.5pt double; text-align: right" title="Statutory Total">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table>
</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
<us-gaap:IncomeTaxReconciliationTaxExemptIncome contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact001687" unitRef="USD"> -28962000 </us-gaap:IncomeTaxReconciliationTaxExemptIncome>
<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact001689" unitRef="USD"> -6082000 </us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2023-01-01to2023-12-31" decimals="INF" id="Fact001691" unitRef="Pure"> 0.210 </us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
<us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact001693" unitRef="USD"> -2244000 </us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="From2023-01-01to2023-12-31" decimals="INF" id="Fact001695" unitRef="Pure"> 0.0775 </us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
<us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact001697" unitRef="USD"> -83000 </us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
<us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="From2023-01-01to2023-12-31" decimals="INF" id="Fact001699" unitRef="Pure"> 0.0029 </us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
<AIM:IncomeTaxReconciliationForeignIncomeRTP contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact001701" unitRef="USD"> -8000 </AIM:IncomeTaxReconciliationForeignIncomeRTP>
<AIM:EffectiveIncomeTaxRateReconciliationRTPPercentage contextRef="From2023-01-01to2023-12-31" decimals="INF" id="Fact001703" unitRef="Pure"> 0.0003 </AIM:EffectiveIncomeTaxRateReconciliationRTPPercentage>
<us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact001705" unitRef="USD"> -479000 </us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="From2023-01-01to2023-12-31" decimals="INF" id="Fact001707" unitRef="Pure"> 0.0165 </us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
<us-gaap:IncomeTaxReconciliationTaxContingenciesStateAndLocal contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact001709" unitRef="USD"> 618000 </us-gaap:IncomeTaxReconciliationTaxContingenciesStateAndLocal>
<us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal contextRef="From2023-01-01to2023-12-31" decimals="INF" id="Fact001711" unitRef="Pure"> -0.0213 </us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal>
<us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact001713" unitRef="USD"> 272000 </us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment contextRef="From2023-01-01to2023-12-31" decimals="INF" id="Fact001715" unitRef="Pure"> 0.0094 </us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
<AIM:EffectiveIncomeTaxRateReconciliationNondeductibleStateNetOperatingLossPercentage contextRef="From2023-01-01to2023-12-31" decimals="INF" id="Fact001719" unitRef="Pure"> 0.0000 </AIM:EffectiveIncomeTaxRateReconciliationNondeductibleStateNetOperatingLossPercentage>
<AIM:IncomeTaxReconciliationNondeductibleNewJerseyStateNetOperatingLoss contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact001721" unitRef="USD"> 1123000 </AIM:IncomeTaxReconciliationNondeductibleNewJerseyStateNetOperatingLoss>
<AIM:EffectiveIncomeTaxRateReconciliationNondeductibleNewJerseyStateNetOperatingLossPercentage contextRef="From2023-01-01to2023-12-31" decimals="INF" id="Fact001723" unitRef="Pure"> -0.0388 </AIM:EffectiveIncomeTaxRateReconciliationNondeductibleNewJerseyStateNetOperatingLossPercentage>
<us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact001725" unitRef="USD"> -1347000 </us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="From2023-01-01to2023-12-31" decimals="INF" id="Fact001727" unitRef="Pure"> 0.0465 </us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
<AIM:IncomeTaxReconciliationNondeductibleExpenseFixedAssets contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact001729" unitRef="USD"> 925000 </AIM:IncomeTaxReconciliationNondeductibleExpenseFixedAssets>
<AIM:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFixedAssets contextRef="From2023-01-01to2023-12-31" decimals="INF" id="Fact001731" unitRef="Pure"> -0.0319 </AIM:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFixedAssets>
<us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact001733" unitRef="USD"> -22000 </us-gaap:IncomeTaxReconciliationOtherAdjustments>
<AIM:EffectiveIncomeTaxRateReconciliationOther contextRef="From2023-01-01to2023-12-31" decimals="INF" id="Fact001735" unitRef="Pure"> 0.0008 </AIM:EffectiveIncomeTaxRateReconciliationOther>
<AIM:IncomeTaxReconciliationNetOperatingLossRefundValuationAllowance contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact001737" unitRef="USD"> 486000 </AIM:IncomeTaxReconciliationNetOperatingLossRefundValuationAllowance>
<AIM:EffectiveIncomeTaxRateReconciliationNetOperatingLossRefundValuationAllowancePercentage contextRef="From2023-01-01to2023-12-31" decimals="INF" id="Fact001739" unitRef="Pure"> -0.0168 </AIM:EffectiveIncomeTaxRateReconciliationNetOperatingLossRefundValuationAllowancePercentage>
<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2023-01-01to2023-12-31" decimals="-3" id="Fact001741" unitRef="USD"> 7385000 </us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
<AIM:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateValuationAllowance contextRef="From2023-01-01to2023-12-31" decimals="INF" id="Fact001743" unitRef="Pure"> -0.2550 </AIM:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateValuationAllowance>
<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="From2023-01-01to2023-12-31" decimals="INF" id="Fact001747" unitRef="Pure"> 0.000 </us-gaap:EffectiveIncomeTaxRateContinuingOperations>
<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001749">
<p id="xdx_808_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zpy4TpPKA85b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(13) <span id="xdx_827_zxlV1UX3tDal">Certain Relationships and Related Transactions</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has an employment agreement with its NEOs and has granted its NEOs and directors options to purchase its common stock. Please see details of these Employment Agreements in Note 10 - Employment Agreements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
<us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001751">
<p id="xdx_806_eus-gaap--ConcentrationRiskDisclosureTextBlock_zyjoNCG16AJ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(14) <span id="xdx_827_zJu5FExLjD6e">Concentrations of Risk</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash, cash equivalents, investments and accounts receivable. The Company places its cash with high-quality financial institutions and, at times, such amounts in non-interest-bearing accounts may be in excess of Federal Deposit Insurance Corporation insurance limits. There were no credit-based sales for 2023 and 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There are a limited number of suppliers in the United States and abroad available to provide the raw and packaging materials/reagents for use in manufacturing Ampligen and Alferon N Injection. At present, the Company does not have any agreements with third parties for the supply of any of these materials or it is relying on a limited source of reagent suppliers necessary for the manufacture of Alferon N Injection. Jubilant HollisterStier LLC has manufactured batches of Ampligen for us pursuant to purchase orders. The Company anticipates that additional orders will be placed upon approved quotes and purchase orders provided by us to Jubilant. On December 22, 2020, it added Pharmaceutics International Inc. (“Pii”) as a “Fill & Finish” provider to enhance our capacity to produce the drug Ampligen. This addition amplifies our manufacturing capability by providing redundancy and cost savings. The contracts augment the Company’s existing fill and finish capacity. If the Company is unable to place adequate acceptable purchase orders with Jubilant or Pii in the future at acceptable prices upon acceptable terms, it will need to find another manufacturer. The costs and availability of products and materials the Company would need for the production of Ampligen are subject to fluctuation depending on a variety of factors beyond our control, including competitive factors, changes in technology, ownership of intellectual property, FDA and other governmental regulations. There can be no assurance that the Company will be able to obtain such products and materials on terms acceptable to it or at all.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently, the Alferon N Injection manufacturing process is on hold and there is no definitive timetable to restart production. If the Company is unable to acquire FDA approvals related to the manufacturing process and/or final product of new Alferon N Injection inventory or contract with a CMO, its operations most likely will be materially and/or adversely affected. In light of these contingencies, there can be no assurances that the approved Alferon N Injection product will be returned to production on a timely basis, if at all, or that if and when it is again made commercially available, it will return to prior sales levels.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
</us-gaap:ConcentrationRiskDisclosureTextBlock>
<us-gaap:FairValueDisclosuresTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001753">
<p id="xdx_80C_eus-gaap--FairValueDisclosuresTextBlock_z7t6Ujmx0eg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(15) <span id="xdx_82A_zGHl6kYoQvOj">Fair Value</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company complies with the provisions of FASB ASC 820 “Fair Value Measurements” for its financial and non-financial assets and liabilities. ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for certain assets and liabilities at fair value. The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. AIM categorizes each of its fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 – Quoted prices are available in active markets for identical assets or liabilities at the reporting date. Generally, this includes debt and equity securities that are traded in an active market.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2. </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 – Observable inputs other than Level 1 prices such as quote prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Generally, this includes debt and equity securities that are not traded in an active market.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or other valuation techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. As of September 30, 2023, the Company has classified the warrants with cash settlement features as Level 3. Management evaluates a variety of inputs and then estimates fair value based on those inputs. As discussed above, the Company utilized the Monte Carlo Simulation Model in valuing the warrants. </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zYiMEAm4C2Nf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below presents the balances of assets and liabilities measured at fair value on a recurring basis by level within the hierarchy as (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BD_zYDPDRYoMkN5" style="display: none">Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center">As of December 31, 2023</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; padding-left: 10pt">Cash equivalents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231_z83nUSICobL2" style="width: 11%; text-align: right" title="Cash equivalents-Marketable investments"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,805</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_znsQe2H7u0gd" style="width: 11%; text-align: right" title="Cash equivalents-Marketable investments"><span style="font-size: 10pt">4,805</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zIW3jxiL3P41" style="width: 11%; text-align: right" title="Cash equivalents-Marketable investments"><span style="-sec-ix-hidden: xdx2ixbrl1761">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zlmAm9oNMtB6" style="width: 11%; text-align: right" title="Cash equivalents-Marketable investments"><span style="-sec-ix-hidden: xdx2ixbrl1763">—</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Marketable investments</td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20231231_zRkd83lWcec" style="text-align: right" title="Marketable securities">7,631</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zpcudr0UJGae" style="text-align: right" title="Marketable securities">7,631</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxHMxlgIYp7b" style="text-align: right" title="Marketable securities"><span style="-sec-ix-hidden: xdx2ixbrl1769">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4DudObjdsQh" style="text-align: right" title="Marketable securities"><span style="-sec-ix-hidden: xdx2ixbrl1771">—</span></td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center">As of December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; padding-left: 10pt">Cash equivalents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231_z7Uw3Enumzkj" style="width: 11%; text-align: right" title="Cash equivalent-Marketable investments">25,180</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zEyBWYxyzx58" style="width: 11%; text-align: right" title="Cash equivalent-Marketable investments">25,180</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z9GOjxHIscC2" style="width: 11%; text-align: right" title="Cash equivalent-Marketable investments"><span style="-sec-ix-hidden: xdx2ixbrl1777">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zit80g8CwPqh" style="width: 11%; text-align: right" title="Cash equivalent-Marketable investments"><span style="-sec-ix-hidden: xdx2ixbrl1779">—</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Marketable investments</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20221231_zRecHcLji644" style="text-align: right" title="Marketable securities">7,137</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zd6d9mpbR8Ei" style="text-align: right" title="Marketable securities">7,137</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWmeqeM5NaVg" style="text-align: right" title="Marketable securities"><span style="-sec-ix-hidden: xdx2ixbrl1785">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXTjtmbPREHl" style="text-align: right" title="Marketable securities"><span style="-sec-ix-hidden: xdx2ixbrl1787">—</span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A5_zBi8m8zL5Qy2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s cash balances are representative of their fair values as these balances are comprised of deposits available on demand. For certain instruments, including funds receivable from New Jersey net operating loss, accounts payable and accrued expenses, it was estimated that the carrying values approximated the fair value due to the short-term maturities of these instruments (Level 1).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company also has certain redeemable warrants with a cash settlement feature in the occurrence of a Fundamental Transaction. The fair value of the redeemable warrants (“Redeemable Warrants”) related to the Company’s March 2019 common stock and warrant issuance, are calculated using a Monte Carlo Simulation (Level 3).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recomputes the fair value of the Redeemable Warrants at the issuance date and the end of each quarterly reporting period. Such value computation includes subjective input assumptions that are consistently applied each period. If the Company were to alter its assumptions or the numbers input based on such assumptions, the resulting fair value could be materially different.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zuol2aaJulp9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company utilized the following assumptions to estimate the fair value of the March 2019 Warrants:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B9_zrbXdtHsst85" style="display: none">Schedule of Assumptions to Estimate Fair Value of Warrants </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_492_20231231_z5oIAaJPapa6" style="text-align: center">December 31,</td><td> </td><td> </td> <td colspan="2" id="xdx_49E_20221231_zBYs1s5O9yza" style="text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_403_eus-gaap--SharePrice_iI_pid_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember_zjhTwrN654kc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Underlying price per share</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">0.44</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">0.31</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zto65HqSveZc" style="vertical-align: bottom; background-color: White"> <td>Exercise price per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8.80</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8.80</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pip0_uPure_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zfvhNrKoA4yf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.47</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.67</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expected holding period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z5SLkXNkHcag" title="Warrant term">.19</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z6EQrbmcDZdb" title="Warrant term">1.19</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pip0_uPure_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zbbdzooHRxWa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">80</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">70</td><td style="text-align: left">%</td></tr> <tr id="xdx_407_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z1U3UjDe3iZi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1807">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1808">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zlO3oEZcdMQj" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants measurement input</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1810">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1811">—</span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AC_zsBs6amkn04c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The significant assumptions using the Monte Carlo Simulation approach for valuation of the Warrants are:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risk-Free Interest Rate</i>. The risk-free interest rates for the Warrants are based on U.S. Treasury constant maturities for periods commensurate with the remaining expected holding periods of the warrants.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected Holding Period</i>. The expected holding period represents the period of time that the Warrants are expected to be outstanding until they are exercised. The Company utilizes the remaining contractual term of the Warrants at each valuation date as the expected holding period.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected Volatility</i>. Expected stock volatility is based on daily observations of the Company’s historical stock values for a period commensurate with the remaining expected holding period on the last day of the period for which the computation is made.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv) </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected Dividend Yield</i>. Expected dividend yield is based on the Company’s anticipated dividend payments over the remaining expected holding period. As the Company has never issued dividends, the expected dividend yield is <span id="xdx_901_ecustom--FairValueMeasurementInputPercentage_pid_dp_uPure_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zqowt4ev68Yb" title="Fair value measurement, input percentage">0</span>% and this assumption will be continued in future calculations unless the Company changes its dividend policy.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v) </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected Probability of a Fundamental Transaction.</i> The possibility of the occurrence of a Fundamental Transaction triggering a Put right is extremely remote. As discussed above, a Put right would only arise if a Fundamental Transaction 1) is an all cash transaction; (2) results in the Company going private; or (3) is a transaction involving a person or entity not traded on a national securities exchange. The Company believes such an occurrence is highly unlikely because:</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company only has one product that is FDA approved but is currently not available for commercial sales.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2. </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company will have to perform additional clinical trials for FDA approval of its flagship product.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Industry and market conditions continue to include uncertainty, adding risk to any transaction.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4. </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Available capital for a potential buyer in a cash transaction continues to be limited.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5. </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The nature of a life sciences company is heavily dependent on future funding and high fixed costs, including Research & Development.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6. </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has minimal revenues streams which are insufficient to meet the funding needs for the cost of operations or construction at their manufacturing facility; and</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7. </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s Rights Agreement and Executive Agreements make it less attractive to a potential buyer.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With the above factors utilized in analysis of the likelihood of the Put’s potential Liability, the Company estimated the range of probabilities related to a Put right being triggered as:</span></p> <p id="xdx_89C_ecustom--ScheduleOfRangeOfProbabilitiesTableTextBlock_zLaqpS9nTXRh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B2_z3IoaIciMb6l" style="display: none">Schedule of Range of Probabilities</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: center">Range of Probability</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Probability</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: center">Low</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_903_ecustom--PercentageOfProbability_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_z0pMBIHZAcY" title="Percentage of probability">0.5</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">Medium</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_ecustom--PercentageOfProbability_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--WeightedAverageMember_zAn4iSQ52m1d" title="Percentage of probability">1.0</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">High</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_ecustom--PercentageOfProbability_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zygQUr4pY1p3" title="Percentage of probability">5.0</span></td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8AB_zq7Luw79jzU" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Monte Carlo Simulation has incorporated a <span id="xdx_902_ecustom--PercentageOfProbability_pid_dp_uPure_c20230101__20231231_zaqAl3tBTbV6" title="Percentage of probability">5.0</span>% probability of a Fundamental Transaction to date for the life of the securities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi) </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected Timing of Announcement of a Fundamental Transaction.</i> As the Company has no specific expectation of a Fundamental Transaction, for reasons elucidated above, the Company utilized a discrete uniform probability distribution over the Expected Holding Period to model in the potential announcement of a Fundamental Transaction occurring during the Expected Holding Period.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii) </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected 100 Day Volatility at Announcement of a Fundamental Transaction</i>. An estimate of future volatility is necessary as there is no mechanism for directly measuring future stock price movements. Daily observations of the Company’s historical stock values for the 100 days immediately prior to the Warrants’ grant dates, with a floor of <span id="xdx_902_ecustom--FloorRateUsedAsProxyForFutureVolatilityPercentage_pid_dp_uPure_c20230101__20231231_zW1ASrkrbeO6" title="Floor rate used as proxy for future volatility percentage">100</span>%, were utilized as a proxy for the future volatility.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii) </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected Risk-Free Interest Rate at Announcement of a Fundamental Transaction</i>. The Company utilized a risk-free interest rate corresponding to the forward U.S. Treasury rate for the period equal to the time between the date forecast for the public announcement of a Fundamental Transaction and the Warrant expiration date for each simulation.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(ix) </i></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected Time Between Announcement and Consummation of a Fundamental Transaction.</i> The expected time between the announcement and the consummation of a Fundamental Transaction is based on the Company’s experience with the due diligence process performed by acquirers and is estimated to be six months. The Monte Carlo Simulation approach incorporates this additional period to reflect the delay Warrant Holders would experience in receiving the proceeds of the Put.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While the assumptions remain consistent from period to period (e.g., utilizing historical stock prices), the numbers input change from period to period (e.g., the actual historical prices input for the relevant period). The carrying amount and estimated fair value of the above Warrants was approximately $<span id="xdx_901_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zKtiUPvS1ARh">0 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at December 31, 2023 and 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</us-gaap:FairValueDisclosuresTextBlock>
<us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001755">
<p id="xdx_89D_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zYiMEAm4C2Nf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below presents the balances of assets and liabilities measured at fair value on a recurring basis by level within the hierarchy as (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BD_zYDPDRYoMkN5" style="display: none">Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center">As of December 31, 2023</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; padding-left: 10pt">Cash equivalents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231_z83nUSICobL2" style="width: 11%; text-align: right" title="Cash equivalents-Marketable investments"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,805</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_znsQe2H7u0gd" style="width: 11%; text-align: right" title="Cash equivalents-Marketable investments"><span style="font-size: 10pt">4,805</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zIW3jxiL3P41" style="width: 11%; text-align: right" title="Cash equivalents-Marketable investments"><span style="-sec-ix-hidden: xdx2ixbrl1761">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zlmAm9oNMtB6" style="width: 11%; text-align: right" title="Cash equivalents-Marketable investments"><span style="-sec-ix-hidden: xdx2ixbrl1763">—</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Marketable investments</td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20231231_zRkd83lWcec" style="text-align: right" title="Marketable securities">7,631</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zpcudr0UJGae" style="text-align: right" title="Marketable securities">7,631</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxHMxlgIYp7b" style="text-align: right" title="Marketable securities"><span style="-sec-ix-hidden: xdx2ixbrl1769">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4DudObjdsQh" style="text-align: right" title="Marketable securities"><span style="-sec-ix-hidden: xdx2ixbrl1771">—</span></td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center">As of December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; padding-left: 10pt">Cash equivalents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231_z7Uw3Enumzkj" style="width: 11%; text-align: right" title="Cash equivalent-Marketable investments">25,180</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zEyBWYxyzx58" style="width: 11%; text-align: right" title="Cash equivalent-Marketable investments">25,180</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z9GOjxHIscC2" style="width: 11%; text-align: right" title="Cash equivalent-Marketable investments"><span style="-sec-ix-hidden: xdx2ixbrl1777">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zit80g8CwPqh" style="width: 11%; text-align: right" title="Cash equivalent-Marketable investments"><span style="-sec-ix-hidden: xdx2ixbrl1779">—</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Marketable investments</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20221231_zRecHcLji644" style="text-align: right" title="Marketable securities">7,137</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zd6d9mpbR8Ei" style="text-align: right" title="Marketable securities">7,137</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWmeqeM5NaVg" style="text-align: right" title="Marketable securities"><span style="-sec-ix-hidden: xdx2ixbrl1785">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXTjtmbPREHl" style="text-align: right" title="Marketable securities"><span style="-sec-ix-hidden: xdx2ixbrl1787">—</span></td><td style="text-align: left"> </td></tr> </table>
</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="AsOf2023-12-31" decimals="-3" id="Fact001757" unitRef="USD"> 4805000 </us-gaap:CashAndCashEquivalentsFairValueDisclosure>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact001759" unitRef="USD"> 4805000 </us-gaap:CashAndCashEquivalentsFairValueDisclosure>
<us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2023-12-31" decimals="-3" id="Fact001765" unitRef="USD"> 7631000 </us-gaap:MarketableSecuritiesCurrent>
<us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact001767" unitRef="USD"> 7631000 </us-gaap:MarketableSecuritiesCurrent>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="AsOf2022-12-31" decimals="-3" id="Fact001773" unitRef="USD"> 25180000 </us-gaap:CashAndCashEquivalentsFairValueDisclosure>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact001775" unitRef="USD"> 25180000 </us-gaap:CashAndCashEquivalentsFairValueDisclosure>
<us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2022-12-31" decimals="-3" id="Fact001781" unitRef="USD"> 7137000 </us-gaap:MarketableSecuritiesCurrent>
<us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact001783" unitRef="USD"> 7137000 </us-gaap:MarketableSecuritiesCurrent>
<us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001789">
<p id="xdx_893_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zuol2aaJulp9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company utilized the following assumptions to estimate the fair value of the March 2019 Warrants:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B9_zrbXdtHsst85" style="display: none">Schedule of Assumptions to Estimate Fair Value of Warrants </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_492_20231231_z5oIAaJPapa6" style="text-align: center">December 31,</td><td> </td><td> </td> <td colspan="2" id="xdx_49E_20221231_zBYs1s5O9yza" style="text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_403_eus-gaap--SharePrice_iI_pid_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember_zjhTwrN654kc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Underlying price per share</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">0.44</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">0.31</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zto65HqSveZc" style="vertical-align: bottom; background-color: White"> <td>Exercise price per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8.80</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8.80</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pip0_uPure_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zfvhNrKoA4yf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.47</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.67</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expected holding period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z5SLkXNkHcag" title="Warrant term">.19</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z6EQrbmcDZdb" title="Warrant term">1.19</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pip0_uPure_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zbbdzooHRxWa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">80</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">70</td><td style="text-align: left">%</td></tr> <tr id="xdx_407_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z1U3UjDe3iZi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1807">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1808">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zlO3oEZcdMQj" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants measurement input</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1810">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1811">—</span></td><td style="text-align: left"> </td></tr> </table>
</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
<us-gaap:SharePrice contextRef="AsOf2023-12-31_custom_MarchTwoThousandNineteenWarrantsMember" decimals="INF" id="Fact001791" unitRef="USDPShares"> 0.44 </us-gaap:SharePrice>
<us-gaap:SharePrice contextRef="AsOf2022-12-31_custom_MarchTwoThousandNineteenWarrantsMember" decimals="INF" id="Fact001792" unitRef="USDPShares"> 0.31 </us-gaap:SharePrice>
<us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="AsOf2023-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputExercisePriceMember" decimals="INF" id="Fact001794" unitRef="Pure"> 8.80 </us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
<us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="AsOf2022-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputExercisePriceMember" decimals="INF" id="Fact001795" unitRef="Pure"> 8.80 </us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
<us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="AsOf2023-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" decimals="INF" id="Fact001797" unitRef="Pure"> 5.47 </us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
<us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="AsOf2022-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" decimals="INF" id="Fact001798" unitRef="Pure"> 4.67 </us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
<us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2023-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputExpectedTermMember" id="Fact001800"> P0Y2M8D </us-gaap:WarrantsAndRightsOutstandingTerm>
<us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2022-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputExpectedTermMember" id="Fact001802"> P1Y2M8D </us-gaap:WarrantsAndRightsOutstandingTerm>
<us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="AsOf2023-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember" decimals="INF" id="Fact001804" unitRef="Pure"> 80 </us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
<us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="AsOf2022-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember" decimals="INF" id="Fact001805" unitRef="Pure"> 70 </us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
<AIM:FairValueMeasurementInputPercentage contextRef="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember" decimals="INF" id="Fact001813" unitRef="Pure"> 0 </AIM:FairValueMeasurementInputPercentage>
<AIM:ScheduleOfRangeOfProbabilitiesTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001815">
<p id="xdx_89C_ecustom--ScheduleOfRangeOfProbabilitiesTableTextBlock_zLaqpS9nTXRh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B2_z3IoaIciMb6l" style="display: none">Schedule of Range of Probabilities</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: center">Range of Probability</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Probability</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: center">Low</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_903_ecustom--PercentageOfProbability_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_z0pMBIHZAcY" title="Percentage of probability">0.5</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">Medium</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_ecustom--PercentageOfProbability_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--WeightedAverageMember_zAn4iSQ52m1d" title="Percentage of probability">1.0</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">High</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_ecustom--PercentageOfProbability_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zygQUr4pY1p3" title="Percentage of probability">5.0</span></td><td style="text-align: left">%</td></tr> </table>
</AIM:ScheduleOfRangeOfProbabilitiesTableTextBlock>
<AIM:PercentageOfProbability contextRef="From2023-01-012023-12-31_srt_MinimumMember" decimals="INF" id="Fact001817" unitRef="Pure"> 0.005 </AIM:PercentageOfProbability>
<AIM:PercentageOfProbability contextRef="From2023-01-012023-12-31_srt_WeightedAverageMember" decimals="INF" id="Fact001819" unitRef="Pure"> 0.010 </AIM:PercentageOfProbability>
<AIM:PercentageOfProbability contextRef="From2023-01-012023-12-31_srt_MaximumMember" decimals="INF" id="Fact001821" unitRef="Pure"> 0.050 </AIM:PercentageOfProbability>
<AIM:PercentageOfProbability contextRef="From2023-01-01to2023-12-31" decimals="INF" id="Fact001823" unitRef="Pure"> 0.050 </AIM:PercentageOfProbability>
<AIM:FloorRateUsedAsProxyForFutureVolatilityPercentage contextRef="From2023-01-01to2023-12-31" decimals="INF" id="Fact001825" unitRef="Pure"> 1 </AIM:FloorRateUsedAsProxyForFutureVolatilityPercentage>
<us-gaap:FairValueAdjustmentOfWarrants contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember289848921" decimals="0" id="Fact001826" unitRef="USD"> 0 </us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001828">
<p id="xdx_80F_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zaZ4cv9BcK5h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(16)</b> <b><span id="xdx_82D_zZ6GqmFQwI41">Contingencies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Because litigation is inherently unpredictable, assessing contingencies related to litigation is a complex process involving highly subjective judgment about potential outcomes of future events. When evaluating litigation contingencies, the Company may be unable to provide a meaningful estimate due to a number of factors, including the procedural status of the matter in question, the availability of appellate remedies, insurance coverage related to the claim or claims in question, the presence of complex or novel legal theories, and the ongoing discovery and development of information important to the matter. In addition, damage amounts claimed in litigation against the Company may be unsupported, exaggerated, or unrelated to possible outcomes, and as such are not meaningful indicators of the Company’s potential liability or financial exposure. Accordingly, the Company reviews the adequacy of accruals and disclosures each quarter in consultation with legal counsel, and it assesses the probability and range of possible losses associated with contingencies for potential accrual in the condensed consolidated financial statements. However, the ultimate resolution of litigated claims may differ from the Company current estimates.</p> <p style="font: 13.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">In the normal course of business, there are various claims in process, matters in litigation, and other contingencies, certain of which are covered by insurance policies. When a loss is probable, we record an accrual based on the reasonably estimable loss or range of loss. We do not record liabilities for reasonably possible loss contingencies but do disclose a range of reasonably possible losses if they are material and we are able to estimate such a range. If we cannot provide a range of reasonably possible losses, we explain the factors that prevent us from determining such a range. Historically, adjustments to our estimates have not been material. While it is not possible to predict the outcome of these suits, legal proceedings, and claims with certainty, management is of the opinion that adequate provision for potential losses associated with these matters has been made in the financial statements and that the ultimate resolution of any one of these matters will not have a material adverse effect on the Company’s financial position and results of operations. A significant increase in the number of these claims, or one or more successful claims resulting in greater liabilities than the Company currently anticipates, could materially and adversely affect the Company’s business, financial condition, results of operations, and cash flows.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
<us-gaap:SubsequentEventsTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001830">
<p id="xdx_80F_eus-gaap--SubsequentEventsTextBlock_z12tS2VfdSp3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(17) <span id="xdx_82E_znFnaiO3kAei">Subsequent Events</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 16, 2024, the Company entered into a Note Purchase Agreement with an unrelated party raising $<span id="xdx_909_eus-gaap--ProceedsFromNotesPayable_c20240216__20240216__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__custom--DebtIstrumentAxis__custom--UnsecuredPromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zPd1bN9HZ8Q7" title="Net Proceeds">2,500,000</span> in net proceeds from the sale of an unsecured promissory Note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 28, 2024, the Company entered into a purchase agreement and a registration rights agreement with an unrelated party, pursuant to which this party committed to purchase up to $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240328__20240328__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zph9uGpTxlja" title="Purchase commitment">15,000,000</span> of common stock of the Company for a period of 24 months from the date of the agreement. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2024, the Company sold <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240301__20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--PlanNameAxis__custom--EmployeesPurchasePlanMember_zlBh2vNi0Dkc" title="Sale of stock, number of shares issued in transaction">204,547</span> and <span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240301__20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--PlanNameAxis__custom--DirectorsPurchasePlanMember_zZhZfO9CzpT4" title="Sale of stock, number of shares issued in transaction">38,462</span> shares of its common stock at prices of $<span id="xdx_903_eus-gaap--SaleOfStockPricePerShare_iI_c20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--PlanNameAxis__custom--EmployeesPurchasePlanMember_zDVhkDDuwSc3" title="Sale of stock, price per share">0.33</span> and $<span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_c20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--PlanNameAxis__custom--DirectorsPurchasePlanMember_zxIPrz3YjgB3" title="Sale of stock, price per share">0.39</span> per share, respectively, under the Employees and Directors Purchase Plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>
</us-gaap:SubsequentEventsTextBlock>
<us-gaap:ProceedsFromNotesPayable contextRef="From2024-02-162024-02-16_us-gaap_SubsequentEventMember_custom_UnsecuredPromissoryNoteMember_us-gaap_NonrelatedPartyMember" decimals="0" id="Fact001832" unitRef="USD"> 2500000 </us-gaap:ProceedsFromNotesPayable>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2024-03-282024-03-28_us-gaap_SubsequentEventMember_us-gaap_NonrelatedPartyMember_us-gaap_CommonStockMember" decimals="0" id="Fact001834" unitRef="USD"> 15000000 </us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="From2024-03-012024-03-31_us-gaap_SubsequentEventMember_custom_EmployeesPurchasePlanMember" decimals="INF" id="Fact001836" unitRef="Shares"> 204547 </us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="From2024-03-012024-03-31_us-gaap_SubsequentEventMember_custom_DirectorsPurchasePlanMember" decimals="INF" id="Fact001838" unitRef="Shares"> 38462 </us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
<us-gaap:SaleOfStockPricePerShare contextRef="AsOf2024-03-31_us-gaap_SubsequentEventMember_custom_EmployeesPurchasePlanMember" decimals="INF" id="Fact001840" unitRef="USDPShares"> 0.33 </us-gaap:SaleOfStockPricePerShare>
<us-gaap:SaleOfStockPricePerShare contextRef="AsOf2024-03-31_us-gaap_SubsequentEventMember_custom_DirectorsPurchasePlanMember" decimals="INF" id="Fact001842" unitRef="USDPShares"> 0.39 </us-gaap:SaleOfStockPricePerShare>
</xbrl>

3 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/15/24  AIM ImmunoTech Inc.               10-Q        3/31/24   75:5.3M                                   M2 Compliance LLC/FA
 5/01/24  AIM ImmunoTech Inc.               424B5                  1:260K                                   M2 Compliance LLC/FA
 4/19/24  AIM ImmunoTech Inc.               S-1                    6:628K                                   M2 Compliance LLC/FA

65 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/20/24  AIM ImmunoTech Inc.               8-K:1,2,9   2/16/24   12:11M                                    M2 Compliance LLC/FA
 9/29/23  AIM ImmunoTech Inc.               8-K:1,9     9/28/23   11:275K                                   M2 Compliance LLC/FA
 5/30/23  AIM ImmunoTech Inc.               8-K:1,9     5/22/23   11:266K                                   M2 Compliance LLC/FA
 4/19/23  AIM ImmunoTech Inc.               8-K:1,9     4/19/23   12:517K                                   M2 Compliance LLC/FA
 4/07/23  AIM ImmunoTech Inc.               8-K:1,9     4/04/23   12:312K                                   M2 Compliance LLC/FA
 3/31/23  AIM ImmunoTech Inc.               10-K       12/31/22   87:8.7M                                   M2 Compliance LLC/FA
 2/10/23  AIM ImmunoTech Inc.               8-A12B/A               2:60K                                    M2 Compliance LLC/FA
11/14/22  AIM ImmunoTech Inc.               10-Q        9/30/22   75:5M                                     M2 Compliance LLC/FA
 8/15/22  AIM ImmunoTech Inc.               10-Q        6/30/22   72:6M                                     M2 Compliance LLC/FA
 6/21/22  AIM ImmunoTech Inc.               8-K:1,9     6/16/22   12:1.6M                                   M2 Compliance LLC/FA
 6/17/22  AIM ImmunoTech Inc.               8-K:1,9     6/13/22   11:656K                                   M2 Compliance LLC/FA
 4/12/22  AIM ImmunoTech Inc.               8-K:1,7,9   4/07/22   13:9.1M                                   M2 Compliance LLC/FA
 3/31/22  AIM ImmunoTech Inc.               10-K       12/31/21   90:9.3M                                   M2 Compliance LLC/FA
 1/21/22  AIM ImmunoTech Inc.               S-3                    5:822K                                   M2 Compliance LLC/FA
11/15/21  AIM ImmunoTech Inc.               10-Q        9/30/21   69:5.9M                                   M2 Compliance LLC/FA
 8/16/21  AIM ImmunoTech Inc.               10-Q        6/30/21   69:10M                                    M2 Compliance LLC/FA
 5/17/21  AIM ImmunoTech Inc.               10-Q        3/31/21   73:4.7M                                   M2 Compliance LLC/FA
 3/31/21  AIM ImmunoTech Inc.               10-K       12/31/20   94:7.6M                                   M2 Compliance LLC/FA
11/12/20  AIM ImmunoTech Inc.               10-Q        9/30/20   68:4.1M                                   M2 Compliance LLC/FA
 8/14/20  AIM ImmunoTech Inc.               10-Q        6/30/20   72:4.9M                                   M2 Compliance LLC/FA
 4/27/20  AIM ImmunoTech Inc.               8-K:1,9     4/27/20    2:74K                                    M2 Compliance LLC/FA
 4/06/20  AIM ImmunoTech Inc.               8-K:1,7,9   4/06/20    3:119K                                   M2 Compliance LLC/FA
 3/26/20  AIM ImmunoTech Inc.               8-K:1,7,9   3/26/20    3:233K                                   M2 Compliance LLC/FA
12/11/19  AIM ImmunoTech Inc.               8-K:1,2,9  12/11/19    4:336K                                   M2 Compliance LLC/FA
 9/27/19  AIM ImmunoTech Inc.               8-K:1,8,9   9/27/19    5:739K                                   M2 Compliance LLC/FA
 9/24/19  AIM ImmunoTech Inc.               S-1/A       9/23/19    6:1.1M                                   M2 Compliance LLC/FA
 8/26/19  AIM ImmunoTech Inc.               8-K:5,8,9   8/22/19    3:81K                                    M2 Compliance LLC/FA
 8/23/19  AIM ImmunoTech Inc.               8-K:5,8,9   8/22/19    3:60K                                    M2 Compliance LLC/FA
 8/14/19  AIM ImmunoTech Inc.               10-Q        6/30/19   66:4.8M                                   M2 Compliance LLC/FA
 6/05/19  AIM ImmunoTech Inc.               8-K:5,9     6/03/19    2:773K                                   M2 Compliance LLC/FA
 5/02/19  AIM ImmunoTech Inc.               8-K:1,9     5/02/19    2:72K                                    M2 Compliance LLC/FA
 3/15/19  AIM ImmunoTech Inc.               8-K:1,9     3/13/19    2:58K                                    M2 Compliance LLC/FA
 3/08/19  AIM ImmunoTech Inc.               8-K:5,8,9   3/05/19    3:404K                                   M2 Compliance LLC/FA
 2/27/19  AIM ImmunoTech Inc.               8-K:8,9     2/26/19    4:304K                                   M2 Compliance LLC/FA
 2/06/19  AIM ImmunoTech Inc.               S-1/A                 16:2M                                     M2 Compliance LLC/FA
11/14/18  AIM ImmunoTech Inc.               10-Q        9/30/18   64:4.8M                                   M2 Compliance LLC/FA
10/04/18  AIM ImmunoTech Inc.               8-K:1,2,3,910/04/18    4:348K                                   M2 Compliance LLC/FA
 8/03/18  AIM ImmunoTech Inc.               DEF 14A     8/03/18    1:1.8M                                   M2 Compliance LLC/FA
 4/20/18  AIM ImmunoTech Inc.               8-K:1,3,7,9 4/20/18    6:896K                                   M2 Compliance LLC/FA
 3/30/18  AIM ImmunoTech Inc.               10-K       12/31/17   88:14M                                    M2 Compliance LLC/FA
 3/22/18  AIM ImmunoTech Inc.               8-K:1,9     3/22/18    4:328K                                   M2 Compliance LLC/FA
11/14/17  AIM ImmunoTech Inc.               8-A12B                 2:423K                                   M2 Compliance LLC/FA
 8/29/17  AIM ImmunoTech Inc.               8-K:5,8,9   8/22/17    4:76K                                    M2 Compliance LLC/FA
 8/23/17  AIM ImmunoTech Inc.               8-K:1,3,9   8/23/17    4:301K                                   M2 Compliance LLC/FA
 6/01/17  AIM ImmunoTech Inc.               8-K:1,3,9   6/01/17    4:333K                                   M2 Compliance LLC/FA
 5/15/17  AIM ImmunoTech Inc.               10-Q        3/31/17   61:3.4M                                   M2 Compliance LLC/FA
 5/08/17  AIM ImmunoTech Inc.               8-K/A:1,9   1/17/17    2:313K                                   M2 Compliance LLC/FA
 2/03/17  AIM ImmunoTech Inc.               8-K:1,3,7,9 2/01/17    6:468K                                   S2 Filings LLC/FA
 9/01/16  AIM ImmunoTech Inc.               8-K:1,3,7,9 9/01/16    6:419K                                   S2 Filings LLC/FA
 8/29/16  AIM ImmunoTech Inc.               10-Q/A      3/31/16    5:409K                                   S2 Filings LLC/FA
 8/15/16  AIM ImmunoTech Inc.               10-Q        6/30/16   55:3.1M                                   S2 Filings LLC/FA
 6/27/16  AIM ImmunoTech Inc.               DEF 14A     6/27/16    1:731K                                   S2 Filings LLC/FA
 5/16/16  AIM ImmunoTech Inc.               10-Q        3/31/16   52:2.9M                                   S2 Filings LLC/FA
 3/01/16  AIM ImmunoTech Inc.               8-K:5,9     2/29/16    2:39K                                    S2 Filings LLC/FA
 2/04/16  AIM ImmunoTech Inc.               8-K:5,8,9   1/26/16    4:68K                                    S2 Filings LLC/FA
11/16/15  AIM ImmunoTech Inc.               10-Q        9/30/15   67:4.5M
 8/12/15  AIM ImmunoTech Inc.               10-Q        6/30/15   64:4.5M
 3/19/15  AIM ImmunoTech Inc.               10-K       12/31/14   85:14M
 3/14/14  AIM ImmunoTech Inc.               10-K       12/31/13   96:16M
 8/15/12  AIM ImmunoTech Inc.               8-K:1,9     8/14/12    3:39K                                    Toppan Merrill/FA
 3/14/12  AIM ImmunoTech Inc.               10-K       12/31/11   48:5.4M                                   Toppan Merrill/FA
11/09/11  AIM ImmunoTech Inc.               10-Q        9/30/11   39:4.3M                                   Toppan Merrill/FA
 9/16/11  AIM ImmunoTech Inc.               DEF 14A    10/13/11    1:1.5M                                   Toppan Merrill/FA
 3/12/10  AIM ImmunoTech Inc.               10-K       12/31/09   11:2.5M                                   Toppan Merrill/FA
 4/03/06  AIM ImmunoTech Inc.               10-K       12/31/05    3:626K                                   Toppan Merrill/FA
↑Top
Filing Submission 0001493152-24-012058   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Fri., May 17, 11:43:03.4am ET